0001213900-19-016052.txt : 20190815 0001213900-19-016052.hdr.sgml : 20190815 20190815160325 ACCESSION NUMBER: 0001213900-19-016052 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190815 DATE AS OF CHANGE: 20190815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XYNOMIC PHARMACEUTICALS HOLDINGS, INC. CENTRAL INDEX KEY: 0001697805 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38120 FILM NUMBER: 191030272 BUSINESS ADDRESS: STREET 1: 609-610 21ST CENTURY TOWER STREET 2: 40 LIANGMAQIAO ROAD, CHAOYANG DISTRICT CITY: BEIJING STATE: F4 ZIP: 100016 BUSINESS PHONE: 9493506999 MAIL ADDRESS: STREET 1: 609-610 21ST CENTURY TOWER STREET 2: 40 LIANGMAQIAO ROAD, CHAOYANG DISTRICT CITY: BEIJING STATE: F4 ZIP: 100016 FORMER COMPANY: FORMER CONFORMED NAME: Bison Capital Acquisition Corp. DATE OF NAME CHANGE: 20170621 FORMER COMPANY: FORMER CONFORMED NAME: Bison Capital Acquisition Corp DATE OF NAME CHANGE: 20170209 10-Q 1 f10q0619_xynomicpharmaceutic.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission File Number: 001-38120

XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		83-4696467
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Suite 3306, K. Wah Centre, 1010 Middle

Huaihai Road, Shanghai, China

200031

(Address of principal executive offices)

(Zip Code)

+86 21 54180212

(Registrant’s telephone number, including area code)

Bison Capital Acquisition Corp.

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A

As of August 8, 2019, 46,273,846 shares of common stock, par value $0.0001 per share, were issued and outstanding.

TABLE OF CONTENTS

Part I – FINANCIAL INFORMATION

Item 1.	Financial Statements	1

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	34

Item 4.	Controls and Procedures	34

Part II – OTHER INFORMATION

Item 1.	Legal Proceedings	35

Item 1A.	Risk Factors	35

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	35

Item 3.	Defaults Upon Senior Securities	35

Item 4.	Mine Safety Disclosures	35

Item 5.	Other Information	35

Item 6.	Exhibits	36

SIGNATURES		37

CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s registration statement on Form S-1 (file No. 333-232598, the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 11, 2019. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In U.S. dollars, except share data)

	December 31,			June 30,
	2018			2019
				(Unaudited)
ASSETS

Current assets:
Cash	$	4,746,370		$	1,191,944
Prepaid expenses		277,750			155,805
Total current assets		5,024,120			1,347,749
Property and equipment, net		280,730			444,796
Intangible assets, net		1,937			1,450
Other non-current assets		155,176			219,565

TOTAL ASSETS	$	5,461,963		$	2,013,560

LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ DEFICIT
Current liabilities:
Bank overdraft	$	4,954		$	2,035
Accrued expenses and other current liabilities		14,407,261			16,089,078
Promissory note – related party		-			404,900
Amount due to shareholders		3,233,728			552,873
Total current liabilities		17,645,943			17,048,886

Total liabilities		17,645,943			17,048,886

Commitments and Contingencies

Mezzanine equity:
Angel Preferred Shares (par value US$0.0001 per share as of December 31, 2018; 23,435,379 and 0 shares authorized, issued and outstanding as of December 31, 2018 and June 30, 2019, respectively. Redemption value of US$580,256 as of December 31, 2018; Liquidation value of US$811,332 as of December 31, 2018)		580,256			-
Series A-1 Preferred Shares (par value US$0.0001 per share as of December 31, 2018; 12,147,500 and 0 shares authorized, issued and outstanding as of December 31, 2018 and June 30, 2019, respectively. Redemption value of US$4,905,780 as of December 31, 2018; Liquidation value of US$6,964,223 as of December 31, 2018)		4,905,780			-
Series B Preferred Shares (par value US$0.0001 per share as of December 31, 2018; 5,281,101 and 0 shares authorized, 5,281,101 and 0 shares issued and outstanding as of December 31, 2018 and June 30, 2019, respectively. Redemption value of US$2,424,712 as of December 31, 2018; Liquidation value of US$24,335,989 as of December 31, 2018)		2,424,712			-
Total mezzanine equity		7,910,748			-

Shareholders’ deficit:
Preferred Stock (par value US$0.0001 per share as of December 31, 2018 and June 30, 2019; 50,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2018 and June 30, 2019		-			-
Common stock (par value US$0.0001 per share as of December 31, 2018 and June 30, 2019; 200,000,000 shares authorized, 6,706,068 and 46,273,846 shares issued and outstanding as of December 31, 2018 and June 30, 2019, respectively)		817			4,627
Additional paid-in capital		14,169,060			36,401,911
Accumulated other comprehensive income		58,564			77,613
Accumulated deficit		(34,323,169	)		(51,519,477	)
Total shareholders’ deficit		(20,094,728	)		(15,035,326	)

TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ DEFICIT	$	5,461,963		$	2,013,560

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED statements of COMPREHENSIVE lOSS

(In U.S. dollars, except share data)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2018			2019			2018			2019
Operating expenses:
Research and development	$	3,873,804		$	1,567,799		$	4,340,206		$	6,892,109
General and administrative		745,286			1,443,731			848,761			10,222,980
General and administrative to related parties		97,638			22,500			146,691			48,408

Total operating expenses		4,716,728			3,034,030			5,335,658			17,163,497
Loss from operations		(4,716,728	)		(3,034,030	)		(5,335,658	)		(17,163,497	)

Other income/(expenses)
Investment income		8,178			-			8,178			-
Interest income		89			-			89			-
Interest expenses to a related party		-			(17,723	)		-			(32,811	)
Loss from operations before income tax benefit		(4,708,461	)		(3,051,753	)		(5,327,391	)		(17,196,308	)

Income tax		-			-			-			-
Net loss		(4,708,461	)		(3,051,753	)		(5,327,391	)		(17,196,308	)

Accretion to preferred share redemption value		(100,292	)		-			(197,608	)		(1,697,978	)

Net loss attributable to ordinary shareholders		(4,808,753	)		(3,051,753	)		(5,524,999	)		(18,894,286	)

Other comprehensive income:
Foreign currency translation adjustment, net of nil income taxes		-			56,040			-			19,049
Total other comprehensive income		-			56,040			-			19,049

Comprehensive loss attributable to ordinary shareholders	$	(4,808,753	)	$	(2,995,713	)	$	(5,524,999	)	$	(18,875,237	)

Weighted average ordinary shares outstanding – basic and diluted		(42,860,772	)		(44,623,568	)		(42,860,772	)		(43,747,040	)

Loss per share - basic and diluted	$	(0.11	)	$	(0.07	)	$	(0.13	)	$	(0.43	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED CHANGES IN SHAREHOLDERS’ DEFICIT

(In U.S. dollars)

	Ordinary				Additional paid-in			Accumulated other comprehensive			Accumulated			Total Shareholders’
	Shares		Amount		capital			income			deficit			Deficit
Balance as of December 31, 2018		8,165,377	$	817	$	14,169,060		$	58,564		$	(34,323,169	)	$	(20,094,728	)
Redeemable convertible preferred shares redemption value accretion		-		-		(1,697,978	)		-			-			(1,697,978	)
Net loss		-		-		-			-			(14,144,555	)		(14,144,555	)
Foreign currency translation adjustment, net of nil income taxes		-		-		-			(36,991	)		-			(36,991	)
Share-based compensation		-		-		7,683,282			-			-			7,683,282
Balance as of March 31, 2019		8,165,377		817		20,154,364			21,573			(48,467,724	)		(28,290,970	)
Issuance of backstop common shares		755,873		76		7,672,035			-			-			7,672,111
Conversion of promissory notes and Rights to common shares		55,000		5		499,995			-			-			500,000
Conversion of Rights to common shares		646,955		64		(64	)		-			-			-
Conversion of Preferred Shares to common shares		34,695,395		3,469		9,605,257			-			-			9,608,726
Combination with Xynomic Pharmaceuticals, Inc.		1,955,246		196		(1,499,359	)		-			-			(1,499,163	)
Foreign currency translation adjustment, net of nil income taxes		-		-		-			56,040			-			56,040
Net loss		-		-		-			-			(3,051,753	)		(3,051,753	)
Share-based compensation		-		-		(30,317	)		-			-			(30,317	)
Balance as of June 30, 2019		46,273,846	$	4,627	$	36,401,911		$	77,613		$	(51,519,477	)	$	(15,035,326	)

XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED statements of cash flows

(In U.S. dollars)

	Six Months Ended June 30,
	2018			2019

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(5,327,391)		$	(17,196,308)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		-			7,652,965
Investment income		(8,178	)		-
Amortization		203			491
Depreciation		-			54,593
Changes in operating assets and liabilities:
Prepaid expenses		(349,272	)		119,758
Prepaid expenses to a shareholder		93,968			-
Other non-current assets		-			(64,827	)
Accrued expenses and other payables		2,583,442			1,500,041
Amount due to shareholders		-			(48,797	)
Net cash used in operating activities		(3,007,228	)		(7,982,084	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of short-term investments		(4,447,904	)		-
Sale of short-term investments		2,807,199			-
Purchase of property and equipment		-			(52,340	)
Cash withdrawn from Trust Account		-			63,310,884
Net cash (used in)/provided by investing activities		(1,640,705	)		63,258,544

CASH FLOWS FROM FINANCING ACTIVITIES:
Bank overdraft		(33,128	)		(2,919	)
Proceeds from advance from a Series B shareholder		1,425,959			-
Repayment of advance from a Series B shareholder		-			(746,811	)
Proceeds from issuance of convertible notes		2,500,000			-
Proceeds from promissory note – related party		-			444,900
Proceeds from short-term loan		906,810			-
Proceeds from issuance of backstop ordinary shares		-			4,971,358
Redemption of ordinary shares		-			(64,070,650	)
Advance from a shareholder		536,905			543,296
Net cash provided by/(used in) financing activities		5,336,546			(58,860,826	)

Effect of foreign exchange rate changes on cash		-			29,940

NET INCREASE/(DECREASE) IN CASH		688,613			(3,554,425	)
CASH, BEGINNING OF THE PERIOD		100,344			4,746,370
CASH, END OF THE PERIOD	$	788,957		$	1,191,944

SUPPLEMENTAL INFORMATION
Interest paid	$	-		$	-
Income tax paid		-			-
Acquisition of property and equipment included in accrued expenses and other liabilities	$	-		$	133,061

The accompany notes are an integral part of these unaudited condensed consolidated financial statements.

XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2019

(In U.S. dollars, except share data)

1.	DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Xynomic Pharmaceuticals Holdings, Inc. (formerly known as Bison Capital Acquisition Corp. , the “Company”) was a blank check company incorporated in the British Virgin Islands on October 7, 2016. The Company was formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities (a “Business Combination”).

All activities through May 14, 2019 relate to the Company’s formation, its initial public offering of 6,037,500 units (the “Initial Public Offering”), the simultaneous sale of 432,062 units (the “Private Units”) in a private placement to the Company’s sponsor, Bison Capital Holding Company Limited (“Bison Capital”) and EarlyBirdCapital, Inc. (“EarlyBirdCapital”) and their designees, identifying a target company for a Business Combination and activities in connection with the proposed acquisition of Xynomic Pharmaceuticals, Inc., a Delaware corporation (“Xynomic Pharma”). On March 3, 2019, the Company received a commitment from Xynomic Pharma that it has agreed to contribute to the Company as a loan $0.02 per month for each public share that is not redeemed by the Company’s shareholders (the “Contribution”) in connection with the Extension Amendment. The amount of the Contribution will not bear interest and will be repayable by the Company to Xynomic Pharma upon consummation of a Business Combination. Xynomic Pharma will have the sole discretion whether to continue extending for additional calendar months until the Combination Period and if Xynomic Pharma determines not to continue extending for additional calendar months, its obligation to make Contributions following such determination will terminate. In May 2019, $16,062 was loaned to the Company and deposited into the Trust Account, which amount is equal to $0.02 for each of the 803,080 shares that were not redeemed.

On May 15, 2019 (the “Effective Time”), each share of Xynomic Pharma’s ordinary shares and preferred shares issued and outstanding prior to the Effective Time was automatically converted into the right to receive, on a pro rata basis, the Closing Consideration Shares (as defined in the Merger Agreement) and the Earnout Shares (as defined in the Merger Agreement), and each option to purchase Xynomic Pharma’s ordinary shares that was outstanding immediately prior to the Effective Time was assumed by the Company and automatically converted into an option to purchase shares of common stock of the Xynomic Pharma. In addition to the Closing Consideration Shares, Xynomic Pharma stockholders received an additional 9,852,216 shares of common stock in aggregate (the “Earnout Shares” and, together with the Closing Consideration Shares, the “Merger Consideration Shares”, such transaction is referred as the “Merger”). As a result, the Company issued 42,860,772 common shares as in aggregate Merger Consideration Shares to shareholders of Xynomic Pharma immediately prior to the Effective Time (the “Sellers”). Pursuant to the Merger Agreement, 1,285,822 shares were deposited into an escrow account (the “Escrow Account”) to serve as security for, and the exclusive source of payment of, the Company’s indemnity rights under the Merger Agreement and any excess of the estimated Closing Merger Consideration over the final Closing Merger Consideration amount determined post-Closing.

Following the Merger, the Xynomic Pharma became a wholly-owned subsidiary of the Company. Xynomic Pharma was incorporated in the United States on August 24, 2016. Xynomic Pharma and its subsidiaries are primarily engaged in in-licensing, developing and commercializing oncology drug candidates in the People’s Republic of China (“PRC”), the United States, and rest of the world. As of the Effective Time, Xynomic Pharma’s subsidiaries are as following:

Subsidiaries	Date of incorporation	Place of incorporation /establishment	Percentage of economic ownership

Xynomic Pharmaceuticals (Nanjing) Co., Ltd. (“Xynomic Nanjing”)	November 20, 2017	PRC		100	%
Xynomic Pharmaceuticals (Shanghai) Co., Ltd. (“Xynomic Shanghai”)	July 31, 2018	PRC		100	%
Xynomic Pharmaceuticals (Zhongshan) Co., Ltd. (“Xynomic Zhongshan”)	May 15, 2018	PRC		100	%

The Merger was accounted for as a “reverse acquisition” since, immediately following the consummation of the Merger (the “Closing”), the Sellers effectively controlled the post-combination Company. For accounting purposes, Xynomic Pharma was deemed to be the accounting acquirer in the Merger and, consequently, the Merger is treated as a recapitalization of Xynomic Pharma (i.e., a capital transaction involving the issuance of shares by the Company for the shares of Xynomic Pharma). Accordingly, the consolidated assets, liabilities and results of operations of Xynomic Pharma became the historical financial statements of the Company and its subsidiaries, and the Company’s assets, liabilities and results of operations were consolidated with Xynomic Pharma beginning at the Closing. No step-up in basis or intangible assets or goodwill were recorded in the Merger.

On May 14, 2019, prior to the Closing, the Company continued out of the British Virgin Islands and domesticated as a Delaware corporation (the “Domestication”). As a result, the Company is no longer a company incorporated in the British Virgin Islands.

At the Closing, pursuant to the Backstop Agreement dated May 1, 2019 entered into by and between the Company and Yinglin Mark Xu, Yinglin Mark Xu, together with his assignee Bison Capital Holding Company Limited, purchased from the Company 755,873 shares of common stock at a price of $10.15 per share for a total consideration of $7,672,111 (the “Backstop Shares” and “Backstop Subscription”). As a result of Backstop Subscription, the Company had at least $7,500,001 of net tangible assets remaining at the Closing after giving effect to the redemption of any Ordinary Shares by the public shareholders in connection with the Merger.

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a)

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the United States Securities and Exchange Commission (“SEC”). The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements of Xynomic Pharmaceuticals, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated balance sheet of the Company and Xynomic Pharma as of December 31, 2018, and the related consolidated statements of comprehensive loss, changes in equity and cash flows for the year then ended, included in the Company’s Proxy Statement/Prospectus on Form 8-K filed with the SEC on May 15, 2019.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of June 30, 2019, the results of operations for the three and six months ended June 30, 2018 and 2019 and cash flows for the six months ended June 30, 2018 and 2019, have been made.

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant accounting estimates include, but not limited to the fair value of the ordinary shares to determine the existence of beneficial conversion feature of the redeemable convertible preferred shares, the fair value of share-based compensation awards, depreciable lives of property and equipment, the recoverability of the carrying amounts of property and equipment and the recoverability of deferred income tax assets. Changes in facts and circumstances may result in revised estimates. Actual results could differ from those estimates, and as such, differences may be material to the unaudited condensed consolidated financial statements.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation

Going Concern

The Company and its subsidiaries Xynomic Pharma, Xynomic Nanjing, Xynomic Shanghai and Xynomic Zhongshan (the “Group”) have not generated any revenues from product sales. Substantial additional financing will be required by the Group to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Group’s research and development efforts will be successful.

The Group’s ability to fund operations is based on its ability to attract investors and its ability to borrow funds on reasonable economic terms. Historically, the Group has relied principally on equity financing and shareholder’s borrowings to fund its operations and business development. The Group’s ability to continue as a going concern is dependent on management’s ability to successfully execute its business plan, which includes generating revenues after drug marketing, controlling operating expenses, as well as, continuing to obtain additional equity financing. On April 3, 2018, Xynomic Pharma issued convertible notes to Northern Light Venture Capital V, Ltd., and Bo Tan and received proceeds of US$2,500,000, which were converted into 776,633 Series B Preferred Shares in August 2018. Further in August 2018, Xynomic Pharma raised US$17 million by issuance of 5,281,101 Series B Preferred Shares to certain investors, including the conversion of convertible notes of US$2.5 million. At the Closing of the Merger, 755,873 shares of Backstop Shares were issued for a total consideration of $7,672,111.

On May 15, 2019, the Company received written notice from the staff of the NASDAQ Stock Market LLC (“Nasdaq”) indicating that the Staff had determined to delist its securities from NASDAQ based upon the non-compliance with the requirement of a minimum of 300 round lot holders of and 400 round lot holders of purchase warrants and the requirement of the minimum US$5 million in stockholders’ equity. The Company requested a hearing before the Nasdaq Hearings Panel (the “Panel”), and such request stayed any suspension or delisting action by Nasdaq pending the completion of the hearing process and the expiration of any extension period that may be granted to the Company by the Panel. On July 15, 2019, the Company was notified in writing by the Panel at Nasdaq that they denied the Company’s request for continued listing on Nasdaq based upon the Company’s non-compliance with Nasdaq Listing Rules 5505(a)(3) and 5515(a)(4). As a result, Nasdaq suspended trading in the Company’s securities effective at the open of business on Wednesday, July 17, 2019; and the Company’s shares will subsequently commence trading on the over-the-counter markets. The Company still intends to continue with its compliance plan with the Nasdaq listing requirements and is diligently pursuing courses of action designed to remedy our noncompliance with Nasdaq’s initial listing requirements as set forth above. There can be no assurance, however, that the Company will be able to regain compliance with the mainboard listing requirements.

The Group currently does not have any commitments to obtain additional funds except the potential private placements in details provided in Note 16 herein below and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Group cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs to: commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including another merger or sale of the Group; or cease operations. If the Group engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process.

The Group has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Group has incurred recurring losses from operations since inception. The Group incurred a net loss of US$3,051,753 and US$17,196,308 for the three and six months ended June 30, 2019, respectively. Further, as of June 30, 2019, the Group had net current liabilities (current assets less current liabilities) of US$15,701,138 and accumulated deficit of US$51,519,477. The Group’s ability to continue as a going concern is dependent on its ability to raise capital to fund its current research and development activities and future business plans. Additionally, volatility in the capital markets and general economic conditions in the United States may be a significant obstacle to raising the required funds. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements included herein do not include any adjustments that might be necessary should the Group be unable to continue as a going concern. If the going concern basis were not appropriate for these financial statements, adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used.

Operations of the Group are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Group’s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Group’s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Group’s financial condition and future operations.

(b)

Share-based Compensation

The Company granted share options to its selected employees and non-employee consultants.

Share-based awards granted to employees with service conditions attached are measured at the grant date fair value and are recognized as an expense using graded vesting method over the requisite service period, which is generally the vesting period. The forfeitures are accounted when they occur.

In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). The new guidance largely aligns the accounting for share-based awards issued to employees and nonemployees. Existing guidance for employee awards will apply to non-employee share-based transactions with limited exceptions. The Company adopted this guidance on January 1, 2019.

Share-based awards granted to non-employees are measured at the grant date fair value. When no future services are required to be performed by the non-employee in exchange for an award of equity instruments, the cost of the award is expensed on the grant date.

Option-pricing models are adopted to measure the value of awards at each grant date. The determination of fair value is affected by the share price as well as assumptions relating to a number of complex and subjective variables, including but not limited to the expected share price volatility, actual and projected employee and non-employee share option exercise behavior, risk-free interest rates and expected dividends. The use of the option-pricing model requires extensive actual employee and non-employee exercise behavior data for the relative probability estimation purpose, and a number of complex assumptions.

(c)

Concentration and risk

Concentration of suppliers

The following suppliers for the Group’s research and development activities accounted for 10% or more of research and development expenses for the three and six months ended June 30, 2018 and 2019:

	For the Three Months Ended											For the Six Months Ended
	June 30,											June 30,
	2018					2019						2018					2019
	US$		%			US$			%			US$		%			US$		%
Supplier A		475,000		12	%		(2,531,472	)(1)		(162	)%		475,000		11	%		*		*
Supplier B		*		*			679,436			43	%		*		*			1,358,361		20	%
Supplier C		2,767,441		71	%		936,542			60	%		2,767,441		64	%		1,299,032		19	%
Supplier D		*		*			1,225,569			78	%		*		*			1,225,569		18	%
Supplier E		*		*			183,694			12	%		*		*			*		*

*	Represents less than 10% of research and development expenses for the three and six months ended June 30, 2018 and 2019.
(1)	Supplier A offered $3.57 million credit to offset previously issued invoices to the Company during the three months ended June 30, 2019.

(d)

Recent accounting pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed consolidated financial statements.

CASH

The Company’s cash is deposited in financial institutions at below locations:

	December 31, 2018		June 30, 2019
Financial institutions in the mainland of the PRC
—Denominated in RMB	$	523	$	61,795

Financial institutions in the United States
—Denominated in USD	$	4,745,847	$	1,130,149

Total cash balances held at financial institutions	$	4,746,370	$	1,191,944

4.	INCOME TAXES

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2019			2018			2019

Loss before income taxes	$	(4,708,461	)	$	(3,051,753	)	$	(5,327,391	)	$	(17,196,308	)
Income tax expenses		-			-			-			-
Effective income tax rate		0	%		0	%		0	%		0	%

The effective income tax rates for the three and six months ended June 30, 2018 and 2019 were 0% and 0%, respectively. The effective income tax rate for the three and six months ended June 30, 2018 and 2019 differs from the U.S. Federal statutory corporate income tax rate of 21% is primarily due to the increase in valuation allowance.

5.	PREPAID EXPENSES

Prepaid expenses consist of the following:

	December 31, 2018		June 30, 2019

Prepaid research and development expenses	$	207,988	$	62,980
Prepaid rental expenses		66,371		66,709
Prepaid health insurance		-		20,658
Others		3,391		5,457
Total prepaid expenses	$	277,750	$	155,805

6.	PROPERTY AND EQUIPMENT, NET

	December 31, 2018			June 30, 2019

Leasehold improvement	$	276,839		$	289,470
Lab equipment		-			195,586
Electronic equipment		4,379			14,153
Property and equipment		281,218			499,209
Less: accumulated depreciation		(488	)		(54,413	)
Property and equipment, net	$	280,730		$	444,796

The depreciation expense for property and equipment was nil and US$30,612 for the three months ended June 30, 2018 and 2019, respectively. The depreciation expense for property and equipment was nil and US$54,593 for the six months ended June 30, 2018 and 2019, respectively.

7.	OTHER NON-CURRENT ASSETS

Other non-current assets consist of the following:

	December 31, 2018		June 30, 2019

VAT input tax	$	52,762	$	86,735
Prepaid insurance		93,075		124,076
Deposits		9,339		8,754
Total other non-current assets	$	155,176	$	219,565

8.	ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consist of the following:

	December 31, 2018		June 30, 2019

Research and development expense-Contract Research Organizations	$	10,304,750	$	10,288,625
Research and development expense-Contract Manufacture Organizations		1,874,956		3,125,901
License fee payable		1,000,000		1,000,000
Professional fee		824,360		1,010,112
Payroll and social insurance		147,692		109,599
Payables for equipment		-		140,465
Payable for leasehold improvement		110,736		105,832
Others		144,767		308,544
Total accrued expenses and other current liabilities	$	14,407,261	$	16,089,078

9.	REDEEMABLE CONVERTIBLE PREFERRED SHARES

Redeemable convertible preferred shares were issued by Xynomic Pharma before the Closing and consist of the following:

	Angel Preferred Shares			Series A-1 Preferred Shares			Series B Preferred Shares
Balance as of December 31, 2018	$	580,256		$	4,905,780		$	2,424,712
Redemption value accretion		11,117			93,984			1,592,877
Conversion to common shares		(591,373	)		(4,999,764	)		(4,017,589	)
Balance as of June 30, 2019	$	-		$	-		$	-

At the Closing, all of the outstanding redeemable convertible preferred shares were converted into 34,695,395 common shares of the Company.

10.

SHAREHOLDERS’ EQUITY

Preferred Shares — The Company is authorized to issue 50,000,000 of preferred shares with $0.0001 par value per share as of June 30, 2019. Before the re-domestication, the Company is authorized to issue an unlimited number of no par value preferred shares, divided into five classes, Class A through Class E, each with such designation, rights and preferences as may be determined by a resolution of the Company’s board of directors to amend the Memorandum and Articles of Association to create such designations, rights and preferences. Upon the re-domestication of the Company, it amended the Charter and the authorized preferred shares to 50,000,000 of preferred shares with $0.0001 par value. At June 30, 2019 and December 31, 2018, there are no preferred shares designated, issued or outstanding.

Common Stock — The Company is authorized to issue 200,000,000 common stocks with $0.0001 par value per share. Holders of the Company’s common stocks are entitled to one vote for each share.

At December 31, 2018, the Company was a blank check company incorporated in the British Virgin Islands and there were 7,978,937 ordinary shares issued and outstanding, among which, 6,037,500 ordinary shares are subject to redemption.

From January 1, 2019 to the Closing of the Business Combination, the Company’s Shareholders holding 6,023,689 public shares exercised their right to redeem such public shares for a pro rata portion of the Trust Account. The Company paid cash in the aggregate amount of $64,070,650, or approximately $10.54 per share, to redeeming shareholders.

On May 14, 2019, prior to the Closing, the Company continued out of the British Virgin Islands and domesticated as a Delaware corporation. As a result, the Company is no longer a company incorporated in the British Virgin Islands, and the ordinary shares converted common stocks with $0.0001 par value per share.

As a result, right before the Closing, the Company had 1,955,246 shares of common stock issued and outstanding, and immediately following the Closing, the Rights that were issued in the Company’s Initial Public Offering and Private Placement automatically converted into 646,955 common shares of the Company.

At the Closing, the Company issued 8,165,377 common shares to holders of Xynomic Pharma’s ordinary shares and 34,695,395 common shares to holders of Xynomic Pharma’s convertible preferred shares as the Merger Consideration Shares. At the same time, the Company issued 755,873 common shares as the Backstop Shares to Yinglin Mark XU and Bison Capital for $7,672,111 considerations, which consisted of $4,971,358 cash consideration from Mark Yinglin XU, conversion of $2,560,753 loans Mark Yinglin XU made to Xynomic Pharma, and conversion of $140,000 loans Bison Capital made to the company.

At the Closing, Bison Capital converted the promissory notes of $500,000 into 50,000 common shares of the Company, and the Right attached to the notes into 5,000 common shares of the Company.

As of June 30, 2019, there were 46,273,846 shares of common stock issued and outstanding.

11.

LOSS PER SHARE

Basic and diluted net loss per share for each of the periods presented are calculated as follow:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2018			2019			2018			2019
Numerator:
Net loss attributable to ordinary shareholders	$	(4,808,753	)	$	(3,051,753	)	$	(5,524,999	)	$	(918,894,286	)
Denominator:
Weighted average number of ordinary shares-basic and diluted		42,860,772			44,623,568			42,860,772			43,747,040
Net loss per share-basic and diluted	$	(0.11	)	$	(0.07	)	$	(0.13	)	$	(0.43	)

When the dividends to preferred shares are not fully paid, the ordinary shares holders shall not participate in undistributed earnings. If all dividends to preferred shares holders are fully paid, the holders of the preferred shares and the holders of the ordinary shares participate in undistributed earnings on a pro rata basis, as if the preferred shares had been converted into ordinary shares.

As a result of the Group’s net loss for the three and six months ended June 30, 2018 and 2019, preferred shares and options outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.

12.

LICENSES ARRANGEMENT

License agreement with Pharmacyclics LLC (“Pharmacyclics”)

In February 2017, the Group entered into a license agreement with Pharmacyclics, under which the Group obtained an exclusive and worldwide license or sublicense under certain patents and know-how of Pharmacyclics to develop, manufacture and commercialize Pharmacyclics’s HDAC inhibitor, also known as Abexinostat, for all human and non-human diagnostic, prophylactic, and therapeutic uses.

In addition, the Group will pay to Pharmacyclics royalties at a flat high-teen percentage rate on the net sales of the licensed products. The Group shall have no obligation to pay any royalty with respect to net sales of any licensed product in any country or other jurisdiction after the royalty term for such licensed product in such country or other jurisdiction has expired.

The license agreement with Pharmacyclics will remain in effect until the expiration of the royalty term and may be early terminated by either party for the other party’s uncured material breach, bankruptcy, insolvency, or similar event. Pharmacyclics has the right to terminate the agreement if the Group challenge Pharmacyclics’ patents or fails its diligent obligations to develop or commercialize the licensed product pursuant to the license agreement with Pharmacyclics. In addition, the Group may terminate this agreement for convenience with advance written notice to Pharmacyclics. In the event this license agreement is terminated for any reason other than Pharmacyclics’ material breach, the Group will be responsible for continuing, at its cost for up to six months, to conduct clinical studies it conducts at the termination and transfer the control of the clinical studies to Pharmacyclics. If such transfer is expressly prohibited by a regulatory authority, the Group will continue to conduct such clinical studies to completion, at the Group’s cost.

Patent assignment and licensing agreement with Boehringer Ingelheim International GMBH (“BII”) (XP-102)

In August 2017, the Group entered into a Patent assignment and licensing agreement with BII, under which the Group accepts the assignment and transfer of the patents and know-how of BII to exclusively develop, manufacture and commercialize BII’s Pan-RAF Inhibitor BI 882370, also known as Dabrafenib, for the diagnosis, prevention or treatment of any and all diseases or conditions in humans or animals. BII retains the exclusive right to use the licensed compound to conduct internal preclinical research.

Under the terms of the agreement, the Group made upfront payments to BII totaling US$0.3 million which was recorded as a research and development expense in 2017. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 1st milestone payment of US$ 1,700,000 upon first dosing of a patient in Phase I Clinical Trial in the US or China; 2) 2nd milestone payment of US$ 4,000,000 upon first dosing of a patient in a pivotal Phase III Clinical Trial in the first indication in the US or China; 3) 3rd milestone payment of US$2,000,000 upon first dosing of a patient in a pivotal Phase III Clinical Trial in a second indication in the US or China; 4) 4th milestone payment of US$ 7,000,000 upon the grant of the first marketing authorization of the first indication in the US; 5) 5th milestone payment of US$3,000,000 upon the grant of the first marketing authorization of the first indication in China.

In addition, the Group will pay royalties at a certain percentage of the net sales. The royalty term commences from the first commercial sale of such licensed product in such country until the later of (i) the date on which such licensed product is no longer covered by a valid claim of the assigned patents and assigned invention, (ii) the expiration of regulatory exclusivity of the licensed product in such country, or (iii) the tenth anniversary of the first launch of the respective licensed product in the country, provided the licensed know-how is still proprietary, or such licensed know-how is no longer proprietary owing to a breach of its confidentiality obligations.

The Group has the right to terminate this agreement by providing BII with written notice.

License agreement with BII (XP-105)

In December 2018, Xynomic entered into a license agreement with BII for the worldwide exclusive rights to develop and commercialize XP-105 (also known as BI 860585) for all human and non-human diagnostic, prophylactic, and therapeutic uses.

Under the terms of the agreement, as of June 30, 2019 the Group was obligated to make upfront payments to BII totaling US$1 million which was recorded as a research and development expense for the year ended December 31, 2018 and was included in accrued expenses and other current liabilities as of December 31, 2018. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 1st milestone payment of US$7,000,000 upon first dosing of a patient in Phase II or Phase III Clinical Trial in the first indication either of which is intended to be a pivotal trial; 2) 2nd milestone payment of US$10,000,000 upon the grant of the first Marketing Authorization of the first indication.

In addition, the Group will pay royalties at a certain percentage of the net sales. The royalty term commences from the first commercial sale of such licensed product in such country until the later of (i) the date on which such licensed product is no longer covered by a valid claim of the licensed patents, (ii) the expiration of regulatory exclusivity of the licensed product in such country, or (iii) the tenth anniversary of the first launch of the respective licensed product in the country in the indication, provided the licensed know-how is still proprietary, or such licensed know-how is no longer proprietary owing to a breach of its confidentiality obligations.

The Group has the right to terminate this agreement by providing BII with written notice.

13.

COMMITMENTS AND CONTINGENCIES

(a)

Lease commitments

The Group entered into non-cancelable operating leases, primarily for office space, for initial terms of 12 to 36 months. Minimum rent payments under operating leases are recognized on a straight-line basis over the term of the lease.

Future minimum lease payments under non-cancelable operating leases with remaining lease terms in excess of one year as of June 30, 2019 are:

	Minimum Lease Payment Amount
Year ending June 30, 2019,
2020	$	241,099
2021		236,467
2022		129,658
	$	607,224

Rental expenses for operating leases for the three months ended June 30, 2018 and 2019 were US$24,249 and US$98,434, respectively. Rental expenses for operating leases for the six months ended June 30, 2018 and 2019 were US$40,275 and US$146,598, respectively.

(b)

Registration Rights

Upon the Closing, the Company entered into an amended and restated registration rights agreement with certain existing investors of Bison (including its sponsor), Mark Yinglin Xu (together with his assignee, the “Backstop Investor”) and the Sellers. Pursuant to this registration rights agreement, the Company has agreed to register for resale under the Securities Act of 1993, as amended (1) all or any portion of the 1,509,375 shares of common stock of Bison issued to certain existing investors (the “Founder Shares”), (2) 432,063 private units issued by Bison to certain existing investors in conjunction with the consummation of its initial public offering (the “Private Units”), (3) any private units which may be issued by Bison in payment of working capital loans made to Bison (the “Working Capital Units”, together with Founder Shares, Private Units, the “Existing Registrable Securities”), (4) the Backstop Shares, and (5) the Merger Consideration Share (the “Newly Issued Shares”). The Backstop Shares, Newly issued Shares and the Existing Registrable Securities and any securities of Bison issued as a dividend or distribution with respect thereto or in exchange therefor are referred as the “Registrable Securities”. At any time and from time to time on or after (i) the one month anniversary of the Closing with respect to the Private Units or Working Capital Units, (ii) three months prior to the release of the Founder Shares under the terms of a certain escrow agreement; (iii) the Closing Date with respect to the Backstop Shares, or (iv) nine months after the Closing with respect to the Newly Issued Shares, the holders of a majority of (i) all of the Existing Registrable Securities, (ii) all of the Backstop Shares, or (iii) all of the Newly Issued Shares, calculated on an as-converted basis, may make a written demand for registration under the Securities Act of all or part of their Registrable Securities, and other holders of the Registrable Securities will be entitled to join in such demand registration, provided that the Company shall not be obliged to effect more than two demand registrations in any one year period or more than an aggregate of three demand registrations.

Subject to certain exceptions, if at any time on or after the Closing, the Company proposes to file a registration statement under the Securities Act with respect to an offering of equity securities, under the Registration Rights Agreement, the Company shall give written notice of such proposed filing to the holders of the Registrable Securities and offer them an opportunity to register the sale of such number of Registrable Securities as such holders may request in writing, subject to customary cut-backs.

In addition, subject to certain exceptions, the holders of a majority of (i) all of the Existing Registrable Securities, (ii) all of the Backstop Shares, or (iii) all of the Newly Issued Shares, calculated on an as-converted basis, are entitled under the Registration Rights Agreement to request in writing that the Company register the resale of any or all of such Registrable Securities on Form S-3 or any similar short-form registration that may be available at such time.

The Company agrees to use commercially reasonable efforts to effect the registration and sale of such Registrable Securities in accordance with the registration rights described above as expeditiously as practicable. In addition, the Company agrees to use reasonable best efforts to cause registration with respect to the Backstop Shares to be declared effective no later than one-hundred and eighty (180) days following the Closing Date.

(c)

Other commitments

The Group is a party to or assignee of license and collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (Note 12).

(d)

Legal contingencies

On July 12, 2019, one of the Contract Research Organizations (the “Plaintiff”) of Xynomic Pharma filed a complaint in the Complex Commercial Litigation Division of the Superior Court of the State of Delaware against Xynonmic Pharma for breach of a contract under which Xynomic Pharma engaged the Plaintiff to provide services relating to drug development research, and Xynomic Pharma allegedly failed to pay the amount due to the Plaintiff for the services performed. The Plaintiff seeks $6,992,068 from Xynomic Pharma, plus interest at the contract rate of 1% per month. Xynomic Pharma must respond to the complaint by August 19, 2019.

As of June 30, 2019, Xynomic Pharma had $7,078,037 payable to the Plaintiff, including $273,467 accrued interest according to the contract.

14.

RELATED PARTY TRANSACTIONS

(a)

Amount due to shareholders

Payable due to a shareholder

For the three months ended June 30, 2018 and 2019, Yinglin Mark Xu, the founder and CEO of Xynomic Pharma, advanced US$38,683 and US$130,335, respectively, to Xynomic Pharma to fund its operation. For the six months ended June 30, 2018 and 2019, Yingling Mark XU advanced US$536,905 and US$543,296, respectively.

At the Closing date, the amount due to Yingling Mark XU was $2,560,754 and was fully converted to be part of the consideration to purchase Backstop Shares.

As of December 31, 2018 and June 30, 2019, the amount due to Yinglin Mark XU was US$2,008,936 and US$0, respectively.

ii)

Services purchased from a company affiliated with a shareholder

Eigenbridge, Inc., a company affiliated with Yong Cui, one of Xynomic Pharma’s shareholders and Vice President of Chemistry, Manufacturing and Controls, entered into a contractor agreement with Xynomic Pharma on February 26, 2017. Pursuant to the agreement, Eigenbridge, Inc., provided specialized advisory services to Xynomic Pharma. Xynomic Pharma recognized general and administrative of US$52,723 and US$0 for the three months ended June 30, 2018 and 2019, respectively. Xynomic Pharma recognized general and administrative of US$52,723 and US$25,908 for the six months ended June 30, 2018 and 2019, respectively. The amount due to Eigenbridge, Inc., were US$80,640 and US$0 as of December 31, 2018 and June 30, 2019, respectively.

iii)

Advances from and interest payable to a shareholder

On May 2, 2018, as one of the potential investors of Series B financing, Zhongshan Bison Healthcare Investment Limited (Limited Partnership) (“Zhongshan Bison”) entered into a loan agreement with Xynomic Pharmaceuticals (Nanjing) Co., Ltd. (“Xynomic Nanjing”). On May 13, 2018, Zhongshan Bison made an advance of RMB9,435,000 (equivalent to US$1,425,959) to fund the operations and business development of Xynomic Nanjing. Zhongshan Bison is entitled to withdraw the advance within 5 business days after Zhongshan Bison paid the first investment of Series B financing, or if current shareholders and investors fail to subscribe shares of the Series B financing within 6 months.

On August 16, 2018, Zhongshan Bison became one of the Series B Preferred Shareholders.

On August 23, 2018, Xynomic Nanjing entered into a termination agreement for the advance from Zhongshan Bison. Xynomic Nanjing is required to a) repay RMB1,800,000 of the advance from Zhongshan Bison within 2 days after signing the agreement; and b) repay the remaining RMB7,635,000 of the advance from Zhongshan Bison and interest accrued at annual interest rate of 8% from signing the agreement within six months from the date of the termination agreement.

On August 23, 2018, Xynomic Nanjing repaid RMB1,800,000 (equivalent to US$262,743) of the advance from Zhongshan Bison. As of December 31, 2018, the advance from Zhongshan Bison was US$1,112,455.

On January 21, 2019, Xynomic Nanjing repaid RMB5,064,000 (equivalent to US$747,189) of the advance from Zhongshan Bison. On February 20, 2019, Zhongshan Bison agreed to extend the due date of the remaining advance of RMB2,571,000 (US$383,097) and all accrued interest to April 15, 2019. On April 12, 2019, Zhongshan Bison agreed to further extend the due date of the remaining advance of RMB2,571,000 (US$383,097) and all accrued interest to June 30, 2019. On June 30, 2019, the due date was further extended to September 15, 2019.

Xynomic Nanjing accrued interest expense of US$17,723 for the advance from Zhongshan Bison for the three months ended June 30, 2019. Xynomic Nanjing accrued interest expense of US$32,811 for the advance from Zhongshan Bison for the six months ended June 30, 2019. The interest payable to Zhongshan Bison was US$31,697 and US$64,093 as of December 31, 2018 and June 30, 2019, respectively.

iv)

Promissory note to a shareholder

In order to finance transaction costs in connection with a Business Combination, Bison Capital or the Company’s officers and directors or their respective affiliates may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $500,000 of notes may be converted upon consummation of a Business Combination into additional Private Units at a price of $10.00 per unit (the “Working Capital Units”). As of May 14, 2019, Bison Capital has loaned the Company an aggregate of $500,000, which is evidenced by a promissory note, non-interest bearing, unsecured and payable in cash or convertible in Private Units at $10.00 per unit, at Bison Capital’s discretion, on the consummation of a Business Combination.

In February 2019, $100,000 of loans from Bison Capital were converted into convertible promissory loans and is included in the $500,000 outstanding amount noted above. In addition, as of June 30, 2019, Bison Capital has loaned the Company an aggregate amount of $404,900 in order to finance transaction costs in connection with the Business Combination. The loan is non-interest bearing, unsecured and due to be paid on the consummation of a Business Combination.

At the Closing, Bison Capital converted the $500,000 convertible promissory note to 50,000 common shares of the Company, and converted the Right attached to it into 5,000 common shares of the Company.

At June 30, 2019, an aggregate of $404,900 is owed by the Company to Bison Capital pursuant to the above loans.

(b)

Service purchased from a shareholder

In June 2017, the Group paid US$295,021 to Bridge Pharm International Inc., one of the Company’s shareholders, pursuant to 20 months services agreement. Under the agreement, Bridge Pharm International Inc. provides consulting service, including business development, screening and selection of contract research organizations and contract manufacturing organizations and scouting and references of key scientific and managerial personnel to the Group. The Company recognized general and administrative of US$44,915 and nil for the three months ended June 30, 2018 and 2019, respectively. The Company recognized general and administrative of US$93,968 and nil for the six months ended June 30, 2018 and 2019, respectively. The balance related to the Bridge Pharm International Inc. was nil as of December 31, 2018 and June 30, 2019.

(c)

Administrative Services Arrangement

Bison Capital entered into an agreement whereby, commencing on June 19, 2017 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to make available to the Company certain general and administrative services, including office space, utilities and administrative services, as the Company may require from time to time. The Company will pay Bison Capital $5,000 per month for these services. For the three months ended June 30, 2018 and 2019, the Company incurred $15,000 and $7,500, respectively, in fees for these services. or the six months ended June 30, 2018 and 2019, the Company incurred $27,500 and $22,500, respectively, in fees for these services. At June 30, 2019 and December 31, 2018, $112,500 and $90,000 in administrative fees, respectively, are included in accounts payable and accrued expenses in the accompanying condensed balance sheets.

15.

SHARE-BASED COMPENSATION

2018 Stock Incentive Plan

On August 28, 2018, the Board of Directors of Xynomic Pharma approved a resolution to adopt the 2018 Stock Incentive Plan (the “2018 Plan”) that provides for the granting of options to selected employees, directors and non-employee consultants to acquire ordinary shares of the Company at exercise prices determined by the Board or the administrator appointed by the Board at the time of grant. Upon this resolution, the Board of Directors and shareholders authorized and reserved 8,908,430 ordinary shares for the issuance under the 2018 Plan. The number of ordinary shares available under the Plan shall increase annually on the first day of each fiscal year, beginning with the second fiscal year following the effective date of this Plan, and continuing until (and including) the fiscal year ending December 31, 2028, with such annual increase equal to the lesser of (i) 3,000,000 ordinary shares, (ii) 5% of the number of ordinary shares issued and outstanding on December 31 of the immediately preceding calendar year, and (iii) an amount determined by the Board. As of December 31, 2018 and June 30, 2019, 8,908,430 and 8,022,384 awards remain available for future grants under the 2018 Plan, respectively.

Under the 2018 Plan, Xynomic Pharma granted 886,046 ordinary shares of the Company with the below vesting schedule on January 21, 2019:

Granted to an employee (100,000 shares): 25% of the options is to be vested on April 30, 2019, and 1/48 of the options to be vested each month thereafter. The employee resigned from Xynomic Pharma in May 2019 and the remaining unvested 75% of the options were forfeited.

Granted to a non-employee (786,046 shares): 25% of the options is to be vested on August 31, 2019, and 1/48 of the options to be vested each month thereafter, subject to an acceleration vesting schedule that 75% is to be issued upon completion of Xynomic Pharma’s merger with Bison Capital Acquisition Corp, and 25% to be issued in one year after the closing of the merger. The cost of the share options granted to the non-employee was fully recognized at the grant date, as no substantive future services are required. At the Closing, each option to purchase Xynomic stock that was outstanding immediately prior to the Effective Time was assumed by the Company and automatically converted into an option to purchase shares of common stock of the Company.

Summary of Share Option Activities

The following tables summarize the Company’s share option activities for the six months ended June 30, 2019:

				Weighted		Weighted
				average		remaining		Aggregate
	Number of			exercise		contractual		intrinsic
Granted to Employee	shares			price		years		value
				US$				US$
Outstanding at January 1, 2019		-			-				-

Granted		100,000			1.00

Forfeited		(75,000	)		1.00

Outstanding at June 30, 2019		25,000			1.00		9.57		215,050
Exercisable as of June 30, 2019		25,000			1.00		9.57		215,050

			Weighted		Weighted
			average		remaining		Aggregate
	Number of		exercise		contractual		intrinsic
Granted to Non-employee	shares		price		years		value
			US$				US$
Outstanding at January 1, 2019		-		-				-

Granted		786,046		0.10

Forfeited		-		-

Outstanding at June 30, 2019		786,046		0.10		9.57		7,433,873
Exercisable as of June 30, 2019		589,535		0.10		9.57		5,578,436

No options were exercised during the six months ended June 30, 2019.

Management is responsible for determining the fair value of options granted to employees and non-employees and considered a number of factors including valuations. The Company’s share-based compensation cost is measured at the fair value of the options as calculated under the binomial models.

Assumptions used in the option-pricing model are presented below:

	2019
Risk-free interest rate		2.77	%
Expected term		10 years
Volatility rate		36.1	%
Dividend yield		0	%
Exercise multiple		2.8
Fair value of underlying ordinary share		9.5573

The Company estimated the risk-free rates based on the 10-year U.S. bond as at the option valuation date. Life of the share options is the contract life of the option. Based on the option agreements, the contract life of the option are 10 years from the respective grant date. The expected volatility at the option valuation date was estimated based on historical volatility of comparable companies. The Company has no history or expectation of paying dividends on its ordinary shares. The Company estimated the fair value of the ordinary shares using the equity allocation approach when valuing options granted. As the Company did not have sufficient information of past employee exercise history, the expected exercise multiple was estimated by referencing to How to Value Employee Stock Options (published by John Hull& Allen White, Financial Analysts Journal, 2004 edition), a well-accepted academic publication.

The grant date fair value of the share options granted for the six months ended June 30, 2019 was US$9.3653. Compensation expense of US$7,652,965 were recognized in general and administrative relating to the 886,046 options for the six months ended June 30, 2019. US$30,317 of the general and administrative expense was reversed during the three months ended June 30,2019 due to the employee’s resignation and the forfeiture of the unvested options.

As of June 30, 2019, there was nil unrecognized compensation expenses related to non-vested options.

16.

SUBSEQUENT EVENT

Security Purchase Agreement with Accredited Investors

On or about July 10, 2019, the Company entered into certain Securities Purchase Agreement (the “SPA”) with certain “accredited investors” as defined in Rule 501(a) of Regulation D as promulgated under the Securities Act of 1933, as amended (the “Purchasers”), pursuant to which the Company agreed to sell to such Purchasers an aggregate of approximate USD$10 million of units (the “Reg. D Units”) of the Company, at a purchase price of USD$3.80 per Unit (subject to adjustment) (the “Reg. D Offering”). Each Reg. D Unit consists of one share of common stock and one-half warrant (the “Reg. D Warrant”). Each whole Reg. D Warrant can be exercised to purchase one share of the Company Stock at $7.00 per share and shall expire in three (3) years of the issuance, and have the rights and preference set forth in certain Warrant Agreement. Furthermore, the SPA provides, among other terms, a maximum offering in an aggregate of $15 million with the first closing of a minimum of $5 million upon delivery of the closing conditions set forth in the SPA, provided that no closing shall occur after September 30, 2019 subject to certain exception.

The Reg. D Units, the shares of common stock underlying the Reg. D Units (the “Reg.D Unit Shares”), the Reg. D Warrants issued in the Reg.D Offering, and shares of common stock issuable upon exercise of the Reg. D Warrants (the “Reg.D Warrant Shares”), are exempt from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D.

With delisting from Nasdaq occurred subsequently, the parties have started to renegotiate the terms of the SPA including potential waiver of certain closing conditions.

Delisting from Nasdaq

On July 15, 2019, the Company was notified in writing by the Panel at Nasdaq that they have denied its request for continued listing on Nasdaq based upon the Company’s non-compliance with Nasdaq Listing Rules 5505(a)(3) and 5515(a)(4), which require a minimum of 300 round lot holders of common stock and 400 round lot holders of common stock purchase warrants for initial listing on Nasdaq; as well as non-compliance with the minimum $5 million in stockholders’ equity requirement, as set forth in Nasdaq Listing Rule 5505(b)(1)(A). As a result, Nasdaq suspended trading in the Company’s securities effective at the open of business on Wednesday, July 17, 2019; and the shares subsequently commenced trading on the over-the-counter markets.

Special Meeting of Stockholders

On July 26, 2019, the Company called for a Special Meeting of its stockholders be held on August 26, 2019 for the purpose of authorizing the Company’s Board of Directors to, in its discretion, to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio no less than 1-for-1.5 and no greater than 1-for-5 at any time prior to August 27, 2020, with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders (“Stock Split Proposal”). The Board of Directors may alternatively elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read together with our financial statements and the related notes appearing elsewhere in this Form 10-Q. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements” for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under “Risk Factors” and elsewhere in this Form 10-Q.

Overview

Prior to the consummation of the Business Combination with Xynomomic Pharmaceuticals, Inc., a Delaware corporation (“Xynomic”) on May 15, 2019, we were a blank check company formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities. As a result of the Business Combination, we now are a clinical stage biopharmaceutical company that discovers and develops innovative small molecule drug candidates for the treatment of cancer in humans. Our approach is to focus on drug candidates that target both hematological malignancies and solid tumors. Our lead drug candidate is abexinostat, an orally dosed, hydroxamic acid-based small molecule histone deacetylase (“HDAC”) inhibitor. Our other clinical stage drug candidate is XP-105, an orally bioavailable kinase inhibitor, which inhibits both raptor-mTOR complex 1 and rictor-mTOR complex 2. In addition, Xynomic has several pre-clinical oncology drug candidates in its pipeline. Among these drug candidates, XP-102 (also known as BI 882370), a selective RAF inhibitor, is the closest to clinical testing. The following is a summary of our product development pipeline:

We have not completed any clinical trials since our inception. With respect to the pipeline programs referenced in the above figure, all of the completed clinical trials of abexinostat were conducted by or on behalf of either Pharmacyclics LLC (“Pharmacyclics”) or Servier Laboratories and the one completed clinical trial of XP-105 was conducted by or on behalf of Boehringer Ingelheim International GmbH (“Boehringer Ingelheim” or “BII”). We have obtained exclusive rights to use all the data generated in these previously completed clinical trial.

●

Abexinostat – our most advanced drug candidate, abexinostat, has been evaluated in 18 Phase 1/2 clinical trials for lymphoma and solid tumors. In February 2017, Xynomic entered into a license agreement with Pharmacyclics for the worldwide exclusive rights to develop and commercialize abexinostat for all human and non-human diagnostic, prophylactic, and therapeutic uses. Since its in-licensing of abexinostat, Xynomic has started enrolling patients in clinical trials for three different indications: (1) in follicular lymphoma, as a monotherapy, (2) in renal cell carcinoma, in combination with pazopanib, and (3) in multiple solid tumors, in combination with Keytruda^®. In addition, Xynomic plans to initiate four clinical trials of abexinostat in the next six months.

●

XP-105 (also known as BI 860585) – In December 2018, Xynomic entered into a license agreement with Boehringer Ingelheim for the worldwide exclusive rights to develop and commercialize XP-105 (also known as BI 860585) for all human and non-human diagnostic, prophylactic, and therapeutic uses. Prior to this license, BII had completed one Phase 1 clinical trial for solid tumors. Xynomic plans to initiate two clinical trials of XP-105 in late 2019.

●

Pre-Clinical Programs – In addition, Xynomic has several pre-clinical oncology drug candidates in its pipeline. Among these drug candidates, XP-102 (also known as BI 882370), a selective RAF inhibitor to which Xynomic obtained a worldwide exclusive license from Boehringer Ingelheim, is the closest to clinical testing.

As of the date of this report, the Company has received approval from National Medical Products Administration of the People’s Republic of China (excluding Taiwan, Hong Kong and Macau for purposes of this report, “China”) to start two pivotal clinical trials in China. In these two trials, the Company will test its lead drug candidate abexinostat (as a single agent) as a third-line treatment of diffuse large B-cell lymphoma (“DLBCL”) and as a third-line treatment of follicular lymphoma (“FL”), respectively. It has also filed an application with the U.S. Food and Drug Administration (“U.S. FDA”) seeking Fast-Track designation for its drug candidate abexinostat as a monotherapy for the treatment of relapsed or refractory follicular lymphoma (“r/r FL”).

Business Combination:

On September 12, 2018, Bison Capital Acquisition Corp., our processor at that time (“Bison”) entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with (i) Xynomic; (ii) Bison Capital Merger Sub Inc., a Delaware corporation (“Merger Sub”) (iii) Mark Xu (“Stockholder Representative”), solely in his capacity as the Stockholder Representative thereunder.

On March 21, 2019, Bison’s stockholders approved the following items: (i) an amendment to the Bison’s Amended and Restated Memorandum of Association and Articles of Association extending the date by which Bison must consummate its initial business combination and the date for cessation of operations of Bison if Bison has not completed an initial business combination from March 23, 2019 to June 24, 2019 or such earlier date as determined by the Board of Directors of Bison and (ii) an amendment (the “Amendment to Trust Agreement”) to the Trust Agreement (the “Trust Agreement”) between Bison and the trust agent extending the date on which to commence liquidation of the Trust Account in accordance with the Trust Agreement, as amended by the Amendment to Trust Agreement, from March 23, 2019 to June 24, 2019.

On May 15, 2019 (the “Closing Date”), Bison consummated the previously announced business combination (the “Business Combination”) following a special meeting of shareholders held on May 14, 2019 (the “Special Meeting”) where the shareholders of Bison, which, prior to the consummation of the Business Combination, domesticated as a Delaware corporation and, immediately thereafter known as “Xynomic Pharmaceuticals Holdings, Inc.”, considered and approved, among other matters, a proposal to adopt the Merger Agreement.

Pursuant to the Merger Agreement, among other things, Merger Sub merged with and into Xynomic, with Xynomic continuing as the surviving entity and a wholly-owned subsidiary of the Company (the “Merger” and the “Surviving Company”). The merger became effective on May 15, 2019.

On May 14, 2019, prior to the consummation of the Business Combination, Bison continued out of the British Virgin Islands and domesticated as a Delaware corporation (the “Domestication”). As a result, Bison is no longer a company incorporated in the British Virgin Islands.

At the Closing Date, pursuant to the Backstop Agreement dated May 1, 2019 entered into by and between Bison and Yinglin Mark Xu, Mr. Xu together with his assignee Bison Capital Holding Company Limited, purchased from the Company 755,873 shares of common stock at a price of $10.15 per share for a total consideration of $7,672,111 (the “Backstop Shares” and “Backstop Subscription”). As a result of Backstop Subscription, Bison had at least $7,500,001 of net tangible assets remaining at the Closing after giving effect to the redemption of any ordinary shares, no par value, of Bison, by the public shareholders in connection with the Business Combination.

At the Closing Date, each share of Xynomic common stock and preferred stock issued and outstanding prior to May 15, 2019 (the “Effective Time”) was automatically converted into the right to receive, on a pro rata basis, the Closing Consideration Shares (as defined below) and the Earnout Shares (as defined below), and each option to purchase Xynomic stock that was outstanding immediately prior to the Effective Time was assumed by the Company and automatically converted into an option to purchase shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”).

At the Closing Date, pursuant to the Merger Agreement, all the stockholders of Xynomic immediately prior to the closing of the Business Combination (“Xynomic stockholders”) received a number of newly issued shares of Company common stock equal to the Closing Merger Consideration divided by $10.15 per share (the “Closing Consideration Shares”). The Closing Merger Consideration equals to (a) $350,000,000, minus (i) the amount of Xynomic’s closing indebtedness, plus (ii) the amount of Xynomic’s closing cash, minus (iii) the amount of Xynomic’s transaction expenses, plus (iv) certain closing tax assets, plus (v) the amount, if any, by which Xynomic’s closing working capital exceeds an agreed upon target amount of working capital, minus (vi) the amount, if any, by which such target amount of working capital exceeds Xynomic’s closing working capital.

In addition to the Closing Consideration Shares, Xynomic stockholders received an additional 9,852,216 shares of common stock in aggregate (the “Earnout Shares” and, together with the Closing Consideration Shares, the “Merger Consideration Shares”). As a result, the Company issued 42,860,772 common shares as in aggregate Merger Consideration Shares to shareholders of Xynomic immediately prior to the closing (the “Sellers”).

Pursuant to the Merger Agreement, 1,285,822 shares were deposited into an escrow account (the “Escrow Account”) to serve as security for, and the exclusive source of payment of, the Company’s indemnity rights under the Merger Agreement and any excess of the estimated Closing Merger Consideration over the final Closing Merger Consideration amount determined post-Closing.

As a result of the Business Combination, the Sellers, as the former shareholders of Xynomic, became the controlling shareholders of the Company and Xynomic became a subsidiary of the Company. The Business Combination was accounted for as a reverse merger, wherein Xynomic is considered the acquirer for accounting and financial reporting purposes.

Prior to the Business Combination, we were a “shell company” (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended). As a result of the Business Combination, we have ceased to be a “shell company” and will continue the existing business operations of Xynomic as a publicly traded company under the name “Xynomic Pharmaceuticals Holdings, Inc.”

Nasdaq Listing Compliance

On May 15, 2019, we received written notice from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that the Staff had determined to delist the Company’s securities from Nasdaq based upon the Company’s non-compliance with Nasdaq Listing Rules 5505(a)(3) and 5515(a)(4), which require a minimum of 300 round lot holders of common stock and 400 round lot holders of common stock purchase warrants for initial listing on The Nasdaq Capital Market. The Staff’s determination also cited the Company’s non-compliance with the minimum $5 million in stockholders’ equity requirement, as set forth in Nasdaq Listing Rule 5505(b)(1)(A).

Upon request, a hearing before the Hearings Panel at Nasdaq (the “Panel”) was held on July 11, 2019. On July 15, 2019, we were notified in writing by the Panel that they denied our request for continued listing on Nasdaq based upon the Company’s non-compliance with Nasdaq Listing Rules 5505(a)(3), 5515(a)(4), and 5505(b)(1)(A). As a result, Nasdaq suspended trading in the Company’s securities effective at the open of business on Wednesday, July 17, 2019; and our shares subsequently commenced trading on the over-the-counter markets.

We still intend to continue with its compliance plan with the Nasdaq listing requirements and is diligently pursuing courses of action designed to remedy our noncompliance with Nasdaq’s initial listing requirements as set forth above. There can be no assurance, however, that the Company will be able to regain compliance with the mainboard listing requirements.

Reg. D Offering

On or about July 10, 2019, we entered into certain Securities Purchase Agreement (the “SPA”) with certain “accredited investors” as defined in Rule 501(a) of Regulation D as promulgated under the Securities Act, pursuant to which we agreed to sell to such purchasers an aggregate of approximate USD$10 million of units (the “Reg. D. Units”) of the Company, at a purchase price of USD$3.80 per Reg. D Unit (subject to adjustment) (the “Reg. D Offering”). Each Reg. D Unit consists of one share of Common Stock and one-half warrant (the “Reg. D Warrant”). Each whole Reg. D Warrant can be exercised to purchase one share of Common Stock at $7.00 per share and shall expire in three (3) years of the issuance, and have the rights and preference set forth in certain warrant agreement. Furthermore, the SPA provides, among other terms, a maximum offering in an aggregate of $15 million with the first closing of a minimum of $5 million upon delivery of the closing conditions set forth in the SPA, provided that no closing shall occur after September 30, 2019 subject to certain exception.

The Reg. D Units, the shares of Common Stock underlying the Reg. D Units (the “Reg. D Unit Shares”), the Reg. D Warrants issued in the Reg. D Offering, and shares of Common Stock issuable upon exercise of the Reg. D Warrants (the “Reg. D Warrant Shares”), are exempt from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D.

The proceeds of this Reg. D Offering will be used for working capital and general corporate purposes.

The SPA also contains customary representation and warranties of the Company and the purchasers, indemnification obligations of the Company, termination provisions, and other obligations and rights of the parties. Additionally, we anticipate that the purchasers will enter into a lock-up agreement at the closing pursuant to which that they would agree not to sell or otherwise transfer or dispose the Reg. D Units, Reg. D Unit Shares, Reg. D Warrants, or Reg. D Warrant Shares during the six-month period commencing on the earlier of the effective date of a registration statement in connection with the first follow-on public offering after the date of the SPA or the issuance date of the Reg. D Units.

The Form of the SPA and the Form of the Reg. D Warrants are filed as Exhibits 10.22 and 10.23 to this prospectus, respectively; and such documents are incorporated herein by reference. The foregoing is only a brief description of the material terms of the SPA and the Reg. D Warrants, and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibits.

With the delisting from Nasdaq occurred subsequently, the parties have started to renegotiate the terms of the SPA.

Special Meeting of Stockholders

On July 26, 2019, the Company called for a Special Meeting of its stockholders to be held on August 26, 2019 for the purpose of authorizing the Company’s Board of Directors to, in its discretion, to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio no less than 1-for-1.5 and no greater than 1-for-5 at any time prior to August 27, 2020, with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders (“Stock Split Proposal”). The Board of Directors may alternatively elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Financial Condition

As of June 30, 2019, we operate through wholly-owned subsidiary in the United States, Xynomic Pharmaceuticals, Inc., which has one wholly owned subsidiary in China, Xynomic Pharmaceuticals (Nanjing) Co., Ltd.. Xynomic Pharmaceuticals (Nanjing) Co., Ltd. has two wholly owned subsidiaries, namely Xynomic Pharmaceuticals (Zhongshan) Co., Ltd. and Xynomic Pharmaceuticals (Shanghai) Co., Ltd. We consolidated our financial statements in accordance with U.S. GAAP.

To date, we have not generated any revenue. In the future, we will seek to generate revenue from drug sales and potential strategic relationships. Assuming we commence abexinostat’s pivotal clinical trials in Florida, one ongoing in the U.S. and Europe and another expected in China and such trials generate satisfactory efficacy and safety data to a commercialization approval, the earliest time we would seek to commercialize abexinostat in any region is 2020.

Since we have not generated any revenues from product sales, substantial additional financing will be required to continue to fund our research and development activities. No assurance can be given that any such financing will be available when needed or that our research and development efforts will be successful.

Our ability to fund operations is based on our ability to attract investors and our ability to borrow funds on reasonable economic terms. Historically, we have relied principally on equity financing and shareholder’s borrowings to fund our operations and business development. Our ability to continue as a going concern is dependent on management’s ability to successfully execute our business plan, which includes generating revenues after drug marketing, controlling operating expenses, as well as, continuing to obtain additional equity financing. On April 3, 2018, we issued convertible notes to Northern Light Venture Capital V, Ltd., and Bo Tan and received proceeds of US$2,500,000, which were converted into 776,633 Series B Preferred Shares in August 2018. Further in August 2018, we raised US$17 million by issuance of 5,281,101 Series B Preferred Shares to certain investors, including the conversion of convertible notes of US$2.5 million. On May 15, 2019, we closed the business combination pursuant to an Agreement and Plan of Merger dated September 12, 2018. In connection with the consummation of the business Combination, pursuant to the Backstop Agreement dated May 1, 2019 entered into by and between Bison and Yinglin Mark Xu, Mr. Xu together with his assignee Bison Capital Holding Company Limited, purchased 755,873 shares of common stock at a price of $10.15 per share for a total consideration of $7,672,111 .

We currently do not have any commitments to obtain additional funds except the potential Reg. D Offering that we are contemplating; and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If we cannot obtain the necessary funding, we will need to delay, scale back or eliminate some or all of our research and development programs to: commercialize potential products or technologies that we might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including another merger or sale of the Company; or cease operations. If we engage in collaborations, we may receive lower consideration upon commercialization of such products than if we had not entered into such arrangements or if we entered into such arrangements at later stages in the product development process.

We have prepared our financial statements assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred recurring losses from operations since inception. We incurred a net loss of US$17,196,308 for the six months ended June 30, 2019. Further, as of June 30, 2019, we had net current liabilities (current assets less current liabilities) of US$15,701,137 and accumulated deficit of US$51,519,477. Our ability to continue as a going concern is dependent on our ability to raise capital to fund our current research and development activities and future business plans. Additionally, volatility in the capital markets and general economic conditions in the United States may be a significant obstacle to raising the required funds. These factors raise substantial doubt about our ability to continue as a going concern. The financial statements included herein do not include any adjustments that might be necessary should we be unable to continue as a going concern. If the going concern basis were not appropriate for these financial statements, adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used.

Our operations are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when our product candidates become approved drugs and how significant their market share will be, some of which are outside of our control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect our financial condition and future operations.

Critical Accounting Policies and Estimates

We believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating this “Management’s Discussion and Analysis of Financial Condition and Results of Operation.”

Share-based Compensation

We granted share options to our selected employee and non-employee consultants.

Results of Operations

Three Months Ended June 30, 2019 as Compared to Three Months Ended June 30, 2018

The following table summarizes our results of operations for the three months ended June 30, 2018 and 2019:

	For the Three Months Ended June 30,
	2018			2019
Operating expenses:
Research and development	$	3,873,804		$	1,567,799
General and administrative		745,286			1,443,731
General and administrative to related parties		97,638			22,500
Total operating expenses		4,716,728			3,034,030

Loss from operations		(4,716,728	)		(3,034,030	)

Other income/(expenses)
Investment income		8,178			-
Interest income		89			-
Interest expenses to a related party		-			(17,723	)
Loss from operations before income tax benefit		(4,708,461	)		(3,051,753	)

Income tax		-			-
Net loss	$	(4,708,461	)	$	(3,051,753	)

Research and Development Expense

Research and development expense was $1.57 million for the three months ended June 30, 2019, compared to research and development expense of $3.87 million for the same period in 2018, representing an decrease of $2.31 million or 59.5%. The substantial decrease was mainly due to a major Contract Research Organization of the Company offered $3.57 million credits to the Company to offset previous period invoices. On the other side, the Company accelerated the research and development of Abexinostat and the launch of clinic trials in the second half of year 2018. As the company started phase 3 clinic trials, the cost increased significantly. .

Research and development expense for the three months ended June 30, 2018 was mainly comprised of the following items:

●

$3.86 payments to clinical development costs associated with abexinostat and XP-102;

●

$0.02 payroll expenses to research and development staff.

Research and development expense for the three months ended June 30, 2019 was mainly comprised of the following items:

●

$4.68 million clinical development costs associated with abexinostat;

●

$0.06 million external IND-enabling pre-clinical and toxicology studies for XP-102;

●

$0.38 million payments of research and development staff costs;

●

$3.57 million credit from a major Contract Research Organization reversed the previously recognized expenses.

General and Administrative Expense

General and administrative expense was $1.47 million for the three months ended June 30, 2019, compared to general and administrative expense of $0.84 million for the same period in 2018, representing an increase of $0.73 million or 93.7%. The substantial increase was mainly because we completed merger with Xynomic in May 2019, and we incurred significant professional fees and listing fees which were not incurred in the same period of 2018.

Variance of other general and administrative expenses was mainly due to the following in addition to the expense related to the options abovementioned:

●

professional fees including external legal fees, external auditing fees, corporate communications, and public relations costs increased $0.45 million during the three months ended June 30, 2019 when compared to the same period in year 2018 due to the merger transaction with Xynomic.

●

there were $0.17 million listing fees including SEC filing fee, etc. incurred in the three months ended June 30, 2019 while there was no such fee in the same period of year 2018;

●

we incurred $0.16 million higher taxes due to the Delaware State Franchise incurred by Xynomic for its increased number of shares and share value;

●

personnel salaries and employee benefits increased $0.02 million during the three months ended June 30, 2019 compared to that in the three months ended June 30, 2018;

●

our agreements with some Contract Research Organizations and Contract Manufacture Organizations include terms that interests for overdue invoices. $0.13 million interest expenses was accrued for the three months ended June 30, 2019 due to the invoices that were not paid by the due dates.

We expect that its general and administrative expense will decrease in future periods since we will not incur the expenses associated with the Business Combination in the future.

Interest Expense to a Related Party

Xynomic Nanjing accrued interest expense of US$17,723 for the advance from Zhongshan Bison Healthcare Investment Limited, a limited partnership holding 1,553,265 shares of Series B preferred stock of Xynomic representing approximately 2.96% equity interest in Xynomic immediately prior to the Closing (“Zhongshan Bison”) for the three months ended June 30, 2019. There was no such loan or interest in the three months ended June 30, 2018.

Six Months Ended June 30, 2019 as Compared to Six Months Ended June 30, 2018

The following table summarizes our results of operations for the six months ended June 30, 2018 and 2019:

	For the Six Months Ended June 30,
	2018			2019
Operating expenses:
Research and development	$	4,340,206		$	6,892,109
General and administrative		848,761			10,222,981
General and administrative to related parties		146,691			48,408
Total operating expenses		5,335,658			17,163,497

Loss from operations		(5,335,658	)		(17,163,497	)

Other income/(expenses)
Investment income		8,178			-
Interest income		89			-
Interest expenses to a related party		-			(32,811	)
Loss from operations before income tax benefit		(5,327,391	)		(17,196,308	)

Income tax		-			-
Net loss	$	(5,327,391	)	$	(17,196,308	)

Research and Development Expense

Research and development expense was $6.89 million for the six months ended June 30, 2019, compared to research and development expense of $4.34 million for the same period in 2018, representing an increase of $2.55 million or 58.8%. The substantial increase was mainly because we accelerated the R&D of Abexinostat and the launch of clinic trials in the second half of 2018. As the Company started phase 3 clinic trials, the cost increased significantly.

Research and development expense for the six months ended June 30, 2018 was mainly comprised of the following items:

●

$3.9 million clinical development costs associated with abexinostat;

●

$0.4 million payments to external IND-enabling pre-clinical and toxicology studies as well as the commencement of manufacturing activities for XP-102.

Research and development expense for the six months ended June 30, 2019 was mainly comprised of the following items:

●

$8.68 million clinical development costs associated with abexinostat;

●

$0.33 million external IND-enabling pre-clinical and toxicology studies for XP-102;

●

$0.35 million payments of research and development staff costs;

●

$3.57 million credit from a major Contract Research Organization reversed the previously recognized expenses.

General and Administrative Expense

General and administrative expense was $10.27 million for the six months ended June 30, 2019, compared to general and administrative expense of $1.00 million for the same period in 2018, representing an increase of $9.28 million or 931.8%. The substantial increase was mainly due to the $7.65 million expense related to the options Xynomic issued to an employee and a consultant.

Variance of other general and administrative expenses was primarily attributable to the process of the Business Combination that was started in September 2018 and incurred much higher related expenses since then. The Business Combination was consummated in May 2019, therefore, we incurred significantly higher professional fees, listing fees, etc. during the six months ended June 30, 2019 than the same period of 2018. Additionally, during the six months ended June 30, 2019, we incurred $0.5 million interest expense associated with the overdue invoices from the third-party research and development service providers. The main items were as following in addition to the above-mentioned share based compensation:

●

professional fees including external legal fees, external auditing fees, corporate communications, and public relations costs increased $0.89 million during the six months ended June 30,2019 when compared to the same period in year 2018 due to the merger transaction with Xynomic.

●

there were $0.24 million listing fees including SEC filing fee, etc. incurred in the six months ended June 30, 2019 while there was no such fee in the same period of year 2018;

●

we incurred $0.12 million consulting service fee during the six months ended June 30, 2019;

●

personnel salaries and employee benefits increased $0.08 million during the six months ended June 30, 2019 compared to that in the six months ended June 30, 2018;

●

our agreements some Contract Research Organizations and Contract Manufacture Organizations include terms that interests for overdue invoices. $0.36 million interest expenses was accrued for the six months ended June 30, 2019 due to the invoices that were not paid by the due dates.

We expect that our general and administrative expense will decrease in future periods since: 1) we will not incur the expenses associated with the Business Combination in the future; 2) share based compensation cost will significantly decrease since the cost incurred in the six months ended June 30, 2019 was mainly due to a compensation to an employee to facilitate the consummation of the Business Combination.

Interest Expense to a Related Party

Xynomic Nanjing accrued interest expense of US$32,811 for the advance from Zhongshan Bison for the six months ended June 30, 2019. There was no such loan or interest in the six months ended June 30, 2018.

Liquidity and Capital Resources

Sources of Liquidity

From inception through the date of the Closing, Xynomic has financed its operations primarily through gross proceeds of $21.8 million from private placements of preferred shares, and proceeds of $4.8 million from debt financing.

From inception through June 30, 2019, Xynomic Pharmaceuticals (Nanjing) Co., Ltd. borrowed $0.9 million from Shanghai Jingshu Venture Capital Center pursuant to a loan agreement signed in April 2018 and repaid such loan in August 2018; Xynomic Pharmaceuticals (Nanjing) Co., Ltd. borrowed $1.4 million from Zhongshan Bison Healthcare Investment Limited (Limited Partnership) pursuant to a loan agreement signed in May 2018 and has repaid $1.0 million as of June 30, 2019; we borrowed $2.5 million from Yinglin Mark Xu pursuant to a bridge loan agreement signed in August 2017. We, on a consolidated basis, had $0.4 million in outstanding principal and interest under the aforementioned loan agreements as of June 30, 2019.

From inception through the date of the Closing, Bison has financed its operations primarily through proceeds of $0.7 million from loans (including $0.5 million convertible promissory notes) provided by Bison Capital and $25,000 proceeds from the 1,509,375 shares of Bison ordinary shares issued to Bison Capital Holding Company Limited, a Cayman Islands company (the “ Sponsor”) and James Jiayuan Tong in a private placement prior to the initial public offering of Bison (the “Founder Shares”) equity financing.

At the Closing, the following securities were converted into the Company’s common shares:

●

Xynomic’s outstanding preferred shares;

●

Bison’s $0.5 million convertible promissory notes and the private rights and the public rights (the “Rights”) attached owned by Bison Capital;

In addition, on May 15, 2019, in connection with the consummation of the Business Combination, we closed a backstop subscription whereby Mr. Yinglin Mark Xu together with his assignee Bison Capital Holding Company Limited, purchased 755,873 shares of common stock at a price of $10.15 per share for a total consideration of $7.7 million. $4.97 million of the total consideration was paid in cash by Yinglin Mark Xu, $2.5 million consideration was paid by conversion of Yinglin Mark Xu’s $2.5 million loan to Xynomic, and $0.14 million consideration was paid by conversion of Bison Capital’s $0.14 million loan to Bison.

Subsequent to the consummation of the Business Combination, Bison Capital made additional $0.3 million loans to us. At June 30, 2019, we had $0.5 million outstanding loan balance owed to Bison Capital.

As of June 30, 2019, we had cash of $1.2 million.

Our recurring losses from operations since inception and the net current liabilities (current assets less current liabilities) as of June 30, 2019 raise substantial doubt about its ability to continue as a going concern. Our ability to fund operations is based on our ability to attract investors and its ability to borrow funds on reasonable economic terms.

We also plan to attract institutional investors following the business combination. Further, we can adjust the pace of its clinical development and patient recruitment and control the operating expenses of us.

We currently do not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If we cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs to: commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including another merger or sale of us; or cease operations. If we engage in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process.

We have prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred recurring losses from operations since inception. We incurred a net loss of US$17.2 million for the six months ended June 30, 2019. Further, as of June 30, 2019, we had net current liabilities (current assets less current liabilities) of US$15.7 million and accumulated deficit of US$51.5 million. Our ability to continue as a going concern is dependent on its ability to raise capital to fund its current research and development activities and future business plans. Additionally, volatility in the capital markets and general economic conditions in the United States may be a significant obstacle to raising the required funds. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements included herein do not include any adjustments that might be necessary should we be unable to continue as a going concern. If the going concern basis were not appropriate for these financial statements, adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used.

Operations of us are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when our product candidates become approved drugs and how significant their market share will be, some of which are outside of our control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect our financial condition and future operations.

Cash Flows

The following table provides information regarding our cash flows for the periods reported:

	For the Six Months ended June 30,
	2018			2019
Net cash used in operating activities	$	(3,007,228	)	$	(7,982,084	)
Net cash (used in)/provided by investing activities		(1,640,705	)		63,258,544
Net cash provided by/(used in) financing activities		5,336,546			(58,860,826	)
Effect of foreign exchange rate changes on cash		-			29,940
Net increase/(decrease) in cash and cash equivalents	$	688,613		$	(3,554,425	)

Net Cash Used in Operating Activities

The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. Net cash used in operating activities was $3.0 million and $8.0 million for the six months ended June 30, 2018 and 2019, respectively. The net cash used in operating activities in the six months ended June 30, 2018 was mainly due to the payments to Contract Manufacture Organizations (the “CMO”) and Contract Research Organizations (the “CRO”) for the research and development of abexinostat of $2.2 million, and $0.2 million payment for patent maintenance, 0.3 million payment for staff salaries and benefit. The net cash used in operating activities in the six months ended June 30, 2019 was mainly due to the payments to CMOs of 0.8 million and CROs of $4.0 million for the research and development of abexinostat and XP-102, payments of $1.1 million to professional service providers such as lawyers and accountants, $1.0 million payments for staff salaries.

Net Cash Provided by (Used in) Investing Activities

Net cash used in investing activities was $1.6 million for the six months ended June 30, 2018 which was mainly used to purchase short-term investment securities offset by sales of short-term investment securities. Net cash provided by investing activities was $63.3 million for the six months ended June 30, 2019 which is mainly due to cash withdrawn from our trust account to pay redeeming shareholders.

Net Cash Provided by (Used in) Financing Activities

Net cash provided by financing activities was $5.3 million for the six months ended June 30, 2018 and net cash used in financing activities was $58.9 million for the six months ended June 30, 2019. Net cash provided by financing activities during six months ended June 30, 2018 was primarily from $2.5 million advance from a Series B preferred shareholder, $1.4 million loan from Bison Capital, $0.9 million loan from Shanghai Jingshu Venture Capital Center, and $0.5 million loan from shareholder Yinglin Mark Xu. Net cash used in financing activities during the six months ended June 30, 2019 was primarily due to the payment of $64 million to redeeming shareholders and $0.75 million payment to repay the advance from a Series B preferred shareholder of Xynomic. The cash outflow was off-set by cash inflow of $5.0 million proceeds from Yinglin Mark Xu for Backstop Shares purchase, $0.5 million loan from Yinglin Mark Xu and $0.4 million loan from Bison Capital.

Funding Requirements

We expect our expenses to increase in connection with its ongoing activities, particularly as we continue the research and development of, initiates clinical trials of, and seeks marketing approval for, our drug candidates. In addition, if we obtain marketing approval for any of its drug candidates, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing, and distribution to the extent that such sales, marketing, and distribution are not the responsibility of potential collaborators. Furthermore, as a public reporting company, we start to incur additional costs associated with operating as a public company. Accordingly, we may need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed, or are unable to raise capital on favorable terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.

Our future capital requirements will depend on many factors, including:

●

the scope, progress, results, and costs of drug discovery, pre-clinical development, laboratory testing, and clinical trials for our drug candidates;

●

the scope, prioritization, and number of our research and development programs;

●

the costs, timing, and outcome of regulatory review of our drug candidates;

●

our ability to establish and maintain collaborations on favorable terms, if at all;

●

the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we currently have and may have in the future;

●

the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any;

●

the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims;

●

the extent to which we acquire or in-license other drug candidates and technologies;

●

the costs of securing manufacturing arrangements for commercial production; and

●

the costs of establishing, or contracting for, sales and marketing capabilities if we obtain regulatory approvals to market its drug candidates.

Identifying potential drug candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive, and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve drug sales. In addition, our drug candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for quite a few years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve its business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

Until such time, if ever, as we can generate substantial drug revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements.

If we raise funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to its future revenue streams, research programs, or drug candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our drug development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.

Contractual Obligations

The following table summarizes our significant contractual obligations as of payment due date by period at June 30, 2019:

	Total		Less than 1 Year		1 to 3 Years		3 to 5 Years		More than 5 years

Debt repayments (1)	$	843,470	$	843,470		-		-		-

(1)

Consists of payment obligations for loan agreement with Bison Capital and Zhongshan Bison Healthcare Investment Limited (Limited Partnership). As of June 30, 2019, we had $404,900 in outstanding principal under the agreement with Bison Capital and $438,570 outstanding principal and interest under the agreement with Zhongshan Bison Healthcare Investment Limited (Limited Partnership).

We also have obligations to make future payments to third party licensors that become due and payable on the achievement of certain development, regulatory and commercial milestones. This includes milestone payments associated with our license agreements. Possible future payments under our license arrangements include up to $10.5 million in payments related to abexinostat, up to $17.7 million related to XP-102, and up to $18 million related to XP-105. We have not included these commitments on our balance sheet or in the table above because the commitments are cancellable if the milestones are not completed and achievement and timing of these obligations are not fixed or determinable.

Xynomic enters into agreements in the normal course of business with contract research organizations (“CRO”) for clinical trials and clinical supply manufacturing and with vendors for pre-clinical research studies, synthetic chemistry, and other services and products for operating purposes. We have not included these payments in the table of contractual obligations above since the contracts are cancelable at any time by us, generally upon 30 days prior written notice to the vendor.

Off-Balance Sheet Arrangements

We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable Securities and Exchange Commission rules.

Quantitative and Qualitative Disclosures about Market Risk

We are exposed to market risks related to changes in interest rates. Our primary exposure to market risks is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates.

We are also exposed to market risk related to changes in foreign currency exchange rates. We contract with vendors that are located in Asia and Europe, which are denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these agreements. We do not currently hedge our foreign currency exchange rate risk. As of June 30, 2019, we had $1.3 million liabilities denominated in foreign currencies.

Inflation generally affects us by increasing our labor costs and clinical trial costs. We do not believe that inflation had a material effect on its business, financial condition, or results of operations since its inception.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES .

(a) Evaluation of Disclosure Controls and Procedures

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Report, is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our current chief executive officer and chief financial officer (our “Certifying Officers”), the effectiveness of our disclosure controls and procedures as of June 30, 2019, pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of June 30, 2019, our disclosure controls and procedures were effective.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

(b) Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter covered by this report that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Please read Note 13 to the Consolidated Financial Statements, “Commitments and Contingencies,” which is incorporated herein by reference.

ITEM 1A. RISK FACTORS

Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our registration statement on Form S-1(file No. 333-232598, the “Registration Statement”) filed with the SEC on July 11, 2019. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in the Registration Statement, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The 42,860,772 Merger Consideration Shares and the 755,873 Backstop Shares were issued in reliance upon an exemption from the registration requirements of the Securities Act, pursuant to the Section 4(a) (2) of the Securities Act and Regulation S promulgated under the Securities Act. The Sellers and Yinglin Mark Xu receiving the shares represented their intentions to acquire the shares for investment only and not with a view to or for sale in connection with any distribution, and appropriate restrictive legends were affixed to the certificates representing the shares. The parties also had adequate access, through business or other relationships, to information about the Company. For additional information of the Merger Consideration Shares and Backstop Shares, please see Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations – Overview on page 21.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

No.		Description of Exhibit
2.1		Merger Agreement (Incorporated by reference to Exhibit 2.1 to the registrant’s Current Report on Form 8-K filed by the registrant on September 13, 2018)
2.2		Amendment No.1 to the Merger Agreement (Incorporated by reference to Exhibit 2.2 to the registrant’s Form S-4/A filed by the registrant on February 12, 2019)
2.3		Amendment No. 2 to the Merger Agreement (Incorporated by reference to Exhibit 2.1 to the registrant’s Current Report on Form 8-K filed by the registrant on February 27, 2019)
2.4		Amendment No. 3 to the Merger Agreement (Incorporated by reference to Exhibit 2.4 to the registrant’s Form S-4/A filed by the registrant on April 4, 2019)
3.1		Certificate of Incorporation of the Company, effective on May 14, 2019 (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on May 15, 2019)
3.2		Amended and Restated Certificate of Incorporation of the Company, effective on May 15, 2019 (Incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed on May 15, 2019)
3.3		Bylaws of the Company, effective as of May 15, 2019 (Incorporated by reference to Exhibit 3.3 to the registrant’s Current Report on Form 8-K filed on May 15, 2019)
10.1		Amended and Restated Registration Rights Agreement dated May 15, 2019 ((Incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed on May 15, 2019)
10.2		Form of Lock-Up Agreement (Incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed by the registrant on September 13, 2018)
10.3		Form of Non-Competition Agreement (Incorporated by reference to Exhibit 10.5 to the registrant’s Current Report on Form 8-K filed by the registrant on September 13, 2018)
10.4		Escrow Agreement dated May 13, 2019 (Incorporated by reference to Exhibit 10.4 to the registrant’s Current Report on Form 8-K filed on May 15, 2019)
10.5		Letter of Transmittal (Incorporated by reference to Exhibit 10.6 to the registrant’s Current Report on Form 8-K filed by the registrant on September 13, 2018)
10.6		Backstop and Subscription Agreement, dated as of May 1, 2019 between Bison Capital Acquisition Corp. and Yinglin Mark Xu (Incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed by the registrant on May 2, 2019)
10.7		Form of Indemnification Agreement with each director and office (Incorporated by reference to Exhibit 10.7 to the registrant’s Current Report on Form 8-K filed on May 15, 2019)
14.1		Insider Trading Policy (Incorporated by reference to Exhibit 14.1 to the registrant’s Current Report on Form 8-K filed on May 15, 2019)
17.1		Resignation of Peixin Xu (Incorporated by reference to Exhibit 17.1 to the registrant’s Current Report on Form 8-K filed on May 15, 2019)
31.1*		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		XBRL Instance Document
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*		XBRL Taxonomy Extension Schema Document
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

August 15, 2019	XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

	By:	/s/ Yinglin Mark Xu
		Yinglin Mark Xu
		Chief Executive Officer, Interim
		Chief Financial Officer, President, Chairman

	By:	/s/ Jinwei Coco Wei
		Jinwei Coco Wei
		Interim Chief Accounting Officer

EX-31.1 2 f10q0619ex31-1_xynomic.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Yinglin Mark Xu, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of XYNOMIC PHARMACEUTICALS HOLDINGS, INC.:

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 15, 2019	/s/ Yinglin Mark Xu
	Yinglin Mark Xu
	Chief Executive Officer, Interim
	Chief Financial Officer, President, Chairman

EX-31.2 3 f10q0619ex31-2_xynomic.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Yinglin Mark Xu, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of XYNOMIC PHARMACEUTICALS HOLDINGS, INC.:

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 15, 2019	/s/ Yinglin Mark Xu
	Yinglin Mark Xu
	Chief Executive Officer, Interim
	Chief Financial Officer, President, Chairman

EX-32.1 4 f10q0619ex32-1_xynomic.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of XYNOMIC PHARMACEUTICALS HOLDINGS, INC. (the “Company”) on Form 10-Q for the period ended June 30, 2019 (the “Report”), I, Yinglin Mark Xu, Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 15, 2019	/s/ Yinglin Mark Xu
	Yinglin Mark Xu
	Chief Executive Officer, Interim
	Chief Financial Officer, President, Chairman

EX-32.2 5 f10q0619ex32-2_xynomic.htm CERTIFICATION

Exhibit 32.2

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of XYNOMIC PHARMACEUTICALS HOLDINGS, INC. (the “Company”) on Form 10-Q for the period ended June 30, 2019 (the “Report”), I, Yinglin Mark Xu, Interim Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 15, 2019	/s/ Yinglin Mark Xu
	Yinglin Mark Xu
	Chief Executive Officer, Interim
	Chief Financial Officer, President, Chairman

EX-101.INS 6 xyno-20190630.xml XBRL INSTANCE FILE 0001697805 2018-12-31 0001697805 2019-06-30 0001697805 2019-01-01 2019-06-30 0001697805 2018-01-01 2018-06-30 0001697805 xyno:AdministrativeServicesArrangementMember 2017-06-01 2017-06-19 0001697805 xyno:BisonCapitalHoldingCompanyLimitedMember 2019-06-30 0001697805 xyno:AdministrativeServicesArrangementMember 2019-01-01 2019-06-30 0001697805 xyno:AdministrativeServicesArrangementMember 2018-01-01 2018-06-30 0001697805 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001697805 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001697805 us-gaap:RetainedEarningsMember 2018-12-31 0001697805 us-gaap:RetainedEarningsMember 2019-06-30 0001697805 2017-12-31 0001697805 us-gaap:CommonStockMember 2018-12-31 0001697805 us-gaap:CommonStockMember 2019-06-30 0001697805 2019-02-18 2019-03-03 0001697805 xyno:AdministrativeServicesArrangementMember 2018-01-01 2018-12-31 0001697805 xyno:SupplierOneMember 2019-01-01 2019-06-30 0001697805 xyno:SupplierOneMember 2018-01-01 2018-06-30 0001697805 xyno:SupplierOneMember 2018-04-01 2018-06-30 0001697805 xyno:SupplierOneMember 2019-04-01 2019-06-30 0001697805 xyno:SupplierTwoMember 2019-01-01 2019-06-30 0001697805 xyno:SupplierTwoMember 2019-04-01 2019-06-30 0001697805 xyno:SupplierTwoMember 2018-01-01 2018-06-30 0001697805 xyno:SupplierTwoMember 2018-04-01 2018-06-30 0001697805 xyno:SupplierThreeMember 2019-01-01 2019-06-30 0001697805 xyno:SupplierThreeMember 2018-01-01 2018-06-30 0001697805 xyno:SupplierThreeMember 2018-04-01 2018-06-30 0001697805 xyno:SupplierThreeMember 2019-04-01 2019-06-30 0001697805 xyno:SupplierFourMember 2019-01-01 2019-06-30 0001697805 xyno:SupplierFourMember 2018-01-01 2018-06-30 0001697805 xyno:SupplierFourMember 2018-04-01 2018-06-30 0001697805 xyno:SupplierFourMember 2019-04-01 2019-06-30 0001697805 xyno:SupplierFiveMember 2019-01-01 2019-06-30 0001697805 xyno:SupplierFiveMember 2018-01-01 2018-06-30 0001697805 xyno:SupplierFiveMember 2018-04-01 2018-06-30 0001697805 xyno:SupplierFiveMember 2019-04-01 2019-06-30 0001697805 xyno:XynomicPharmaceuticalsNanjingMember 2019-01-01 2019-06-30 0001697805 xyno:XynomicPharmaceuticalsShanghaiMember 2019-01-01 2019-06-30 0001697805 xyno:XynomicPharmaceuticalsZhongshaniMember 2019-01-01 2019-06-30 0001697805 xyno:XynomicPharmaceuticalsNanjingMember 2019-06-30 0001697805 xyno:XynomicPharmaceuticalsShanghaiMember 2019-06-30 0001697805 xyno:XynomicPharmaceuticalsZhongshaniMember 2019-06-30 0001697805 xyno:MergerConsiderationAgreementMember 2019-05-15 0001697805 xyno:MergerConsiderationAgreementMember 2019-05-02 2019-05-15 0001697805 us-gaap:PrivatePlacementMember 2019-05-02 2019-05-14 0001697805 us-gaap:IPOMember 2019-05-02 2019-05-14 0001697805 xyno:XynomicPharmaMember 2019-05-02 2019-05-15 0001697805 xyno:YinglinMarkXuMember 2019-05-31 0001697805 xyno:YinglinMarkXuMember 2019-05-06 2019-05-31 0001697805 xyno:PRCMember 2018-12-31 0001697805 xyno:PRCMember 2019-06-30 0001697805 xyno:USDMember 2018-12-31 0001697805 xyno:USDMember 2019-06-30 0001697805 2019-04-01 2019-06-30 0001697805 2018-04-01 2018-06-30 0001697805 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001697805 us-gaap:EquipmentMember 2018-12-31 0001697805 us-gaap:OfficeEquipmentMember 2018-12-31 0001697805 us-gaap:LeaseholdImprovementsMember 2019-06-30 0001697805 us-gaap:EquipmentMember 2019-06-30 0001697805 us-gaap:OfficeEquipmentMember 2019-06-30 0001697805 xyno:AngelPreferredSharesMember 2018-12-31 0001697805 xyno:AngelPreferredSharesMember 2019-06-30 0001697805 us-gaap:SeriesAPreferredStockMember 2018-12-31 0001697805 us-gaap:SeriesAPreferredStockMember 2019-06-30 0001697805 us-gaap:SeriesBPreferredStockMember 2018-12-31 0001697805 us-gaap:SeriesBPreferredStockMember 2019-06-30 0001697805 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001697805 us-gaap:CommonStockMember 2019-03-31 0001697805 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001697805 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001697805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001697805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001697805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001697805 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001697805 us-gaap:RetainedEarningsMember 2019-03-31 0001697805 2019-01-01 2019-03-31 0001697805 2019-03-31 0001697805 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001697805 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001697805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001697805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001697805 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001697805 2018-06-30 0001697805 xyno:BritishVirginIslandsMember 2018-12-31 0001697805 xyno:BritishVirginIslandsMember 2019-01-16 2019-02-01 0001697805 xyno:BritishVirginIslandsMember 2019-02-01 0001697805 us-gaap:CommonStockMember 2019-05-14 0001697805 xyno:MarkYinglinXUMember 2019-01-01 2019-06-30 0001697805 xyno:MarkYinglinXUMember 2019-06-30 0001697805 xyno:BisonCapitalMember 2019-06-30 0001697805 xyno:BisonCapitalMember 2019-01-01 2019-06-30 0001697805 xyno:BisonCapitalMember us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001697805 us-gaap:EmployeeStockMember 2019-01-01 2019-06-30 0001697805 us-gaap:EmployeeStockMember 2018-12-31 0001697805 us-gaap:EmployeeStockMember 2019-06-30 0001697805 xyno:NonEmployeeStockMember 2019-01-01 2019-06-30 0001697805 xyno:NonEmployeeStockMember 2018-12-31 0001697805 xyno:NonEmployeeStockMember 2019-06-30 0001697805 xyno:TwoThousandStockIncentivePlanMember 2018-08-01 2018-08-28 0001697805 xyno:TwoThousandStockIncentivePlanMember 2019-01-03 2019-01-21 0001697805 xyno:TwoThousandStockIncentivePlanMember 2019-01-01 2019-06-30 0001697805 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001697805 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001697805 xyno:PharmacyclicsMember 2017-02-01 2017-02-28 0001697805 xyno:BoehringerIngelheimInternationalMember 2017-08-01 2017-08-31 0001697805 xyno:BIIXPMember 2018-12-01 2018-12-31 0001697805 xyno:AngelPreferredSharesMember 2019-01-01 2019-06-30 0001697805 xyno:SeriesA1PreferredSharesMember 2019-01-01 2019-06-30 0001697805 xyno:SeriesA1PreferredSharesMember 2018-12-31 0001697805 xyno:SeriesA1PreferredSharesMember 2019-06-30 0001697805 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-06-30 0001697805 srt:MaximumMember 2019-01-01 2019-06-30 0001697805 srt:MinimumMember 2019-01-01 2019-06-30 0001697805 xyno:XynomicPharmaMember 2019-01-01 2019-06-30 0001697805 xyno:XynomicPharmaMember 2019-07-01 2019-07-12 0001697805 xyno:XynomicPharmaMember 2019-06-30 0001697805 us-gaap:SubsequentEventMember 2019-07-01 2019-07-10 0001697805 us-gaap:SubsequentEventMember 2019-07-01 2019-07-26 0001697805 xyno:XynomicPharmaMember 2018-03-20 2018-04-03 0001697805 2019-08-08 0001697805 xyno:BisonCapitalMember xyno:RelatedPartyLoansAndPromissoryNotesMember 2019-06-30 0001697805 xyno:BisonCapitalMember xyno:RelatedPartyLoansAndPromissoryNotesMember 2019-01-01 2019-06-30 0001697805 xyno:BisonCapitalMember xyno:RelatedPartyLoansAndPromissoryNotesMember 2019-05-14 0001697805 xyno:YinglinMarkXuMember 2018-04-01 2018-06-30 0001697805 xyno:YinglinMarkXuMember 2019-04-01 2019-06-30 0001697805 xyno:YinglinMarkXuMember 2018-01-01 2018-06-30 0001697805 xyno:YinglinMarkXuMember 2019-01-01 2019-06-30 0001697805 xyno:YinglinMarkXuMember 2019-06-30 0001697805 xyno:YinglinMarkXuMember 2018-12-31 0001697805 xyno:XynomicPharmaMember 2018-04-01 2018-06-30 0001697805 xyno:XynomicPharmaMember 2019-04-01 2019-06-30 0001697805 xyno:XynomicPharmaMember 2018-01-01 2018-06-30 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember 2018-05-01 2018-05-13 0001697805 xyno:EigenbridgeIncMember 2019-06-30 0001697805 xyno:EigenbridgeIncMember 2018-12-31 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember xyno:RmbMember 2018-05-01 2018-05-13 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember xyno:RmbMember 2018-08-01 2018-08-23 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember xyno:RmbMember 2019-01-01 2019-06-30 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember 2018-08-01 2018-08-23 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember xyno:XynomicPharmaceuticalsNanjingMember 2018-08-01 2018-08-23 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember xyno:XynomicPharmaceuticalsNanjingMember xyno:RmbMember 2018-08-09 2018-08-23 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember xyno:XynomicPharmaceuticalsNanjingMember 2019-01-09 2019-01-21 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember xyno:XynomicPharmaceuticalsNanjingMember xyno:RmbMember 2019-01-09 2019-01-21 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember 2019-01-01 2019-06-30 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember 2019-06-30 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember 2018-12-31 0001697805 xyno:BisonCapitalMember 2019-02-02 2019-02-28 0001697805 xyno:BisonCapitalMember 2019-02-28 0001697805 us-gaap:ShareholderServiceMember 2018-04-01 2018-06-30 0001697805 us-gaap:ShareholderServiceMember 2019-04-01 2019-06-30 0001697805 us-gaap:ShareholderServiceMember 2019-01-01 2019-06-30 0001697805 us-gaap:ShareholderServiceMember 2018-01-01 2018-06-30 0001697805 us-gaap:ShareholderServiceMember 2017-06-01 2017-06-30 0001697805 xyno:AdministrativeServicesArrangementMember 2018-04-01 2018-06-30 0001697805 xyno:AdministrativeServicesArrangementMember 2019-04-01 2019-06-30 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember xyno:XynomicPharmaceuticalsNanjingMember xyno:RmbMember 2019-02-02 2019-02-20 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember xyno:XynomicPharmaceuticalsNanjingMember 2019-02-02 2019-02-20 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember xyno:XynomicPharmaceuticalsNanjingMember 2019-04-01 2019-04-12 0001697805 xyno:ZhongshanBisonHealthcareInvestmentLimitedMember xyno:XynomicPharmaceuticalsNanjingMember xyno:RmbMember 2019-04-01 2019-04-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:CNY

23435379

12147500

5281101

0.0001

6706068

46273846

7978937

XYNOMIC PHARMACEUTICALS HOLDINGS, INC. 0001697805 false --12-31 10-Q 2019-06-30 Q2 2019 Non-accelerated Filer

6706068

46273846

7978937

42860772

432062

6037500

9852216

755873

610000

16062

500000

true true false

190000

5461963

2013560

1937

1450

5024120

1347749

277750

155805

17645943

17048886

404900

3233728

552873

7910748

5461963

2013560

-20094728

-15035326

14169060

36401911

-34323169

-51519477

817

4627

817

20154364

58564

21573

-48467724

-28290970

77613

-34323169

-51519477

817

4627

-17163497

-5335658

-3034030

-4716728

17163497

5335658

3034030

4716728

43747040

42860772

44623568

42860772

-17196308

-5327391

-3051753

-4708461

-14144555

-3051753

8165377

46273846

8165377

-7982084

-3007228

-119758

349272

63258544

-1640705

63310884

4746370

1191944

100344

788957

-3554425

688613

-58860826

5336546

0.02

0.0001

10.00

46273846

5000

803080

50000

5000

66371

66709

20658

3391

5457

277750

155805

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(a)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Basis of Presentation</td></tr> </table>   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the United States Securities and Exchange Commission ("SEC"). The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements of Xynomic Pharmaceuticals, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated balance sheet of the Company and Xynomic Pharma as of December 31, 2018, and the related consolidated statements of comprehensive loss, changes in equity and cash flows for the year then ended, included in the Company's Proxy Statement/Prospectus on Form 8-K filed with the SEC on May 15, 2019.   In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of June 30, 2019, the results of operations for the three and six months ended June 30, 2018 and 2019 and cash flows for the six months ended June 30, 2018 and 2019, have been made.   The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant accounting estimates include, but not limited to the fair value of the ordinary shares to determine the existence of beneficial conversion feature of the redeemable convertible preferred shares, the fair value of share-based compensation awards, depreciable lives of property and equipment, the recoverability of the carrying amounts of property and equipment and the recoverability of deferred income tax assets. Changes in facts and circumstances may result in revised estimates. Actual results could differ from those estimates, and as such, differences may be material to the unaudited condensed consolidated financial statements.   Principles of Consolidation   The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation   Going Concern   The Company and its subsidiaries Xynomic Pharma, Xynomic Nanjing, Xynomic Shanghai and Xynomic Zhongshan (the "Group") have not generated any revenues from product sales. Substantial additional financing will be required by the Group to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Group's research and development efforts will be successful.   The Group's ability to fund operations is based on its ability to attract investors and its ability to borrow funds on reasonable economic terms. Historically, the Group has relied principally on equity financing and shareholder's borrowings to fund its operations and business development. The Group's ability to continue as a going concern is dependent on management's ability to successfully execute its business plan, which includes generating revenues after drug marketing, controlling operating expenses, as well as, continuing to obtain additional equity financing. On April 3, 2018, Xynomic Pharma issued convertible notes to Northern Light Venture Capital V, Ltd., and Bo Tan and received proceeds of US$2,500,000, which were converted into 776,633 Series B Preferred Shares in August 2018. Further in August 2018, Xynomic Pharma raised US$17 million by issuance of 5,281,101 Series B Preferred Shares to certain investors, including the conversion of convertible notes of US$2.5 million. At the Closing of the Merger, 755,873 shares of Backstop Shares were issued for a total consideration of $7,672,111.   On May 15, 2019, the Company received written notice from the staff of the NASDAQ Stock Market LLC ("Nasdaq") indicating that the Staff had determined to delist its securities from NASDAQ based upon the non-compliance with the requirement of a minimum of 300 round lot holders of and 400 round lot holders of purchase warrants and the requirement of the minimum US$5 million in stockholders' equity. The Company requested a hearing before the Nasdaq Hearings Panel (the "Panel"), and such request stayed any suspension or delisting action by Nasdaq pending the completion of the hearing process and the expiration of any extension period that may be granted to the Company by the Panel. On July 15, 2019, the Company was notified in writing by the Panel at Nasdaq that they denied the Company's request for continued listing on Nasdaq based upon the Company's non-compliance with Nasdaq Listing Rules 5505(a)(3) and 5515(a)(4). As a result, Nasdaq suspended trading in the Company's securities effective at the open of business on Wednesday, July 17, 2019; and the Company's shares will subsequently commence trading on the over-the-counter markets. The Company still intends to continue with its compliance plan with the Nasdaq listing requirements and is diligently pursuing courses of action designed to remedy our noncompliance with Nasdaq's initial listing requirements as set forth above. There can be no assurance, however, that the Company will be able to regain compliance with the mainboard listing requirements.   The Group currently does not have any commitments to obtain additional funds except the potential private placements in details provided in Note 16 herein below and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Group cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs to: commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including another merger or sale of the Group; or cease operations. If the Group engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process.   The Group has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Group has incurred recurring losses from operations since inception. The Group incurred a net loss of US$3,051,753 and US$17,196,308 for the three and six months ended June 30, 2019, respectively. Further, as of June 30, 2019, the Group had net current liabilities (current assets less current liabilities) of US$15,701,138 and accumulated deficit of US$51,519,477. The Group's ability to continue as a going concern is dependent on its ability to raise capital to fund its current research and development activities and future business plans. Additionally, volatility in the capital markets and general economic conditions in the United States may be a significant obstacle to raising the required funds. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements included herein do not include any adjustments that might be necessary should the Group be unable to continue as a going concern. If the going concern basis were not appropriate for these financial statements, adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used.   Operations of the Group are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Group's product candidates become approved drugs and how significant their market share will be, some of which are outside of the Group's control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Group's financial condition and future operations.   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(b)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Share-based Compensation</td></tr> </table>   The Company granted share options to its selected employees and non-employee consultants.   Share-based awards granted to employees with service conditions attached are measured at the grant date fair value and are recognized as an expense using graded vesting method over the requisite service period, which is generally the vesting period. The forfeitures are accounted when they occur.    In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"). The new guidance largely aligns the accounting for share-based awards issued to employees and nonemployees. Existing guidance for employee awards will apply to non-employee share-based transactions with limited exceptions. The Company adopted this guidance on January 1, 2019.   Share-based awards granted to non-employees are measured at the grant date fair value. When no future services are required to be performed by the non-employee in exchange for an award of equity instruments, the cost of the award is expensed on the grant date.   Option-pricing models are adopted to measure the value of awards at each grant date. The determination of fair value is affected by the share price as well as assumptions relating to a number of complex and subjective variables, including but not limited to the expected share price volatility, actual and projected employee and non-employee share option exercise behavior, risk-free interest rates and expected dividends. The use of the option-pricing model requires extensive actual employee and non-employee exercise behavior data for the relative probability estimation purpose, and a number of complex assumptions.   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(c)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Concentration and risk</td></tr> </table>   Concentration of suppliers   The following suppliers for the Group's research and development activities accounted for 10% or more of research and development expenses for the three and six months ended June 30, 2018 and 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold"> </td><td> </td> <td colspan="14" style="text-align: center">For the Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">Supplier A</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">475,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">(2,531,472</td><td style="width: 3%; text-align: left">)(1)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">(162</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">475,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">*</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">   * </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Supplier B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> * </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">679,436</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,358,361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Supplier C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,767,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">936,542</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,767,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,299,032</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Supplier D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> * </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,225,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> * </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,225,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Supplier E</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">183,694</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">*</td> <td style="width: 96%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Represents less than 10% of research and development expenses for the three and six months ended June 30, 2018 and 2019.</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">(1)</td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Supplier A offered $3.57 million credit to offset previously issued invoices to the Company during the three months ended June 30, 2019.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(d)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recent accounting pronouncements</td></tr> </table>   Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company's condensed consolidated financial statements.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(c)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Concentration and risk</td></tr> </table>   Concentration of suppliers   The following suppliers for the Group's research and development activities accounted for 10% or more of research and development expenses for the three and six months ended June 30, 2018 and 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold"> </td><td> </td> <td colspan="14" style="text-align: center">For the Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">Supplier A</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">475,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">(2,531,472</td><td style="width: 3%; text-align: left">)(1)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">(162</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">475,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">*</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">   * </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Supplier B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> * </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">679,436</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,358,361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Supplier C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,767,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">936,542</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,767,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,299,032</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Supplier D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> * </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,225,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> * </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,225,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Supplier E</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">183,694</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">*</td> <td style="width: 96%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Represents less than 10% of research and development expenses for the three and six months ended June 30, 2018 and 2019.</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">(1)</td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Supplier A offered $3.57 million credit to offset previously issued invoices to the Company during the three months ended June 30, 2019.</td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(d)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recent accounting pronouncements</td></tr> </table>   Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company's condensed consolidated financial statements.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold"> </td><td> </td> <td colspan="14" style="text-align: center">For the Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">Supplier A</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">475,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">(2,531,472</td><td style="width: 3%; text-align: left">)(1)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">(162</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">475,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">*</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">   * </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Supplier B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> * </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">679,436</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,358,361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Supplier C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,767,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">936,542</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,767,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,299,032</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Supplier D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> * </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,225,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> * </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,225,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Supplier E</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">183,694</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*</td><td style="text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">*</td> <td style="width: 96%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Represents less than 10% of research and development expenses for the three and six months ended June 30, 2018 and 2019.</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">(1)</td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Supplier A offered $3.57 million credit to offset previously issued invoices to the Company during the three months ended June 30, 2019.</td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">1.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</td></tr> </table>   Xynomic Pharmaceuticals Holdings, Inc. (formerly known as Bison Capital Acquisition Corp. , the "Company") was a blank check company incorporated in the British Virgin Islands on October 7, 2016. The Company was formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities (a "Business Combination").   All activities through May 14, 2019 relate to the Company's formation, its initial public offering of 6,037,500 units (the "Initial Public Offering"), the simultaneous sale of 432,062 units (the "Private Units") in a private placement to the Company's sponsor, Bison Capital Holding Company Limited ("Bison Capital") and EarlyBirdCapital, Inc. ("EarlyBirdCapital") and their designees, identifying a target company for a Business Combination and activities in connection with the proposed acquisition of Xynomic Pharmaceuticals, Inc., a Delaware corporation ("Xynomic Pharma"). On March 3, 2019, the Company received a commitment from Xynomic Pharma that it has agreed to contribute to the Company as a loan $0.02 per month for each public share that is not redeemed by the Company's shareholders (the "Contribution") in connection with the Extension Amendment. The amount of the Contribution will not bear interest and will be repayable by the Company to Xynomic Pharma upon consummation of a Business Combination. Xynomic Pharma will have the sole discretion whether to continue extending for additional calendar months until the Combination Period and if Xynomic Pharma determines not to continue extending for additional calendar months, its obligation to make Contributions following such determination will terminate. In May 2019, $16,062 was loaned to the Company and deposited into the Trust Account, which amount is equal to $0.02 for each of the 803,080 shares that were not redeemed.   On May 15, 2019 (the "Effective Time"), each share of Xynomic Pharma's ordinary shares and preferred shares issued and outstanding prior to the Effective Time was automatically converted into the right to receive, on a pro rata basis, the Closing Consideration Shares (as defined in the Merger Agreement) and the Earnout Shares (as defined in the Merger Agreement), and each option to purchase Xynomic Pharma's ordinary shares that was outstanding immediately prior to the Effective Time was assumed by the Company and automatically converted into an option to purchase shares of common stock of the Xynomic Pharma. In addition to the Closing Consideration Shares, Xynomic Pharma stockholders received an additional 9,852,216 shares of common stock in aggregate (the "Earnout Shares" and, together with the Closing Consideration Shares, the "Merger Consideration Shares", such transaction is referred as the "Merger"). As a result, the Company issued 42,860,772 common shares as in aggregate Merger Consideration Shares to shareholders of Xynomic Pharma immediately prior to the Effective Time (the "Sellers"). Pursuant to the Merger Agreement, 1,285,822 shares were deposited into an escrow account (the "Escrow Account") to serve as security for, and the exclusive source of payment of, the Company's indemnity rights under the Merger Agreement and any excess of the estimated Closing Merger Consideration over the final Closing Merger Consideration amount determined post-Closing.   Following the Merger, the Xynomic Pharma became a wholly-owned subsidiary of the Company. Xynomic Pharma was incorporated in the United States on August 24, 2016. Xynomic Pharma and its subsidiaries are primarily engaged in in-licensing, developing and commercializing oncology drug candidates in the People's Republic of China ("PRC"), the United States, and rest of the world. As of the Effective Time, Xynomic Pharma's subsidiaries are as following:    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Subsidiaries</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date of incorporation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Place of incorporation  /establishment</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage of economic ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; text-indent: -9pt; padding-left: 9pt">Xynomic Pharmaceuticals (Nanjing) Co., Ltd. ("Xynomic Nanjing")</td><td style="width: 1%"> </td> <td style="width: 20%; text-align: center">November 20, 2017</td><td style="width: 1%"> </td> <td style="width: 20%; text-align: center">PRC</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Xynomic Pharmaceuticals (Shanghai) Co., Ltd. ("Xynomic Shanghai")</td><td> </td> <td style="text-align: center">July 31, 2018</td><td> </td> <td style="text-align: center">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Xynomic Pharmaceuticals (Zhongshan) Co., Ltd. ("Xynomic Zhongshan")</td><td> </td> <td style="text-align: center">May 15, 2018</td><td> </td> <td style="text-align: center">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> </table>     The Merger was accounted for as a "reverse acquisition" since, immediately following the consummation of the Merger (the "Closing"), the Sellers effectively controlled the post-combination Company. For accounting purposes, Xynomic Pharma was deemed to be the accounting acquirer in the Merger and, consequently, the Merger is treated as a recapitalization of Xynomic Pharma (i.e., a capital transaction involving the issuance of shares by the Company for the shares of Xynomic Pharma). Accordingly, the consolidated assets, liabilities and results of operations of Xynomic Pharma became the historical financial statements of the Company and its subsidiaries, and the Company's assets, liabilities and results of operations were consolidated with Xynomic Pharma beginning at the Closing. No step-up in basis or intangible assets or goodwill were recorded in the Merger.   On May 14, 2019, prior to the Closing, the Company continued out of the British Virgin Islands and domesticated as a Delaware corporation (the "Domestication"). As a result, the Company is no longer a company incorporated in the British Virgin Islands.   At the Closing, pursuant to the Backstop Agreement dated May 1, 2019 entered into by and between the Company and Yinglin Mark Xu, Yinglin Mark Xu, together with his assignee Bison Capital Holding Company Limited, purchased from the Company 755,873 shares of common stock at a price of $10.15 per share for a total consideration of $7,672,111 (the "Backstop Shares" and "Backstop Subscription"). As a result of Backstop Subscription, the Company had at least $7,500,001 of net tangible assets remaining at the Closing after giving effect to the redemption of any Ordinary Shares by the public shareholders in connection with the Merger.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="font-weight: bold; border-bottom: Black 1.5pt solid">Subsidiaries</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date of incorporation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Place of incorporation  /establishment</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage of economic ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; text-indent: -9pt; padding-left: 9pt">Xynomic Pharmaceuticals (Nanjing) Co., Ltd. ("Xynomic Nanjing")</td><td style="width: 1%"> </td> <td style="width: 20%; text-align: center">November 20, 2017</td><td style="width: 1%"> </td> <td style="width: 20%; text-align: center">PRC</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Xynomic Pharmaceuticals (Shanghai) Co., Ltd. ("Xynomic Shanghai")</td><td> </td> <td style="text-align: center">July 31, 2018</td><td> </td> <td style="text-align: center">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Xynomic Pharmaceuticals (Zhongshan) Co., Ltd. ("Xynomic Zhongshan")</td><td> </td> <td style="text-align: center">May 15, 2018</td><td> </td> <td style="text-align: center">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr></table> 2017-11-20 2018-07-31 2018-05-15 PRC PRC PRC

1.00

1285822 9852216 Entered into by and between Bison Capital and Yinglin Mark Xu, together with his assignee Bison Capital Holding Company Limited, has purchased from the Company 755,873 shares of common stock at a price of $10.15 per share for a total consideration of $7,672,111 (the "Backstop Shares" and "Backstop Subscription"). As a result of Backstop Subscription, the Company had at least $7,500,001 of net tangible assets remaining at the Closing after giving effect to the redemption of any Ordinary Shares by the public shareholders in connection with the Business Combination.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Financial institutions in the mainland of the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">—Denominated in RMB</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">523</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">61,795</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financial institutions in the United States</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">—Denominated in USD</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,745,847</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,130,149</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total cash balances held at financial institutions</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,746,370</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,191,944</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr></table>

4746370

1191944

523

61795

4745847

1130149

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">4.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">INCOME TAXES</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Loss before income taxes</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,708,461</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,051,753</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,327,391</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,196,308</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income tax expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Effective income tax rate</td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right">0</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right">0</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right">0</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right">0</td><td style="font-style: italic; text-align: left">%</td></tr> </table>   The effective income tax rates for the three and six months ended June 30, 2018 and 2019 were 0% and 0%, respectively. The effective income tax rate for the three and six months ended June 30, 2018 and 2019 differs from the U.S. Federal statutory corporate income tax rate of 21% is primarily due to the increase in valuation allowance.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Loss before income taxes</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,708,461</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,051,753</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,327,391</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,196,308</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income tax expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Effective income tax rate</td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right">0</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right">0</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right">0</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right">0</td><td style="font-style: italic; text-align: left">%</td></tr></table>

-5327391

-17196308

-4708461

-3051753

0.00

0.21

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">6.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">PROPERTY AND EQUIPMENT, NET</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30,  2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Leasehold improvement</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">276,839</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">289,470</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">195,586</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Electronic equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,379</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,153</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">281,218</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,209</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(488</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54,413</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">280,730</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">444,796</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>   The depreciation expense for property and equipment was nil and US$30,612 for the three months ended June 30, 2018 and 2019, respectively. The depreciation expense for property and equipment was nil and US$54,593 for the six months ended June 30, 2018 and 2019, respectively.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30,  2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Leasehold improvement</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">276,839</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">289,470</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">195,586</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Electronic equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,379</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,153</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">281,218</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,209</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(488</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54,413</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">280,730</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">444,796</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr></table>

281218

499209

276839

4379

289470

195586

14153

488

54413

280730

444796

54593

30612

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development expense-Contract Research Organizations</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,304,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,288,625</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expense-Contract Manufacture Organizations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,874,956</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,125,901</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">License fee payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fee</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">824,360</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,010,112</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Payroll and social insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">147,692</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109,599</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Payables for equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140,465</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Payable for leasehold improvement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110,736</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">105,832</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">144,767</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">308,544</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total accrued expenses and other current liabilities</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,407,261</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,089,078</td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 0.5in; font-size: 10pt">11.</td> <td style="text-align: justify; font-size: 10pt">LOSS PER SHARE</td></tr> </table>   Basic and diluted net loss per share for each of the periods presented are calculated as follow:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator:</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Net loss attributable to ordinary shareholders</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left">$</td><td style="width: 9%; text-align: right">(4,808,753</td><td style="width: 0; text-align: left">)</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left">$</td><td style="width: 9%; text-align: right">(3,051,753</td><td style="width: 0; text-align: left">)</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left">$</td><td style="width: 9%; text-align: right">(5,524,999</td><td style="width: 0; text-align: left">)</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left">$</td><td style="width: 9%; text-align: right">(918,894,286</td><td style="width: 0; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Weighted average number of ordinary shares-basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid">42,860,772</td><td style="text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid">44,623,568</td><td style="text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid">42,860,772</td><td style="text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid">43,747,040</td><td style="text-align: left; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Net loss per share-basic and diluted</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">(0.11</td><td style="text-align: left; padding-bottom: 4pt">)</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">(0.07</td><td style="text-align: left; padding-bottom: 4pt">)</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">(0.13</td><td style="text-align: left; padding-bottom: 4pt">)</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">(0.43</td><td style="text-align: left; padding-bottom: 4pt">)</td></tr> </table>    When the dividends to preferred shares are not fully paid, the ordinary shares holders shall not participate in undistributed earnings. If all dividends to preferred shares holders are fully paid, the holders of the preferred shares and the holders of the ordinary shares participate in undistributed earnings on a pro rata basis, as if the preferred shares had been converted into ordinary shares.   As a result of the Group's net loss for the three and six months ended June 30, 2018 and 2019, preferred shares and options outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator:</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Net loss attributable to ordinary shareholders</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left">$</td><td style="width: 9%; text-align: right">(4,808,753</td><td style="width: 0; text-align: left">)</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left">$</td><td style="width: 9%; text-align: right">(3,051,753</td><td style="width: 0; text-align: left">)</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left">$</td><td style="width: 9%; text-align: right">(5,524,999</td><td style="width: 0; text-align: left">)</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left">$</td><td style="width: 9%; text-align: right">(918,894,286</td><td style="width: 0; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Weighted average number of ordinary shares-basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid">42,860,772</td><td style="text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid">44,623,568</td><td style="text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid">42,860,772</td><td style="text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid">43,747,040</td><td style="text-align: left; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Net loss per share-basic and diluted</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">(0.11</td><td style="text-align: left; padding-bottom: 4pt">)</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">(0.07</td><td style="text-align: left; padding-bottom: 4pt">)</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">(0.13</td><td style="text-align: left; padding-bottom: 4pt">)</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">(0.43</td><td style="text-align: left; padding-bottom: 4pt">)</td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: bottom"><td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Minimum Lease Payment Amount</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 86%">Year ending June 30, 2019,</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>2020</td> <td> </td> <td>$</td> <td style="text-align: right">241,099</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">236,467</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>2022</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">129,658</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">607,224</td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 0.5in">15.</td> <td style="text-align: justify">SHARE-BASED COMPENSATION</td></tr> </table>   2018 Stock Incentive Plan   On August 28, 2018, the Board of Directors of Xynomic Pharma approved a resolution to adopt the 2018 Stock Incentive Plan (the "2018 Plan") that provides for the granting of options to selected employees, directors and non-employee consultants to acquire ordinary shares of the Company at exercise prices determined by the Board or the administrator appointed by the Board at the time of grant. Upon this resolution, the Board of Directors and shareholders authorized and reserved 8,908,430 ordinary shares for the issuance under the 2018 Plan. The number of ordinary shares available under the Plan shall increase annually on the first day of each fiscal year, beginning with the second fiscal year following the effective date of this Plan, and continuing until (and including) the fiscal year ending December 31, 2028, with such annual increase equal to the lesser of (i) 3,000,000 ordinary shares, (ii) 5% of the number of ordinary shares issued and outstanding on December 31 of the immediately preceding calendar year, and (iii) an amount determined by the Board. As of December 31, 2018 and June 30, 2019, 8,908,430 and 8,022,384 awards remain available for future grants under the 2018 Plan, respectively.   Under the 2018 Plan, Xynomic Pharma granted 886,046 ordinary shares of the Company with the below vesting schedule on January 21, 2019:   Granted to an employee (100,000 shares): 25% of the options is to be vested on April 30, 2019, and 1/48 of the options to be vested each month thereafter. The employee resigned from Xynomic Pharma in May 2019 and the remaining unvested 75% of the options were forfeited.   Granted to a non-employee (786,046 shares): 25% of the options is to be vested on August 31, 2019, and 1/48 of the options to be vested each month thereafter, subject to an acceleration vesting schedule that 75% is to be issued upon completion of Xynomic Pharma's merger with Bison Capital Acquisition Corp, and 25% to be issued in one year after the closing of the merger.  The cost of the share options granted to the non-employee was fully recognized at the grant date, as no substantive future services are required. At the Closing, each option to purchase Xynomic stock that was outstanding immediately prior to the Effective Time was assumed by the Company and automatically converted into an option to purchase shares of common stock of the Company.   Summary of Share Option Activities   The following tables summarize the Company's share option activities for the six months ended June 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; padding-bottom: 1.5pt">Granted to Employee</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Outstanding at January 1, 2019</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Granted</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right">100,000</td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right">1.00</td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 0; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(75,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Outstanding at June 30, 2019</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">25,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1.00</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9.57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">215,050</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 4pt">Exercisable as of June 30, 2019</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">25,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1.00</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9.57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">215,050</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; padding-bottom: 1.5pt">Granted to Non-employee</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Outstanding at January 1, 2019</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Granted</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right">786,046</td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right">0.10</td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 0; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Outstanding at June 30, 2019</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">786,046</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">0.10</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9.57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,433,873</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 4pt">Exercisable as of June 30, 2019</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">589,535</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">0.10</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9.57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,578,436</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>   No options were exercised during the six months ended June 30, 2019.   Management is responsible for determining the fair value of options granted to employees and non-employees and considered a number of factors including valuations. The Company's share-based compensation cost is measured at the fair value of the options as calculated under the binomial models.   Assumptions used in the option-pricing model are presented below:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 91%; text-align: left">Risk-free interest rate</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right">2.77</td><td style="width: 0; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Volatility rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise multiple</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.8</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fair value of underlying ordinary share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.5573</td><td style="text-align: left"> </td></tr> </table>   The Company estimated the risk-free rates based on the 10-year U.S. bond as at the option valuation date. Life of the share options is the contract life of the option. Based on the option agreements, the contract life of the option are 10 years from the respective grant date. The expected volatility at the option valuation date was estimated based on historical volatility of comparable companies. The Company has no history or expectation of paying dividends on its ordinary shares. The Company estimated the fair value of the ordinary shares using the equity allocation approach when valuing options granted. As the Company did not have sufficient information of past employee exercise history, the expected exercise multiple was estimated by referencing to How to Value Employee Stock Options (published by John Hull& Allen White, Financial Analysts Journal, 2004 edition), a well-accepted academic publication.   The grant date fair value of the share options granted for the six months ended June 30, 2019 was US$9.3653. Compensation expense of US$7,652,965 were recognized in general and administrative relating to the 886,046 options for the six months ended June 30, 2019. US$30,317 of the general and administrative expense was reversed during the three months ended June 30,2019 due to the employee's resignation and the forfeiture of the unvested options.   As of June 30, 2019, there was nil unrecognized compensation expenses related to non-vested options.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td></td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; padding-bottom: 1.5pt">Granted to Employee</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Outstanding at January 1, 2019</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Granted</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right">100,000</td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right">1.00</td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 0; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(75,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Outstanding at June 30, 2019</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">25,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1.00</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9.57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">215,050</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 4pt">Exercisable as of June 30, 2019</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">25,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1.00</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9.57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">215,050</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; padding-bottom: 1.5pt">Granted to Non-employee</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Outstanding at January 1, 2019</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Granted</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right">786,046</td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right">0.10</td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 0; text-align: left"> </td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 0; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Outstanding at June 30, 2019</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">786,046</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">0.10</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9.57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,433,873</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 4pt">Exercisable as of June 30, 2019</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">589,535</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">0.10</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9.57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,578,436</td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 91%; text-align: left">Risk-free interest rate</td><td style="width: 0%"> </td> <td style="width: 0; text-align: left"> </td><td style="width: 9%; text-align: right">2.77</td><td style="width: 0; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Volatility rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise multiple</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.8</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fair value of underlying ordinary share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.5573</td><td style="text-align: left"> </td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">9.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">REDEEMABLE CONVERTIBLE PREFERRED SHARES</td></tr> </table>   Redeemable convertible preferred shares were issued by Xynomic Pharma before the Closing and consist of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Angel Preferred Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Series A-1 Preferred Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Series B Preferred Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Balance as of December 31, 2018</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">580,256</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">4,905,780</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">2,424,712</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Redemption value accretion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,117</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,984</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,592,877</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Conversion to common shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(591,373</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,999,764</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,017,589</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 4pt">Balance as of June 30, 2019</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>   At the Closing, all of the outstanding redeemable convertible preferred shares were converted into 34,695,395 common shares of the Company. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Angel Preferred Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Series A-1 Preferred Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Series B Preferred Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Balance as of December 31, 2018</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">580,256</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">4,905,780</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">2,424,712</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Redemption value accretion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,117</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,984</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,592,877</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Conversion to common shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(591,373</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,999,764</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,017,589</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 4pt">Balance as of June 30, 2019</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 0.5in; text-align: left">16.</td><td style="text-align: justify">SUBSEQUENT EVENT</td> </tr></table>   Security Purchase Agreement with Accredited Investors   On or about July 10, 2019, the Company entered into certain Securities Purchase Agreement (the "SPA") with certain "accredited investors" as defined in Rule 501(a) of Regulation D as promulgated under the Securities Act of 1933, as amended (the "Purchasers"), pursuant to which the Company agreed to sell to such Purchasers an aggregate of approximate USD$10 million of units (the "Reg. D Units") of the Company, at a purchase price of USD$3.80 per Unit (subject to adjustment) (the "Reg. D Offering"). Each Reg. D Unit consists of one share of common stock and one-half warrant (the "Reg. D Warrant"). Each whole Reg. D Warrant can be exercised to purchase one share of the Company Stock at $7.00 per share and shall expire in three (3) years of the issuance, and have the rights and preference set forth in certain Warrant Agreement. Furthermore, the SPA provides, among other terms, a maximum offering in an aggregate of $15 million with the first closing of a minimum of $5 million upon delivery of the closing conditions set forth in the SPA, provided that no closing shall occur after September 30, 2019 subject to certain exception.   The Reg. D Units, the shares of common stock underlying the Reg. D Units (the "Reg.D Unit Shares"), the Reg. D Warrants issued in the Reg.D Offering, and shares of common stock issuable upon exercise of the Reg. D Warrants (the "Reg.D Warrant Shares"), are exempt from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D.   With delisting from Nasdaq occurred subsequently, the parties have started to renegotiate the terms of the SPA including potential waiver of certain closing conditions.   Delisting from Nasdaq   On July 15, 2019, the Company was notified in writing by the Panel at Nasdaq that they have denied its request for continued listing on Nasdaq based upon the Company's non-compliance with Nasdaq Listing Rules 5505(a)(3) and 5515(a)(4), which require a minimum of 300 round lot holders of common stock and 400 round lot holders of common stock purchase warrants for initial listing on Nasdaq; as well as non-compliance with the minimum $5 million in stockholders' equity requirement, as set forth in Nasdaq Listing Rule 5505(b)(1)(A). As a result, Nasdaq suspended trading in the Company's securities effective at the open of business on Wednesday, July 17, 2019; and the shares subsequently commenced trading on the over-the-counter markets.   Special Meeting of Stockholders   On July 26, 2019, the Company called for a Special Meeting of its stockholders be held on August 26, 2019 for the purpose of authorizing the Company's Board of Directors to, in its discretion, to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio no less than 1-for-1.5 and no greater than 1-for-5 at any time prior to August 27, 2020, with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders ("Stock Split Proposal"). The Board of Directors may alternatively elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion.

6892109

4340206

475000

-2531472

1358361

679436

1299032

2767441

936542

1225569

183694

1567799

3873804

10222980

848761

1443731

745286

25908

52723

44915

93968

48408

146691

22500

97638

8178

32811

17723

-17196308

-5327391

-3051753

-4708461

-18894286

-5524999

-3051753

-4808753

19049

56040

19049

56040

-18875237

-5524999

-2995713

-4808753

-0.43

-0.13

-0.07

-0.11

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">VAT input tax</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">52,762</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">86,735</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">124,076</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Deposits</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,339</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,754</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total other non-current assets</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">155,176</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">219,565</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

52762 86735

93075

124076

9339

8754

155176

219565

4954

2035

14407261

16089078

17645943

17048886

580256

4905780

2424712

14169060

36401911

58564

77613

0.0001

23435379

12147500

5281101

23435379

12147500

5281101

580256

4905780

2424712

811332

6964223

24335989

50000000

200000000

-1697978 -1697978

56040

-36991

56040

7652965

-30317

7683282

-30317

886046

30317

7672111

7672035

55000

-64

646955

34695395 -1499163 196 -1499359 1955246

-17196308

-5327391

8178

491

203

-93968

64827

1500041

2583442

-48797

4447904

2807199

52340

-2919

-33128

-1425959 -1425959 -9435000

-746811

2500000

444900

906810

4971358 64070650 -543296 -536905 -38683 -130335 -536905 -543296

29940

-133061 Yes false 001-38120 Yes D8

144767

308544

110736

105832

147692

109599

824360

1010112

1000000 1000000 140465 10304750 10288625 1874956 3125901 6037500

6023689

64070650

10.54

4971358 7672111

2560753

140000

-591373

-4999764

-4017589

25000

786046

75000

100000

786046

886046

25000

589535

0.1

P9Y6M25D

215050

7433873

215050

5578436

0.00

0.361

P10Y

0.0277

2.8

9.5573

(i) 3,000,000 ordinary shares, (ii) 5% of the number of ordinary shares issued and outstanding on December 31 of the immediately preceding calendar year, and (iii) an amount determined by the Board. As of December 31, 2018 and June 30, 2019, 8,908,430 and 8,022,384 awards remain available for future grants under the 2018 Plan, respectively.

9.3653

Under the terms of the agreement, the Group made upfront payments of US$3.5 million in 2017 and 1st milestone payment of US$3.5 million in 2018 to Pharmacyclics which were recorded as research and development expenses in 2017 and 2018, respectively. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 2nd milestone payment of US$6,500,000 upon regulatory approval for the first indication for a licensed product in China or in the United States; 2) 3rd milestone payment of US$4,000,000 upon regulatory approval for the second indication for a licensed product in China or in the United States. Under the terms of the agreement, the Group made upfront payments to BII totaling US$0.3 million which was recorded as a research and development expense in 2017. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 1st milestone payment of US$ 1,700,000 upon first dosing of a patient in Phase I Clinical Trial in the US or China; 2) 2nd milestone payment of US$ 4,000,000 upon first dosing of a patient in a pivotal Phase III Clinical Trial in the first indication in the US or China; 3) 3rd milestone payment of US$2,000,000 upon first dosing of a patient in a pivotal Phase III Clinical Trial in a second indication in the US or China; 4) 4th milestone payment of US$ 7,000,000 upon the grant of the first marketing authorization of the first indication in the US; 5) 5th milestone payment of US$3,000,000 upon the grant of the first marketing authorization of the first indication in China. Under the terms of the agreement, as of June 30, 2019 the Group was obligated to make upfront payments to BII totaling US$1 million which was recorded as a research and development expense for the year ended December 31, 2018 and was included in accrued expenses and other current liabilities as of December 31, 2018. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 1st milestone payment of US$7,000,000 upon first dosing of a patient in Phase II or Phase III Clinical Trial in the first indication either of which is intended to be a pivotal trial; 2) 2nd milestone payment of US$10,000,000 upon the grant of the first Marketing Authorization of the first indication. In addition, the Group will pay royalties at a certain percentage of the net sales. The royalty term commences from the first commercial sale of such licensed product in such country until the later of (i) the date on which such licensed product is no longer covered by a valid claim of the licensed patents, (ii) the expiration of regulatory exclusivity of the licensed product in such country, or (iii) the tenth anniversary of the first launch of the respective licensed product in the country in the indication, provided the licensed know-how is still proprietary, or such licensed know-how is no longer proprietary owing to a breach of its confidentiality obligations.

-0.13

-0.43

-0.11

-0.07

580256 2424712 4905780

11117

93984

1592877

34695395

241099

236467

129658

607224

P36M P12M

146598

40275

98434

24249

(1) all or any portion of the 1,509,375 shares of common stock of Bison issued to certain existing investors (the "Founder Shares"), (2) 432,063 private units issued by Bison to certain existing investors in conjunction with the consummation of its initial public offering (the "Private Units"),

The Plaintiff seeks $6,992,068 from Xynomic Pharma, plus interest at the contract rate of 1% per month. Xynomic Pharma must respond to the complaint by August 19, 2019.

7078037

273467

64093

31697

The Company called for a Special Meeting of its stockholders be held on August 26, 2019 for the purpose of authorizing the Company's Board of Directors to, in its discretion, to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio no less than 1-for-1.5 and no greater than 1-for-5 at any time prior to August 27, 2020

The Company entered into certain Securities Purchase Agreement (the "SPA") with certain "accredited investors" as defined in Rule 501(a) of Regulation D as promulgated under the Securities Act of 1933, as amended (the "Purchasers"), pursuant to which the Company agreed to sell to such Purchasers an aggregate of approximate USD$10 million of units (the "Reg. D Units") of the Company, at a purchase price of USD$3.80 per Unit (subject to adjustment) (the "Reg. D Offering"). Each Reg. D Unit consists of one share of common stock and one-half warrant (the "Reg. D Warrant"). Each whole Reg. D Warrant can be exercised to purchase one share of the Company Stock at $7.00 per share and shall expire in three (3) years of the issuance, and have the rights and preference set forth in certain Warrant Agreement. Furthermore, the SPA provides, among other terms, a maximum offering in an aggregate of $15 million with the first closing of a minimum of $5 million upon delivery of the closing conditions set forth in the SPA, provided that no closing shall occur after September 30, 2019 subject to certain exception.

0.11

0.0012

-0.0162

0.20

0.43

0.19

0.64

0.71

0.60

0.18

0.78

0.12

Xynomic Pharma issued convertible notes to Northern Light Venture Capital V, Ltd., and Bo Tan and received proceeds of US$2,500,000, which were converted into 776,633 Series B Preferred Shares in August 2018. Further in August 2018, Xynomic Pharma raised US$17 million by issuance of 5,281,101 Series B Preferred Shares to certain investors, including the conversion of convertible notes of US$2.5 million. At the Closing of the Merger, 755,873 shares of Backstop Shares were issued for a total consideration of $7,672,111.

15701138 less than 10% less than 10%

3570000

-1697978 -197608 -100292

500000 5 499995 9608726 3469 9605257

2560754

2008936

80640

1800000

7635000

262743

1800000

747189

5064000

2571000

383097

2571000

112455

500000

10.00

100000

500000

404900

500000

295021

5000

22500

27500

15000

7500

112500

90000

0.08

2019-09-15

Supplier A offered $3.57 million credit to offset previously issued invoices to the Company during the three months ended June 30, 2019. Represents less than 10% of research and development expenses for the three and six months ended June 30, 2018 and 2019.

EX-101.SCH 7 xyno-20190630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Unaudited Condensed Consolidated Statements Of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Unaudited Condensed Consolidated Changes In Shareholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Description of Organization and Business Operations link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Cash link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Prepaid Expenses link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Other Non-Current Assets link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Accrued Expenses And Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Redeemable Convertible Preferred Shares link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Licenses Arrangement link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Description of Organization and Business Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Cash (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Prepaid Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Other Non-Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Accrued Expenses And Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Redeemable Convertible Preferred Shares (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Commitments And Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Description of Organization and Business Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Description of Organization and Business Operations (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Cash (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Prepaid Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Property and Equipment, Net (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Other Non-Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Accrued Expenses And Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Redeemable Convertible Preferred Shares (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Redeemable Convertible Preferred Shares (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Licenses Arrangement (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 xyno-20190630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 xyno-20190630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 xyno-20190630_lab.xml XBRL LABEL FILE Income Statement Location [Axis] Administrative Services Arrangement [Member] Title of Individual [Axis] Bison Capital [Member] Equity Components [Axis] Additional Paid-In Capital Retained Earnings / Accumulated Deficit Common Stock Supplier [Axis] Supplier A [Member] Supplier B [Member] Supplier C [Member] Supplier D [Member] Supplier E [Member] Xynomic Pharmaceuticals Nanjing [Member] Xynomic Pharmaceuticals Shanghai [Member] Xynomic Pharmaceuticals Zhongshan [Member] Business Acquisition [Axis] Merger Consideration Agreement [Member] Sale of Stock [Axis] Private Placement [Member] IPO [Member] Xynomic Pharma [Member ] Related Party [Axis] Yinglin Mark Xu [Member] Geographical [Axis] PRC [Member] Currency [Axis] USD [Member] Property, Plant and Equipment, Type [Axis] Leasehold Improvements [Member] Equipment [Member] Office Equipment [Member] Class of Stock [Axis] Angel Preferred Shares [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Other Comprehensive Income / Loss British Virgin Islands [Member] Mark Yinglin XU [Member] Bison Capital [Member] Employee [Member] Non Employee [Member] Plan Name [Axis] 2018 Stock Incentive Plan [Member] General and Administrative Expense [Member] Agreement [Axis] Pharmacyclics [Member] Boehringer Ingelheim International [Member] BIIXP [Member] Series A-1 Preferred Shares [Member] Statistical Measurement [Axis] Maximum [Member] Minimum [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Short-term Debt, Type [Axis] Related Party Loans and Promissory Notes [Member] Zhongshan Bison [Member] Eigenbridge, Inc [Member ] RMB [Member] Product and Service [Axis] Service purchased from shareholder [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Current Reporting Status Entity Filer Category Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity File Number Entity Interactive Data Current Entity Incorporation State Country Code Statement [Table] Statement [Line Items] Angel Preferred Shares Series A Preferred Stock Series B Preferred Stock ASSETS Current assets: Cash Prepaid expenses Total current assets Property and equipment, net Intangible assets, net Other non-current assets TOTAL ASSETS LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT Current liabilities: Bank overdraft Accrued expenses and other current liabilities Promissory note - related party Amount due to shareholders Total current liabilities Total liabilities Commitments and Contingencies Mezzanine equity: Preferred Shares Total mezzanine equity Shareholders' deficit: Preferred Stock (par value US$0.0001 per share as of December 31, 2018 and June 30, 2019; 50,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2018 and June 30, 2019 Common stock (par value US$0.0001 per share as of December 31, 2018 and June 30, 2019; 200,000,000 shares authorized, 6,706,068 and 46,273,846 shares issued and outstanding as of December 31, 2018 and June 30, 2019, respectively) Additional paid-in capital Accumulated other comprehensive income Accumulated deficit Total shareholders' deficit TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT Series A Preferred Shares Series B Preferred Shares Preferred shares, par value Preferred shares, authorized Preferred shares, issued Preferred shares,outstanding Preferred equity, redemption value Preferred equity, liquidation value Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: Research and development General and administrative General and administrative to related parties Total operating expenses Loss from operations Other income/(expenses) Investment income Interest income Interest expenses to a related party Loss from operations before income tax benefit Income tax Net loss Accretion to preferred share redemption value Net loss attributable to ordinary shareholders Other comprehensive income: Foreign currency translation adjustment, net of nil income taxes Total other comprehensive income Comprehensive loss attributable to ordinary shareholders Weighted average ordinary shares outstanding - basic and diluted Loss per share - basic and diluted Ordinary Additional paid-in capital Accumulated other comprehensive income Accumulated deficit Balance Balance, shares Redeemable convertible preferred shares redemption value accretion Issuance of backstop common shares Issuance of backstop common shares, shares Conversion of promissory notes and Rights to common shares Conversion of promissory notes and Rights to common shares, shares Conversion of Rights to common shares Conversion of Rights to common shares, shares Conversion of Preferred Shares to common shares Conversion of Preferred Shares to common shares, shares Combination with Xynomic Pharmaceuticals, Inc. Combination with Xynomic Pharmaceuticals, Inc. shares Net loss Foreign currency translation adjustment, net of nil income taxes Share-based compensation Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Investment income Amortization Depreciation Changes in operating assets and liabilities: Prepaid expenses Prepaid expenses to a shareholder Other non-current assets Accrued expenses and other payables Amount due to shareholders Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of short-term investments Sale of short-term investments Purchase of property and equipment Cash withdrawn from Trust Account Net cash (used in)/provided by investing activities CASH FLOWS FROM FINANCING ACTIVITIES: EX-101.PRE 11 xyno-20190630_pre.xml XBRL PRESENTATION FILE GRAPHIC 12 image_001.jpg GRAPHIC begin 644 image_001.jpg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�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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.19.2

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2019

Aug. 08, 2019

Document and Entity Information [Abstract]

Entity Registrant Name XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Entity Central Index Key 0001697805

Amendment Flag false

Current Fiscal Year End Date --12-31

Document Type 10-Q

Document Period End Date Jun. 30, 2019

Document Fiscal Period Focus Q2

Document Fiscal Year Focus 2019

Entity Current Reporting Status Yes

Entity Filer Category Non-accelerated Filer

Entity Small Business true

Entity Shell Company false

Entity Emerging Growth Company true

Entity Ex Transition Period false

Entity Common Stock, Shares Outstanding 46,273,846

Entity File Number 001-38120

Entity Interactive Data Current Yes

Entity Incorporation State Country Code D8

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_DocumentAndEntityInformationAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.19.2

Condensed Consolidated Balance Sheets - USD ($)

Jun. 30, 2019

Dec. 31, 2018

Current assets:

Cash $ 1,191,944 $ 4,746,370

Prepaid expenses 155,805 277,750

Total current assets 1,347,749 5,024,120

Property and equipment, net 444,796 280,730

Intangible assets, net 1,450 1,937

Other non-current assets 219,565 155,176

TOTAL ASSETS 2,013,560 5,461,963

Current liabilities:

Bank overdraft 2,035 4,954

Accrued expenses and other current liabilities 16,089,078 14,407,261

Promissory note - related party 404,900

Amount due to shareholders 552,873 3,233,728

Total current liabilities 17,048,886 17,645,943

Total liabilities 17,048,886 17,645,943

Commitments and Contingencies

Mezzanine equity:

Total mezzanine equity 7,910,748

Shareholders' deficit:

Preferred Stock (par value US$0.0001 per share as of December 31, 2018 and June 30, 2019; 50,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2018 and June 30, 2019

Common stock (par value US$0.0001 per share as of December 31, 2018 and June 30, 2019; 200,000,000 shares authorized, 6,706,068 and 46,273,846 shares issued and outstanding as of December 31, 2018 and June 30, 2019, respectively) 4,627 817

Additional paid-in capital 36,401,911 14,169,060

Accumulated other comprehensive income 77,613 58,564

Accumulated deficit (51,519,477) (34,323,169)

Total shareholders' deficit (15,035,326) (20,094,728)

TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT 2,013,560 5,461,963

Angel Preferred Shares

Mezzanine equity:

Preferred Shares 580,256

Series A Preferred Stock

Mezzanine equity:

Preferred Shares 4,905,780

Series B Preferred Stock

Mezzanine equity:

Preferred Shares $ 2,424,712

X

- Definition
Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(b))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_AssetsHeldInTrustNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_BankOverdrafts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph 14
-URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph (12)(c)
-URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph 15
-URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph (16)(c)
-URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764
+ Details

Name: us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=xyno_AngelPreferredSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 15 R3.htm IDEA: XBRL DOCUMENT v3.19.2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)

Jun. 30, 2019

Dec. 31, 2018

Preferred stock, par value $ 0.0001 $ 0.0001

Preferred stock, shares authorized 50,000,000 50,000,000

Preferred stock, shares issued

Preferred stock, shares outstanding

Common stock, par value $ 0.0001 $ 0.0001

Common stock, shares authorized 200,000,000 200,000,000

Common stock, shares issued 46,273,846 6,706,068

Common stock, shares outstanding 46,273,846 6,706,068

Angel Preferred Shares

Preferred shares, par value $ 0.0001

Preferred shares, authorized 0 23,435,379

Preferred shares, issued 0 23,435,379

Preferred shares,outstanding 0 23,435,379

Preferred equity, redemption value $ 580,256

Preferred equity, liquidation value $ 811,332

Series A Preferred Shares

Preferred shares, par value $ 0.0001

Preferred shares, authorized 0 12,147,500

Preferred shares, issued 0 12,147,500

Preferred shares,outstanding 0 12,147,500

Preferred equity, redemption value $ 4,905,780

Preferred equity, liquidation value $ 6,964,223

Series B Preferred Shares

Preferred shares, par value $ 0.0001

Preferred shares, authorized 0 5,281,101

Preferred shares, issued 0 5,281,101

Preferred shares,outstanding 0 5,281,101

Preferred equity, redemption value $ 2,424,712

Preferred equity, liquidation value $ 24,335,989

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquityLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (27)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=xyno_AngelPreferredSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 16 R4.htm IDEA: XBRL DOCUMENT v3.19.2

Unaudited Condensed Consolidated Statements Of Comprehensive Loss - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Operating expenses:

Research and development $ 1,567,799 $ 3,873,804 $ 6,892,109 $ 4,340,206

General and administrative 1,443,731 745,286 10,222,980 848,761

General and administrative to related parties 22,500 97,638 48,408 146,691

Total operating expenses 3,034,030 4,716,728 17,163,497 5,335,658

Loss from operations (3,034,030) (4,716,728) (17,163,497) (5,335,658)

Investment income 8,178 8,178

Interest income 89 89

Interest expenses to a related party (17,723) (32,811)

Loss from operations before income tax benefit (3,051,753) (4,708,461) (17,196,308) (5,327,391)

Income tax

Net loss (3,051,753) (4,708,461) (17,196,308) (5,327,391)

Accretion to preferred share redemption value (100,292) (1,697,978) (197,608)

Net loss attributable to ordinary shareholders (3,051,753) (4,808,753) (18,894,286) (5,524,999)

Other comprehensive income:

Foreign currency translation adjustment, net of nil income taxes 56,040 19,049

Total other comprehensive income 56,040 19,049

Comprehensive loss attributable to ordinary shareholders $ (2,995,713) $ (4,808,753) $ (18,875,237) $ (5,524,999)

Weighted average ordinary shares outstanding - basic and diluted (44,623,568) (42,860,772) (43,747,040) (42,860,772)

Loss per share - basic and diluted $ (0.07) $ (0.11) $ (0.43) $ (0.13)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest expense incurred on a debt or other obligation to related party.
+ References
No definition available.
+ Details

Name: us-gaap_InterestExpenseRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net amount of operating interest income (expense).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.10)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(a),(b))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_InvestmentIncomeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 35
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118948100&loc=d3e30304-110892

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b,d)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of general and administrative expense classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_AccretionToPreferredSharesRedemptionValue

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 17 R5.htm IDEA: XBRL DOCUMENT v3.19.2

Unaudited Condensed Consolidated Changes In Shareholders' Deficit - USD ($)

Ordinary

Additional paid-in capital

Accumulated other comprehensive income

Accumulated deficit

Total

Balance at Dec. 31, 2018 $ 817 $ 14,169,060 $ 58,564 $ (34,323,169) $ (20,094,728)

Balance, shares at Dec. 31, 2018 8,165,377

Redeemable convertible preferred shares redemption value accretion (1,697,978) (1,697,978)

Net loss (14,144,555) (14,144,555)

Foreign currency translation adjustment, net of nil income taxes (36,991) (36,991)

Share-based compensation 7,683,282 7,683,282

Balance at Mar. 31, 2019 $ 817 20,154,364 21,573 (48,467,724) (28,290,970)

Balance, shares at Mar. 31, 2019 8,165,377

Balance at Dec. 31, 2018 $ 817 14,169,060 58,564 (34,323,169) (20,094,728)

Balance, shares at Dec. 31, 2018 8,165,377

Net loss (17,196,308)

Share-based compensation 7,652,965

Balance at Jun. 30, 2019 $ 4,627 36,401,911 77,613 (51,519,477) (15,035,326)

Balance, shares at Jun. 30, 2019 46,273,846

Balance at Mar. 31, 2019 $ 817 20,154,364 21,573 (48,467,724) (28,290,970)

Balance, shares at Mar. 31, 2019 8,165,377

Issuance of backstop common shares $ 76 7,672,035 7,672,111

Issuance of backstop common shares, shares 755,873

Conversion of promissory notes and Rights to common shares $ 5 499,995 500,000

Conversion of promissory notes and Rights to common shares, shares 55,000

Conversion of Rights to common shares $ 64 (64)

Conversion of Rights to common shares, shares 646,955

Conversion of Preferred Shares to common shares $ 3,469 9,605,257 9,608,726

Conversion of Preferred Shares to common shares, shares 34,695,395

Combination with Xynomic Pharmaceuticals, Inc. $ 196 (1,499,359) (1,499,163)

Combination with Xynomic Pharmaceuticals, Inc. shares 1,955,246

Net loss (3,051,753) (3,051,753)

Foreign currency translation adjustment, net of nil income taxes 56,040 56,040

Share-based compensation (30,317) (30,317)

Balance at Jun. 30, 2019 $ 4,627 $ 36,401,911 $ 77,613 $ (51,519,477) $ (15,035,326)

Balance, shares at Jun. 30, 2019 46,273,846

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b,c)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: xyno_CombinationWithXynomicPharmaceuticalsInc.

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_CombinationWithXynomicPharmaceuticalsInc.Shares

Namespace Prefix: xyno_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_ConversionOfPreferredSharesToCommonShare

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_ConversionOfPreferredSharesToCommonSharesShares

Namespace Prefix: xyno_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_ConversionOfPromissoryNotesAndRightsToCommonShare

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_ConversionOfPromissoryNotesAndRightsToCommonSharesShares

Namespace Prefix: xyno_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_RedeemableConvertiblePreferredSharesRedemptionValueAccretion

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 18 R6.htm IDEA: XBRL DOCUMENT v3.19.2

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (17,196,308) $ (5,327,391)

Adjustments to reconcile net loss to net cash used in operating activities:

Share-based compensation 7,652,965

Investment income (8,178)

Amortization 491 203

Depreciation 54,593

Changes in operating assets and liabilities:

Prepaid expenses 119,758 (349,272)

Prepaid expenses to a shareholder 93,968

Other non-current assets (64,827)

Accrued expenses and other payables 1,500,041 2,583,442

Amount due to shareholders (48,797)

Net cash used in operating activities (7,982,084) (3,007,228)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of short-term investments (4,447,904)

Sale of short-term investments 2,807,199

Purchase of property and equipment (52,340)

Cash withdrawn from Trust Account 63,310,884

Net cash (used in)/provided by investing activities 63,258,544 (1,640,705)

CASH FLOWS FROM FINANCING ACTIVITIES:

Bank overdraft (2,919) (33,128)

Proceeds from advance from a Series B shareholder 1,425,959

Repayment of advance from a Series B shareholder (746,811)

Proceeds from issuance of convertible notes 2,500,000

Proceeds from promissory note - related party 444,900

Proceeds from short-term loan 906,810

Proceeds from issuance of backstop ordinary shares 4,971,358

Redemption of ordinary shares (64,070,650)

Advance from a shareholder 543,296 536,905

Net cash provided by/(used in) financing activities (58,860,826) 5,336,546

Effect of foreign exchange rate changes on cash 29,940

NET INCREASE/(DECREASE) IN CASH (3,554,425) 688,613

CASH, BEGINNING OF THE PERIOD 4,746,370 100,344

CASH, END OF THE PERIOD 1,191,944 788,957

SUPPLEMENTAL INFORMATION

Interest paid

Income tax paid

Acquisition of property and equipment included in accrued expenses and other liabilities $ 133,061

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDueToRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in noncurrent assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpensesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow from the excess drawing from an existing cash balance, which will be honored by the bank but reflected as a loan to the drawer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 9
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3098-108585
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfBankOverdrafts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) for debt classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfOtherDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The Amount of Acquisition of property and equipment included in accrued expenses and other liabilities.
+ References
No definition available.
+ Details

Name: xyno_AcquisitionOfPropertyAndEquipmentIncludedInAccruedExpensesAndOtherLiabilities

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash withdrawn from trust account.
+ References
No definition available.
+ Details

Name: xyno_InvestmentToCashWithdrawnForTrustAccount

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of Proceeds from advance to shareholder
+ References
No definition available.
+ Details

Name: xyno_ProceedsFromAdvanceToShareholder

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The Number of Proceeds from issuance of ordinary shares.
+ References
No definition available.
+ Details

Name: xyno_ProceedsFromIssuanceOfOrdinaryShares

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The Amount Of Proceeds From Shareholders Advance.
+ References
No definition available.
+ Details

Name: xyno_ProceedsFromShareholdersAdvance

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of Redemption of ordinary shares.
+ References
No definition available.
+ Details

Name: xyno_RedemptionOfOrdinaryShares

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 19 R7.htm IDEA: XBRL DOCUMENT v3.19.2

Description of Organization and Business Operations
6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Xynomic Pharmaceuticals Holdings, Inc. (formerly known as Bison Capital Acquisition Corp. , the "Company") was a blank check company incorporated in the British Virgin Islands on October 7, 2016. The Company was formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities (a "Business Combination").

All activities through May 14, 2019 relate to the Company's formation, its initial public offering of 6,037,500 units (the "Initial Public Offering"), the simultaneous sale of 432,062 units (the "Private Units") in a private placement to the Company's sponsor, Bison Capital Holding Company Limited ("Bison Capital") and EarlyBirdCapital, Inc. ("EarlyBirdCapital") and their designees, identifying a target company for a Business Combination and activities in connection with the proposed acquisition of Xynomic Pharmaceuticals, Inc., a Delaware corporation ("Xynomic Pharma"). On March 3, 2019, the Company received a commitment from Xynomic Pharma that it has agreed to contribute to the Company as a loan $0.02 per month for each public share that is not redeemed by the Company's shareholders (the "Contribution") in connection with the Extension Amendment. The amount of the Contribution will not bear interest and will be repayable by the Company to Xynomic Pharma upon consummation of a Business Combination. Xynomic Pharma will have the sole discretion whether to continue extending for additional calendar months until the Combination Period and if Xynomic Pharma determines not to continue extending for additional calendar months, its obligation to make Contributions following such determination will terminate. In May 2019, $16,062 was loaned to the Company and deposited into the Trust Account, which amount is equal to $0.02 for each of the 803,080 shares that were not redeemed.

On May 15, 2019 (the "Effective Time"), each share of Xynomic Pharma's ordinary shares and preferred shares issued and outstanding prior to the Effective Time was automatically converted into the right to receive, on a pro rata basis, the Closing Consideration Shares (as defined in the Merger Agreement) and the Earnout Shares (as defined in the Merger Agreement), and each option to purchase Xynomic Pharma's ordinary shares that was outstanding immediately prior to the Effective Time was assumed by the Company and automatically converted into an option to purchase shares of common stock of the Xynomic Pharma. In addition to the Closing Consideration Shares, Xynomic Pharma stockholders received an additional 9,852,216 shares of common stock in aggregate (the "Earnout Shares" and, together with the Closing Consideration Shares, the "Merger Consideration Shares", such transaction is referred as the "Merger"). As a result, the Company issued 42,860,772 common shares as in aggregate Merger Consideration Shares to shareholders of Xynomic Pharma immediately prior to the Effective Time (the "Sellers"). Pursuant to the Merger Agreement, 1,285,822 shares were deposited into an escrow account (the "Escrow Account") to serve as security for, and the exclusive source of payment of, the Company's indemnity rights under the Merger Agreement and any excess of the estimated Closing Merger Consideration over the final Closing Merger Consideration amount determined post-Closing.

Following the Merger, the Xynomic Pharma became a wholly-owned subsidiary of the Company. Xynomic Pharma was incorporated in the United States on August 24, 2016. Xynomic Pharma and its subsidiaries are primarily engaged in in-licensing, developing and commercializing oncology drug candidates in the People's Republic of China ("PRC"), the United States, and rest of the world. As of the Effective Time, Xynomic Pharma's subsidiaries are as following:



Subsidiaries Date of incorporation Place of incorporation
/establishment Percentage of economic ownership

Xynomic Pharmaceuticals (Nanjing) Co., Ltd.
("Xynomic Nanjing") November 20, 2017 PRC 100 %

Xynomic Pharmaceuticals (Shanghai) Co., Ltd. ("Xynomic Shanghai") July 31, 2018 PRC 100 %

Xynomic Pharmaceuticals (Zhongshan) Co., Ltd. ("Xynomic Zhongshan") May 15, 2018 PRC 100 %

The Merger was accounted for as a "reverse acquisition" since, immediately following the consummation of the Merger (the "Closing"), the Sellers effectively controlled the post-combination Company. For accounting purposes, Xynomic Pharma was deemed to be the accounting acquirer in the Merger and, consequently, the Merger is treated as a recapitalization of Xynomic Pharma (i.e., a capital transaction involving the issuance of shares by the Company for the shares of Xynomic Pharma). Accordingly, the consolidated assets, liabilities and results of operations of Xynomic Pharma became the historical financial statements of the Company and its subsidiaries, and the Company's assets, liabilities and results of operations were consolidated with Xynomic Pharma beginning at the Closing. No step-up in basis or intangible assets or goodwill were recorded in the Merger.

On May 14, 2019, prior to the Closing, the Company continued out of the British Virgin Islands and domesticated as a Delaware corporation (the "Domestication"). As a result, the Company is no longer a company incorporated in the British Virgin Islands.

At the Closing, pursuant to the Backstop Agreement dated May 1, 2019 entered into by and between the Company and Yinglin Mark Xu, Yinglin Mark Xu, together with his assignee Bison Capital Holding Company Limited, purchased from the Company 755,873 shares of common stock at a price of $10.15 per share for a total consideration of $7,672,111 (the "Backstop Shares" and "Backstop Subscription"). As a result of Backstop Subscription, the Company had at least $7,500,001 of net tangible assets remaining at the Closing after giving effect to the redemption of any Ordinary Shares by the public shareholders in connection with the Merger.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.19.2

Summary of Significant Accounting Policies
6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the United States Securities and Exchange Commission ("SEC"). The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements of Xynomic Pharmaceuticals, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated balance sheet of the Company and Xynomic Pharma as of December 31, 2018, and the related consolidated statements of comprehensive loss, changes in equity and cash flows for the year then ended, included in the Company's Proxy Statement/Prospectus on Form 8-K filed with the SEC on May 15, 2019.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of June 30, 2019, the results of operations for the three and six months ended June 30, 2018 and 2019 and cash flows for the six months ended June 30, 2018 and 2019, have been made.

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant accounting estimates include, but not limited to the fair value of the ordinary shares to determine the existence of beneficial conversion feature of the redeemable convertible preferred shares, the fair value of share-based compensation awards, depreciable lives of property and equipment, the recoverability of the carrying amounts of property and equipment and the recoverability of deferred income tax assets. Changes in facts and circumstances may result in revised estimates. Actual results could differ from those estimates, and as such, differences may be material to the unaudited condensed consolidated financial statements.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation

Going Concern

The Company and its subsidiaries Xynomic Pharma, Xynomic Nanjing, Xynomic Shanghai and Xynomic Zhongshan (the "Group") have not generated any revenues from product sales. Substantial additional financing will be required by the Group to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Group's research and development efforts will be successful.

The Group's ability to fund operations is based on its ability to attract investors and its ability to borrow funds on reasonable economic terms. Historically, the Group has relied principally on equity financing and shareholder's borrowings to fund its operations and business development. The Group's ability to continue as a going concern is dependent on management's ability to successfully execute its business plan, which includes generating revenues after drug marketing, controlling operating expenses, as well as, continuing to obtain additional equity financing. On April 3, 2018, Xynomic Pharma issued convertible notes to Northern Light Venture Capital V, Ltd., and Bo Tan and received proceeds of US$2,500,000, which were converted into 776,633 Series B Preferred Shares in August 2018. Further in August 2018, Xynomic Pharma raised US$17 million by issuance of 5,281,101 Series B Preferred Shares to certain investors, including the conversion of convertible notes of US$2.5 million. At the Closing of the Merger, 755,873 shares of Backstop Shares were issued for a total consideration of $7,672,111.

On May 15, 2019, the Company received written notice from the staff of the NASDAQ Stock Market LLC ("Nasdaq") indicating that the Staff had determined to delist its securities from NASDAQ based upon the non-compliance with the requirement of a minimum of 300 round lot holders of and 400 round lot holders of purchase warrants and the requirement of the minimum US$5 million in stockholders' equity. The Company requested a hearing before the Nasdaq Hearings Panel (the "Panel"), and such request stayed any suspension or delisting action by Nasdaq pending the completion of the hearing process and the expiration of any extension period that may be granted to the Company by the Panel. On July 15, 2019, the Company was notified in writing by the Panel at Nasdaq that they denied the Company's request for continued listing on Nasdaq based upon the Company's non-compliance with Nasdaq Listing Rules 5505(a)(3) and 5515(a)(4). As a result, Nasdaq suspended trading in the Company's securities effective at the open of business on Wednesday, July 17, 2019; and the Company's shares will subsequently commence trading on the over-the-counter markets. The Company still intends to continue with its compliance plan with the Nasdaq listing requirements and is diligently pursuing courses of action designed to remedy our noncompliance with Nasdaq's initial listing requirements as set forth above. There can be no assurance, however, that the Company will be able to regain compliance with the mainboard listing requirements.

The Group currently does not have any commitments to obtain additional funds except the potential private placements in details provided in Note 16 herein below and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Group cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs to: commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including another merger or sale of the Group; or cease operations. If the Group engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process.

The Group has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Group has incurred recurring losses from operations since inception. The Group incurred a net loss of US$3,051,753 and US$17,196,308 for the three and six months ended June 30, 2019, respectively. Further, as of June 30, 2019, the Group had net current liabilities (current assets less current liabilities) of US$15,701,138 and accumulated deficit of US$51,519,477. The Group's ability to continue as a going concern is dependent on its ability to raise capital to fund its current research and development activities and future business plans. Additionally, volatility in the capital markets and general economic conditions in the United States may be a significant obstacle to raising the required funds. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements included herein do not include any adjustments that might be necessary should the Group be unable to continue as a going concern. If the going concern basis were not appropriate for these financial statements, adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used.

Operations of the Group are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Group's product candidates become approved drugs and how significant their market share will be, some of which are outside of the Group's control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Group's financial condition and future operations.

(b) Share-based Compensation

The Company granted share options to its selected employees and non-employee consultants.

Share-based awards granted to employees with service conditions attached are measured at the grant date fair value and are recognized as an expense using graded vesting method over the requisite service period, which is generally the vesting period. The forfeitures are accounted when they occur.



In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"). The new guidance largely aligns the accounting for share-based awards issued to employees and nonemployees. Existing guidance for employee awards will apply to non-employee share-based transactions with limited exceptions. The Company adopted this guidance on January 1, 2019.

Share-based awards granted to non-employees are measured at the grant date fair value. When no future services are required to be performed by the non-employee in exchange for an award of equity instruments, the cost of the award is expensed on the grant date.

Option-pricing models are adopted to measure the value of awards at each grant date. The determination of fair value is affected by the share price as well as assumptions relating to a number of complex and subjective variables, including but not limited to the expected share price volatility, actual and projected employee and non-employee share option exercise behavior, risk-free interest rates and expected dividends. The use of the option-pricing model requires extensive actual employee and non-employee exercise behavior data for the relative probability estimation purpose, and a number of complex assumptions.

(c) Concentration and risk

Concentration of suppliers

The following suppliers for the Group's research and development activities accounted for 10% or more of research and development expenses for the three and six months ended June 30, 2018 and 2019:

For the Three Months Ended For the Six Months Ended

June 30, June 30,

2018 2019 2018 2019

US$ % US$ % US$ % US$ %

Supplier A 475,000 12 % (2,531,472 )(1) (162 )% 475,000 11 % * *

Supplier B * * 679,436 43 % * * 1,358,361 20 %

Supplier C 2,767,441 71 % 936,542 60 % 2,767,441 64 % 1,299,032 19 %

Supplier D * * 1,225,569 78 % * * 1,225,569 18 %

Supplier E * * 183,694 12 % * * * *

* Represents less than 10% of research and development expenses for the three and six months ended June 30, 2018 and 2019.

(1) Supplier A offered $3.57 million credit to offset previously issued invoices to the Company during the three months ended June 30, 2019.

(d) Recent accounting pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company's condensed consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.19.2

Cash
6 Months Ended

Jun. 30, 2019

Cash Abstract

CASH
3. CASH

The Company's cash is deposited in financial institutions at below locations:

December 31,
2018 June 30,
2019

Financial institutions in the mainland of the PRC

—Denominated in RMB $ 523 $ 61,795

Financial institutions in the United States

—Denominated in USD $ 4,745,847 $ 1,130,149

Total cash balances held at financial institutions $ 4,746,370 $ 1,191,944

X

- Definition
The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash [Abstract]
+ References
No definition available.
+ Details

Name: xyno_CashAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.19.2

Income Taxes
6 Months Ended

Jun. 30, 2019

Income Tax Disclosure [Abstract]

INCOME TAXES

4. INCOME TAXES

Three Months Ended
June 30, Six Months Ended
June 30,

2018 2019 2018 2019

Loss before income taxes $ (4,708,461 ) $ (3,051,753 ) $ (5,327,391 ) $ (17,196,308 )

Income tax expenses - - - -

Effective income tax rate 0 % 0 % 0 % 0 %

The effective income tax rates for the three and six months ended June 30, 2018 and 2019 were 0% and 0%, respectively. The effective income tax rate for the three and six months ended June 30, 2018 and 2019 differs from the U.S. Federal statutory corporate income tax rate of 21% is primarily due to the increase in valuation allowance.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.19.2

Prepaid Expenses
6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

PREPAID EXPENSES

5. PREPAID EXPENSES

Prepaid expenses consist of the following:

December 31,
2018
June 30,

2019

Prepaid research and development expenses $ 207,988 $ 62,980

Prepaid rental expenses 66,371 66,709

Prepaid health insurance - 20,658

Others 3,391 5,457

Total prepaid expenses $ 277,750 $ 155,805

X

- References
No definition available.
+ Details

Name: xyno_DisclosureOfAccountsReceivableAndPrepaidExpensesTextBlock

Namespace Prefix: xyno_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Notes to Financial Statements [Abstract]
+ References
No definition available.
+ Details

Name: xyno_NotesToFinancialStatementsAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.19.2

Property and Equipment, Net
6 Months Ended

Jun. 30, 2019

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT, NET

6. PROPERTY AND EQUIPMENT, NET

December 31,

2018

June 30,

2019

Leasehold improvement $ 276,839 $ 289,470

Lab equipment - 195,586

Electronic equipment 4,379 14,153

Property and equipment 281,218 499,209

Less: accumulated depreciation (488 ) (54,413 )

Property and equipment, net $ 280,730 $ 444,796

The depreciation expense for property and equipment was nil and US$30,612 for the three months ended June 30, 2018 and 2019, respectively. The depreciation expense for property and equipment was nil and US$54,593 for the six months ended June 30, 2018 and 2019, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.19.2

Other Non-Current Assets
6 Months Ended

Jun. 30, 2019

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

OTHER NON-CURRENT ASSETS
7. OTHER NON-CURRENT ASSETS

Other non-current assets consist of the following:

December 31,

2018

June 30,

2019

VAT input tax $ 52,762 $ 86,735

Prepaid insurance 93,075 124,076

Deposits 9,339 8,754

Total other non-current assets $ 155,176 $ 219,565

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other current assets.
+ References
No definition available.
+ Details

Name: us-gaap_OtherCurrentAssetsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.19.2

Accrued Expenses And Other Current Liabilities
6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consist of the following:

December 31,

2018

June 30,

2019

Research and development expense-Contract Research Organizations $ 10,304,750 $ 10,288,625

Research and development expense-Contract Manufacture Organizations 1,874,956 3,125,901

License fee payable 1,000,000 1,000,000

Professional fee 824,360 1,010,112

Payroll and social insurance 147,692 109,599

Payables for equipment - 140,465

Payable for leasehold improvement 110,736 105,832

Others 144,767 308,544

Total accrued expenses and other current liabilities $ 14,407,261 $ 16,089,078

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Notes to Financial Statements [Abstract]
+ References
No definition available.
+ Details

Name: xyno_NotesToFinancialStatementsAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.19.2

Redeemable Convertible Preferred Shares
6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

REDEEMABLE CONVERTIBLE PREFERRED SHARES
9. REDEEMABLE CONVERTIBLE PREFERRED SHARES

Redeemable convertible preferred shares were issued by Xynomic Pharma before the Closing and consist of the following:

Angel Preferred Shares Series A-1 Preferred Shares Series B Preferred Shares

Balance as of December 31, 2018 $ 580,256 $ 4,905,780 $ 2,424,712

Redemption value accretion 11,117 93,984 1,592,877

Conversion to common shares (591,373 ) (4,999,764 ) (4,017,589 )

Balance as of June 30, 2019 $ - $ - $ -

At the Closing, all of the outstanding redeemable convertible preferred shares were converted into 34,695,395 common shares of the Company.

X

- Definition
Notes to Financial Statements [Abstract]
+ References
No definition available.
+ Details

Name: xyno_NotesToFinancialStatementsAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.
+ References
No definition available.
+ Details

Name: xyno_RedeemableConvertiblePreferredSharesTextBlock

Namespace Prefix: xyno_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.19.2

Shareholders' Equity
6 Months Ended

Jun. 30, 2019

Equity [Abstract]

SHAREHOLDERS' EQUITY
10. SHAREHOLDERS' EQUITY

Preferred Shares — The Company is authorized to issue 50,000,000 of preferred shares with $0.0001 par value per share as of June 30, 2019. Before the re-domestication, the Company is authorized to issue an unlimited number of no par value preferred shares, divided into five classes, Class A through Class E, each with such designation, rights and preferences as may be determined by a resolution of the Company's board of directors to amend the Memorandum and Articles of Association to create such designations, rights and preferences. Upon the re-domestication of the Company, it amended the Charter and the authorized preferred shares to 50,000,000 of preferred shares with $0.0001 par value. At June 30, 2019 and December 31, 2018, there are no preferred shares designated, issued or outstanding.

Common Stock — The Company is authorized to issue 200,000,000 common stocks with $0.0001 par value per share. Holders of the Company's common stocks are entitled to one vote for each share.

At December 31, 2018, the Company was a blank check company incorporated in the British Virgin Islands and there were 7,978,937 ordinary shares issued and outstanding, among which, 6,037,500 ordinary shares are subject to redemption.

From January 1, 2019 to the Closing of the Business Combination, the Company's Shareholders holding 6,023,689 public shares exercised their right to redeem such public shares for a pro rata portion of the Trust Account. The Company paid cash in the aggregate amount of $64,070,650, or approximately $10.54 per share, to redeeming shareholders.

On May 14, 2019, prior to the Closing, the Company continued out of the British Virgin Islands and domesticated as a Delaware corporation. As a result, the Company is no longer a company incorporated in the British Virgin Islands, and the ordinary shares converted common stocks with $0.0001 par value per share.

As a result, right before the Closing, the Company had 1,955,246 shares of common stock issued and outstanding, and immediately following the Closing, the Rights that were issued in the Company's Initial Public Offering and Private Placement automatically converted into 646,955 common shares of the Company.

At the Closing, the Company issued 8,165,377 common shares to holders of Xynomic Pharma's ordinary shares and 34,695,395 common shares to holders of Xynomic Pharma's convertible preferred shares as the Merger Consideration Shares. At the same time, the Company issued 755,873 common shares as the Backstop Shares to Yinglin Mark XU and Bison Capital for $7,672,111 considerations, which consisted of $4,971,358 cash consideration from Mark Yinglin XU, conversion of $2,560,753 loans Mark Yinglin XU made to Xynomic Pharma, and conversion of $140,000 loans Bison Capital made to the company.

At the Closing, Bison Capital converted the promissory notes of $500,000 into 50,000 common shares of the Company, and the Right attached to the notes into 5,000 common shares of the Company.

As of June 30, 2019, there were 46,273,846 shares of common stock issued and outstanding.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.19.2

Loss Per Share
6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

LOSS PER SHARE
11. LOSS PER SHARE

Basic and diluted net loss per share for each of the periods presented are calculated as follow:

Three Months Ended Six Months Ended

June 30, June 30,

2018 2019 2018 2019

Numerator:

Net loss attributable to ordinary shareholders $ (4,808,753 ) $ (3,051,753 ) $ (5,524,999 ) $ (918,894,286 )

Denominator:

Weighted average number of ordinary shares-basic and diluted 42,860,772 44,623,568 42,860,772 43,747,040

Net loss per share-basic and diluted $ (0.11 ) $ (0.07 ) $ (0.13 ) $ (0.43 )



When the dividends to preferred shares are not fully paid, the ordinary shares holders shall not participate in undistributed earnings. If all dividends to preferred shares holders are fully paid, the holders of the preferred shares and the holders of the ordinary shares participate in undistributed earnings on a pro rata basis, as if the preferred shares had been converted into ordinary shares.

As a result of the Group's net loss for the three and six months ended June 30, 2018 and 2019, preferred shares and options outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.19.2

Licenses Arrangement
6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

LICENSES ARRANGEMENT
12. LICENSES ARRANGEMENT

License agreement with Pharmacyclics LLC ("Pharmacyclics")

In February 2017, the Group entered into a license agreement with Pharmacyclics, under which the Group obtained an exclusive and worldwide license or sublicense under certain patents and know-how of Pharmacyclics to develop, manufacture and commercialize Pharmacyclics's HDAC inhibitor, also known as Abexinostat, for all human and non-human diagnostic, prophylactic, and therapeutic uses.

Under the terms of the agreement, the Group made upfront payments of US$3.5 million in 2017 and 1st milestone payment of US$3.5 million in 2018 to Pharmacyclics which were recorded as research and development expenses in 2017 and 2018, respectively. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 2nd milestone payment of US$6,500,000 upon regulatory approval for the first indication for a licensed product in China or in the United States; 2) 3rd milestone payment of US$4,000,000 upon regulatory approval for the second indication for a licensed product in China or in the United States.

In addition, the Group will pay to Pharmacyclics royalties at a flat high-teen percentage rate on the net sales of the licensed products. The Group shall have no obligation to pay any royalty with respect to net sales of any licensed product in any country or other jurisdiction after the royalty term for such licensed product in such country or other jurisdiction has expired.

The license agreement with Pharmacyclics will remain in effect until the expiration of the royalty term and may be early terminated by either party for the other party's uncured material breach, bankruptcy, insolvency, or similar event. Pharmacyclics has the right to terminate the agreement if the Group challenge Pharmacyclics' patents or fails its diligent obligations to develop or commercialize the licensed product pursuant to the license agreement with Pharmacyclics. In addition, the Group may terminate this agreement for convenience with advance written notice to Pharmacyclics. In the event this license agreement is terminated for any reason other than Pharmacyclics' material breach, the Group will be responsible for continuing, at its cost for up to six months, to conduct clinical studies it conducts at the termination and transfer the control of the clinical studies to Pharmacyclics. If such transfer is expressly prohibited by a regulatory authority, the Group will continue to conduct such clinical studies to completion, at the Group's cost.

Patent assignment and licensing agreement with Boehringer Ingelheim International GMBH ("BII") (XP-102)

In August 2017, the Group entered into a Patent assignment and licensing agreement with BII, under which the Group accepts the assignment and transfer of the patents and know-how of BII to exclusively develop, manufacture and commercialize BII's Pan-RAF Inhibitor BI 882370, also known as Dabrafenib, for the diagnosis, prevention or treatment of any and all diseases or conditions in humans or animals. BII retains the exclusive right to use the licensed compound to conduct internal preclinical research.

Under the terms of the agreement, the Group made upfront payments to BII totaling US$0.3 million which was recorded as a research and development expense in 2017. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 1st milestone payment of US$ 1,700,000 upon first dosing of a patient in Phase I Clinical Trial in the US or China; 2) 2nd milestone payment of US$ 4,000,000 upon first dosing of a patient in a pivotal Phase III Clinical Trial in the first indication in the US or China; 3) 3rd milestone payment of US$2,000,000 upon first dosing of a patient in a pivotal Phase III Clinical Trial in a second indication in the US or China; 4) 4th milestone payment of US$ 7,000,000 upon the grant of the first marketing authorization of the first indication in the US; 5) 5th milestone payment of US$3,000,000 upon the grant of the first marketing authorization of the first indication in China.

In addition, the Group will pay royalties at a certain percentage of the net sales. The royalty term commences from the first commercial sale of such licensed product in such country until the later of (i) the date on which such licensed product is no longer covered by a valid claim of the assigned patents and assigned invention, (ii) the expiration of regulatory exclusivity of the licensed product in such country, or (iii) the tenth anniversary of the first launch of the respective licensed product in the country, provided the licensed know-how is still proprietary, or such licensed know-how is no longer proprietary owing to a breach of its confidentiality obligations.

The Group has the right to terminate this agreement by providing BII with written notice.

License agreement with BII (XP-105)

In December 2018, Xynomic entered into a license agreement with BII for the worldwide exclusive rights to develop and commercialize XP-105 (also known as BI 860585) for all human and non-human diagnostic, prophylactic, and therapeutic uses.

Under the terms of the agreement, as of June 30, 2019 the Group was obligated to make upfront payments to BII totaling US$1 million which was recorded as a research and development expense for the year ended December 31, 2018 and was included in accrued expenses and other current liabilities as of December 31, 2018. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 1st milestone payment of US$7,000,000 upon first dosing of a patient in Phase II or Phase III Clinical Trial in the first indication either of which is intended to be a pivotal trial; 2) 2nd milestone payment of US$10,000,000 upon the grant of the first Marketing Authorization of the first indication.

In addition, the Group will pay royalties at a certain percentage of the net sales. The royalty term commences from the first commercial sale of such licensed product in such country until the later of (i) the date on which such licensed product is no longer covered by a valid claim of the licensed patents, (ii) the expiration of regulatory exclusivity of the licensed product in such country, or (iii) the tenth anniversary of the first launch of the respective licensed product in the country in the indication, provided the licensed know-how is still proprietary, or such licensed know-how is no longer proprietary owing to a breach of its confidentiality obligations.

The Group has the right to terminate this agreement by providing BII with written notice.

X

- References
No definition available.
+ Details

Name: xyno_LicenseAgreementTextBlock

Namespace Prefix: xyno_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Notes to Financial Statements [Abstract]
+ References
No definition available.
+ Details

Name: xyno_NotesToFinancialStatementsAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.19.2

Commitments and Contingencies
6 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES
13. COMMITMENTS AND CONTINGENCIES

(a) Lease commitments

The Group entered into non-cancelable operating leases, primarily for office space, for initial terms of 12 to 36 months. Minimum rent payments under operating leases are recognized on a straight-line basis over the term of the lease.

Future minimum lease payments under non-cancelable operating leases with remaining lease terms in excess of one year as of June 30, 2019 are:

Minimum
Lease Payment
Amount

Year ending June 30, 2019,

2020 $ 241,099

2021 236,467

2022 129,658

$ 607,224

Rental expenses for operating leases for the three months ended June 30, 2018 and 2019 were US$24,249 and US$98,434, respectively. Rental expenses for operating leases for the six months ended June 30, 2018 and 2019 were US$40,275 and US$146,598, respectively.

(b) Registration Rights

Upon the Closing, the Company entered into an amended and restated registration rights agreement with certain existing investors of Bison (including its sponsor), Mark Yinglin Xu (together with his assignee, the "Backstop Investor") and the Sellers. Pursuant to this registration rights agreement, the Company has agreed to register for resale under the Securities Act of 1993, as amended (1) all or any portion of the 1,509,375 shares of common stock of Bison issued to certain existing investors (the "Founder Shares"), (2) 432,063 private units issued by Bison to certain existing investors in conjunction with the consummation of its initial public offering (the "Private Units"), (3) any private units which may be issued by Bison in payment of working capital loans made to Bison (the "Working Capital Units", together with Founder Shares, Private Units, the "Existing Registrable Securities"), (4) the Backstop Shares, and (5) the Merger Consideration Share (the "Newly Issued Shares"). The Backstop Shares, Newly issued Shares and the Existing Registrable Securities and any securities of Bison issued as a dividend or distribution with respect thereto or in exchange therefor are referred as the "Registrable Securities". At any time and from time to time on or after (i) the one month anniversary of the Closing with respect to the Private Units or Working Capital Units, (ii) three months prior to the release of the Founder Shares under the terms of a certain escrow agreement; (iii) the Closing Date with respect to the Backstop Shares, or (iv) nine months after the Closing with respect to the Newly Issued Shares, the holders of a majority of (i) all of the Existing Registrable Securities, (ii) all of the Backstop Shares, or (iii) all of the Newly Issued Shares, calculated on an as-converted basis, may make a written demand for registration under the Securities Act of all or part of their Registrable Securities, and other holders of the Registrable Securities will be entitled to join in such demand registration, provided that the Company shall not be obliged to effect more than two demand registrations in any one year period or more than an aggregate of three demand registrations.

Subject to certain exceptions, if at any time on or after the Closing, the Company proposes to file a registration statement under the Securities Act with respect to an offering of equity securities, under the Registration Rights Agreement, the Company shall give written notice of such proposed filing to the holders of the Registrable Securities and offer them an opportunity to register the sale of such number of Registrable Securities as such holders may request in writing, subject to customary cut-backs.

In addition, subject to certain exceptions, the holders of a majority of (i) all of the Existing Registrable Securities, (ii) all of the Backstop Shares, or (iii) all of the Newly Issued Shares, calculated on an as-converted basis, are entitled under the Registration Rights Agreement to request in writing that the Company register the resale of any or all of such Registrable Securities on Form S-3 or any similar short-form registration that may be available at such time.

The Company agrees to use commercially reasonable efforts to effect the registration and sale of such Registrable Securities in accordance with the registration rights described above as expeditiously as practicable. In addition, the Company agrees to use reasonable best efforts to cause registration with respect to the Backstop Shares to be declared effective no later than one-hundred and eighty (180) days following the Closing Date.

(c) Other commitments

The Group is a party to or assignee of license and collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (Note 12).

(d) Legal contingencies

On July 12, 2019, one of the Contract Research Organizations (the "Plaintiff") of Xynomic Pharma filed a complaint in the Complex Commercial Litigation Division of the Superior Court of the State of Delaware against Xynonmic Pharma for breach of a contract under which Xynomic Pharma engaged the Plaintiff to provide services relating to drug development research, and Xynomic Pharma allegedly failed to pay the amount due to the Plaintiff for the services performed. The Plaintiff seeks $6,992,068 from Xynomic Pharma, plus interest at the contract rate of 1% per month. Xynomic Pharma must respond to the complaint by August 19, 2019.

As of June 30, 2019, Xynomic Pharma had $7,078,037 payable to the Plaintiff, including $273,467 accrued interest according to the contract.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.19.2

Related Party Transactions
6 Months Ended

Jun. 30, 2019

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS
14. RELATED PARTY TRANSACTIONS

(a) Amount due to shareholders

i) Payable due to a shareholder

For the three months ended June 30, 2018 and 2019, Yinglin Mark Xu, the founder and CEO of Xynomic Pharma, advanced US$38,683 and US$130,335, respectively, to Xynomic Pharma to fund its operation. For the six months ended June 30, 2018 and 2019, Yingling Mark XU advanced US$536,905 and US$543,296, respectively.

At the Closing date, the amount due to Yingling Mark XU was $2,560,754 and was fully converted to be part of the consideration to purchase Backstop Shares.

As of December 31, 2018 and June 30, 2019, the amount due to Yinglin Mark XU was US$2,008,936 and US$0, respectively.

ii) Services purchased from a company affiliated with a shareholder

Eigenbridge, Inc., a company affiliated with Yong Cui, one of Xynomic Pharma's shareholders and Vice President of Chemistry, Manufacturing and Controls, entered into a contractor agreement with Xynomic Pharma on February 26, 2017. Pursuant to the agreement, Eigenbridge, Inc., provided specialized advisory services to Xynomic Pharma. Xynomic Pharma recognized general and administrative of US$52,723 and US$0 for the three months ended June 30, 2018 and 2019, respectively. Xynomic Pharma recognized general and administrative of US$52,723 and US$25,908 for the six months ended June 30, 2018 and 2019, respectively. The amount due to Eigenbridge, Inc., were US$80,640 and US$0 as of December 31, 2018 and June 30, 2019, respectively.

iii) Advances from and interest payable to a shareholder

On May 2, 2018, as one of the potential investors of Series B financing, Zhongshan Bison Healthcare Investment Limited (Limited Partnership) ("Zhongshan Bison") entered into a loan agreement with Xynomic Pharmaceuticals (Nanjing) Co., Ltd. ("Xynomic Nanjing"). On May 13, 2018, Zhongshan Bison made an advance of RMB9,435,000 (equivalent to US$1,425,959) to fund the operations and business development of Xynomic Nanjing. Zhongshan Bison is entitled to withdraw the advance within 5 business days after Zhongshan Bison paid the first investment of Series B financing, or if current shareholders and investors fail to subscribe shares of the Series B financing within 6 months.

On August 16, 2018, Zhongshan Bison became one of the Series B Preferred Shareholders.

On August 23, 2018, Xynomic Nanjing entered into a termination agreement for the advance from Zhongshan Bison. Xynomic Nanjing is required to a) repay RMB1,800,000 of the advance from Zhongshan Bison within 2 days after signing the agreement; and b) repay the remaining RMB7,635,000 of the advance from Zhongshan Bison and interest accrued at annual interest rate of 8% from signing the agreement within six months from the date of the termination agreement.

On August 23, 2018, Xynomic Nanjing repaid RMB1,800,000 (equivalent to US$262,743) of the advance from Zhongshan Bison. As of December 31, 2018, the advance from Zhongshan Bison was US$1,112,455.

On January 21, 2019, Xynomic Nanjing repaid RMB5,064,000 (equivalent to US$747,189) of the advance from Zhongshan Bison. On February 20, 2019, Zhongshan Bison agreed to extend the due date of the remaining advance of RMB2,571,000 (US$383,097) and all accrued interest to April 15, 2019. On April 12, 2019, Zhongshan Bison agreed to further extend the due date of the remaining advance of RMB2,571,000 (US$383,097) and all accrued interest to June 30, 2019. On June 30, 2019, the due date was further extended to September 15, 2019.

Xynomic Nanjing accrued interest expense of US$17,723 for the advance from Zhongshan Bison for the three months ended June 30, 2019. Xynomic Nanjing accrued interest expense of US$32,811 for the advance from Zhongshan Bison for the six months ended June 30, 2019. The interest payable to Zhongshan Bison was US$31,697 and US$64,093 as of December 31, 2018 and June 30, 2019, respectively.

iv) Promissory note to a shareholder

In order to finance transaction costs in connection with a Business Combination, Bison Capital or the Company's officers and directors or their respective affiliates may, but are not obligated to, loan the Company funds as may be required (the "Working Capital Loans"). If the Company completes a Business Combination, the Company would repay the Working Capital Loans. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender's discretion, up to $500,000 of notes may be converted upon consummation of a Business Combination into additional Private Units at a price of $10.00 per unit (the "Working Capital Units"). As of May 14, 2019, Bison Capital has loaned the Company an aggregate of $500,000, which is evidenced by a promissory note, non-interest bearing, unsecured and payable in cash or convertible in Private Units at $10.00 per unit, at Bison Capital's discretion, on the consummation of a Business Combination.

In February 2019, $100,000 of loans from Bison Capital were converted into convertible promissory loans and is included in the $500,000 outstanding amount noted above. In addition, as of June 30, 2019, Bison Capital has loaned the Company an aggregate amount of $404,900 in order to finance transaction costs in connection with the Business Combination. The loan is non-interest bearing, unsecured and due to be paid on the consummation of a Business Combination.

At the Closing, Bison Capital converted the $500,000 convertible promissory note to 50,000 common shares of the Company, and converted the Right attached to it into 5,000 common shares of the Company.

At June 30, 2019, an aggregate of $404,900 is owed by the Company to Bison Capital pursuant to the above loans.

(b) Service purchased from a shareholder

In June 2017, the Group paid US$295,021 to Bridge Pharm International Inc., one of the Company's shareholders, pursuant to 20 months services agreement. Under the agreement, Bridge Pharm International Inc. provides consulting service, including business development, screening and selection of contract research organizations and contract manufacturing organizations and scouting and references of key scientific and managerial personnel to the Group. The Company recognized general and administrative of US$44,915 and nil for the three months ended June 30, 2018 and 2019, respectively. The Company recognized general and administrative of US$93,968 and nil for the six months ended June 30, 2018 and 2019, respectively. The balance related to the Bridge Pharm International Inc. was nil as of December 31, 2018 and June 30, 2019.

(c) Administrative Services Arrangement

Bison Capital entered into an agreement whereby, commencing on June 19, 2017 through the earlier of the Company's consummation of a Business Combination and its liquidation, to make available to the Company certain general and administrative services, including office space, utilities and administrative services, as the Company may require from time to time. The Company will pay Bison Capital $5,000 per month for these services. For the three months ended June 30, 2018 and 2019, the Company incurred $15,000 and $7,500, respectively, in fees for these services. or the six months ended June 30, 2018 and 2019, the Company incurred $27,500 and $22,500, respectively, in fees for these services. At June 30, 2019 and December 31, 2018, $112,500 and $90,000 in administrative fees, respectively, are included in accounts payable and accrued expenses in the accompanying condensed balance sheets.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.19.2

Share-Based Compensation
6 Months Ended

Jun. 30, 2019

Share-based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION
15. SHARE-BASED COMPENSATION

2018 Stock Incentive Plan

On August 28, 2018, the Board of Directors of Xynomic Pharma approved a resolution to adopt the 2018 Stock Incentive Plan (the "2018 Plan") that provides for the granting of options to selected employees, directors and non-employee consultants to acquire ordinary shares of the Company at exercise prices determined by the Board or the administrator appointed by the Board at the time of grant. Upon this resolution, the Board of Directors and shareholders authorized and reserved 8,908,430 ordinary shares for the issuance under the 2018 Plan. The number of ordinary shares available under the Plan shall increase annually on the first day of each fiscal year, beginning with the second fiscal year following the effective date of this Plan, and continuing until (and including) the fiscal year ending December 31, 2028, with such annual increase equal to the lesser of (i) 3,000,000 ordinary shares, (ii) 5% of the number of ordinary shares issued and outstanding on December 31 of the immediately preceding calendar year, and (iii) an amount determined by the Board. As of December 31, 2018 and June 30, 2019, 8,908,430 and 8,022,384 awards remain available for future grants under the 2018 Plan, respectively.

Under the 2018 Plan, Xynomic Pharma granted 886,046 ordinary shares of the Company with the below vesting schedule on January 21, 2019:

Granted to an employee (100,000 shares): 25% of the options is to be vested on April 30, 2019, and 1/48 of the options to be vested each month thereafter. The employee resigned from Xynomic Pharma in May 2019 and the remaining unvested 75% of the options were forfeited.

Granted to a non-employee (786,046 shares): 25% of the options is to be vested on August 31, 2019, and 1/48 of the options to be vested each month thereafter, subject to an acceleration vesting schedule that 75% is to be issued upon completion of Xynomic Pharma's merger with Bison Capital Acquisition Corp, and 25% to be issued in one year after the closing of the merger. The cost of the share options granted to the non-employee was fully recognized at the grant date, as no substantive future services are required. At the Closing, each option to purchase Xynomic stock that was outstanding immediately prior to the Effective Time was assumed by the Company and automatically converted into an option to purchase shares of common stock of the Company.

Summary of Share Option Activities

The following tables summarize the Company's share option activities for the six months ended June 30, 2019:

Weighted Weighted

average remaining Aggregate

Number of exercise contractual intrinsic

Granted to Employee shares price years value

US$ US$

Outstanding at January 1, 2019 - - -

Granted 100,000 1.00

Forfeited (75,000 ) 1.00

Outstanding at June 30, 2019 25,000 1.00 9.57 215,050

Exercisable as of June 30, 2019 25,000 1.00 9.57 215,050

Weighted Weighted

average remaining Aggregate

Number of exercise contractual intrinsic

Granted to Non-employee shares price years value

US$ US$

Outstanding at January 1, 2019 - - -

Granted 786,046 0.10

Forfeited - -

Outstanding at June 30, 2019 786,046 0.10 9.57 7,433,873

Exercisable as of June 30, 2019 589,535 0.10 9.57 5,578,436

No options were exercised during the six months ended June 30, 2019.

Management is responsible for determining the fair value of options granted to employees and non-employees and considered a number of factors including valuations. The Company's share-based compensation cost is measured at the fair value of the options as calculated under the binomial models.

Assumptions used in the option-pricing model are presented below:

2019

Risk-free interest rate 2.77 %

Expected term 10 years

Volatility rate 36.1 %

Dividend yield 0 %

Exercise multiple 2.8

Fair value of underlying ordinary share 9.5573

The Company estimated the risk-free rates based on the 10-year U.S. bond as at the option valuation date. Life of the share options is the contract life of the option. Based on the option agreements, the contract life of the option are 10 years from the respective grant date. The expected volatility at the option valuation date was estimated based on historical volatility of comparable companies. The Company has no history or expectation of paying dividends on its ordinary shares. The Company estimated the fair value of the ordinary shares using the equity allocation approach when valuing options granted. As the Company did not have sufficient information of past employee exercise history, the expected exercise multiple was estimated by referencing to How to Value Employee Stock Options (published by John Hull& Allen White, Financial Analysts Journal, 2004 edition), a well-accepted academic publication.

The grant date fair value of the share options granted for the six months ended June 30, 2019 was US$9.3653. Compensation expense of US$7,652,965 were recognized in general and administrative relating to the 886,046 options for the six months ended June 30, 2019. US$30,317 of the general and administrative expense was reversed during the three months ended June 30,2019 due to the employee's resignation and the forfeiture of the unvested options.

As of June 30, 2019, there was nil unrecognized compensation expenses related to non-vested options.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.19.2

Subsequent Event
6 Months Ended

Jun. 30, 2019

Subsequent Events [Abstract]

SUBSEQUENT EVENT
16. SUBSEQUENT EVENT

Security Purchase Agreement with Accredited Investors

On or about July 10, 2019, the Company entered into certain Securities Purchase Agreement (the "SPA") with certain "accredited investors" as defined in Rule 501(a) of Regulation D as promulgated under the Securities Act of 1933, as amended (the "Purchasers"), pursuant to which the Company agreed to sell to such Purchasers an aggregate of approximate USD$10 million of units (the "Reg. D Units") of the Company, at a purchase price of USD$3.80 per Unit (subject to adjustment) (the "Reg. D Offering"). Each Reg. D Unit consists of one share of common stock and one-half warrant (the "Reg. D Warrant"). Each whole Reg. D Warrant can be exercised to purchase one share of the Company Stock at $7.00 per share and shall expire in three (3) years of the issuance, and have the rights and preference set forth in certain Warrant Agreement. Furthermore, the SPA provides, among other terms, a maximum offering in an aggregate of $15 million with the first closing of a minimum of $5 million upon delivery of the closing conditions set forth in the SPA, provided that no closing shall occur after September 30, 2019 subject to certain exception.

The Reg. D Units, the shares of common stock underlying the Reg. D Units (the "Reg.D Unit Shares"), the Reg. D Warrants issued in the Reg.D Offering, and shares of common stock issuable upon exercise of the Reg. D Warrants (the "Reg.D Warrant Shares"), are exempt from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D.

With delisting from Nasdaq occurred subsequently, the parties have started to renegotiate the terms of the SPA including potential waiver of certain closing conditions.

Delisting from Nasdaq

On July 15, 2019, the Company was notified in writing by the Panel at Nasdaq that they have denied its request for continued listing on Nasdaq based upon the Company's non-compliance with Nasdaq Listing Rules 5505(a)(3) and 5515(a)(4), which require a minimum of 300 round lot holders of common stock and 400 round lot holders of common stock purchase warrants for initial listing on Nasdaq; as well as non-compliance with the minimum $5 million in stockholders' equity requirement, as set forth in Nasdaq Listing Rule 5505(b)(1)(A). As a result, Nasdaq suspended trading in the Company's securities effective at the open of business on Wednesday, July 17, 2019; and the shares subsequently commenced trading on the over-the-counter markets.

Special Meeting of Stockholders

On July 26, 2019, the Company called for a Special Meeting of its stockholders be held on August 26, 2019 for the purpose of authorizing the Company's Board of Directors to, in its discretion, to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio no less than 1-for-1.5 and no greater than 1-for-5 at any time prior to August 27, 2020, with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders ("Stock Split Proposal"). The Board of Directors may alternatively elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.19.2

Summary of Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Basis of presentation

(a) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the United States Securities and Exchange Commission ("SEC"). The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements of Xynomic Pharmaceuticals, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated balance sheet of the Company and Xynomic Pharma as of December 31, 2018, and the related consolidated statements of comprehensive loss, changes in equity and cash flows for the year then ended, included in the Company's Proxy Statement/Prospectus on Form 8-K filed with the SEC on May 15, 2019.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of June 30, 2019, the results of operations for the three and six months ended June 30, 2018 and 2019 and cash flows for the six months ended June 30, 2018 and 2019, have been made.

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant accounting estimates include, but not limited to the fair value of the ordinary shares to determine the existence of beneficial conversion feature of the redeemable convertible preferred shares, the fair value of share-based compensation awards, depreciable lives of property and equipment, the recoverability of the carrying amounts of property and equipment and the recoverability of deferred income tax assets. Changes in facts and circumstances may result in revised estimates. Actual results could differ from those estimates, and as such, differences may be material to the unaudited condensed consolidated financial statements.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation

Going Concern

The Company and its subsidiaries Xynomic Pharma, Xynomic Nanjing, Xynomic Shanghai and Xynomic Zhongshan (the "Group") have not generated any revenues from product sales. Substantial additional financing will be required by the Group to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Group's research and development efforts will be successful.

The Group's ability to fund operations is based on its ability to attract investors and its ability to borrow funds on reasonable economic terms. Historically, the Group has relied principally on equity financing and shareholder's borrowings to fund its operations and business development. The Group's ability to continue as a going concern is dependent on management's ability to successfully execute its business plan, which includes generating revenues after drug marketing, controlling operating expenses, as well as, continuing to obtain additional equity financing. On April 3, 2018, Xynomic Pharma issued convertible notes to Northern Light Venture Capital V, Ltd., and Bo Tan and received proceeds of US$2,500,000, which were converted into 776,633 Series B Preferred Shares in August 2018. Further in August 2018, Xynomic Pharma raised US$17 million by issuance of 5,281,101 Series B Preferred Shares to certain investors, including the conversion of convertible notes of US$2.5 million. At the Closing of the Merger, 755,873 shares of Backstop Shares were issued for a total consideration of $7,672,111.

On May 15, 2019, the Company received written notice from the staff of the NASDAQ Stock Market LLC ("Nasdaq") indicating that the Staff had determined to delist its securities from NASDAQ based upon the non-compliance with the requirement of a minimum of 300 round lot holders of and 400 round lot holders of purchase warrants and the requirement of the minimum US$5 million in stockholders' equity. The Company requested a hearing before the Nasdaq Hearings Panel (the "Panel"), and such request stayed any suspension or delisting action by Nasdaq pending the completion of the hearing process and the expiration of any extension period that may be granted to the Company by the Panel. On July 15, 2019, the Company was notified in writing by the Panel at Nasdaq that they denied the Company's request for continued listing on Nasdaq based upon the Company's non-compliance with Nasdaq Listing Rules 5505(a)(3) and 5515(a)(4). As a result, Nasdaq suspended trading in the Company's securities effective at the open of business on Wednesday, July 17, 2019; and the Company's shares will subsequently commence trading on the over-the-counter markets. The Company still intends to continue with its compliance plan with the Nasdaq listing requirements and is diligently pursuing courses of action designed to remedy our noncompliance with Nasdaq's initial listing requirements as set forth above. There can be no assurance, however, that the Company will be able to regain compliance with the mainboard listing requirements.

The Group currently does not have any commitments to obtain additional funds except the potential private placements in details provided in Note 16 herein below and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Group cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs to: commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including another merger or sale of the Group; or cease operations. If the Group engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process.

The Group has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Group has incurred recurring losses from operations since inception. The Group incurred a net loss of US$3,051,753 and US$17,196,308 for the three and six months ended June 30, 2019, respectively. Further, as of June 30, 2019, the Group had net current liabilities (current assets less current liabilities) of US$15,701,138 and accumulated deficit of US$51,519,477. The Group's ability to continue as a going concern is dependent on its ability to raise capital to fund its current research and development activities and future business plans. Additionally, volatility in the capital markets and general economic conditions in the United States may be a significant obstacle to raising the required funds. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements included herein do not include any adjustments that might be necessary should the Group be unable to continue as a going concern. If the going concern basis were not appropriate for these financial statements, adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used.

Operations of the Group are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Group's product candidates become approved drugs and how significant their market share will be, some of which are outside of the Group's control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Group's financial condition and future operations.

Share-based Compensation

(b) Share-based Compensation

The Company granted share options to its selected employees and non-employee consultants.

Share-based awards granted to employees with service conditions attached are measured at the grant date fair value and are recognized as an expense using graded vesting method over the requisite service period, which is generally the vesting period. The forfeitures are accounted when they occur.



In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"). The new guidance largely aligns the accounting for share-based awards issued to employees and nonemployees. Existing guidance for employee awards will apply to non-employee share-based transactions with limited exceptions. The Company adopted this guidance on January 1, 2019.

Share-based awards granted to non-employees are measured at the grant date fair value. When no future services are required to be performed by the non-employee in exchange for an award of equity instruments, the cost of the award is expensed on the grant date.

Option-pricing models are adopted to measure the value of awards at each grant date. The determination of fair value is affected by the share price as well as assumptions relating to a number of complex and subjective variables, including but not limited to the expected share price volatility, actual and projected employee and non-employee share option exercise behavior, risk-free interest rates and expected dividends. The use of the option-pricing model requires extensive actual employee and non-employee exercise behavior data for the relative probability estimation purpose, and a number of complex assumptions.

Concentration and risk

(c) Concentration and risk

Concentration of suppliers

The following suppliers for the Group's research and development activities accounted for 10% or more of research and development expenses for the three and six months ended June 30, 2018 and 2019:

For the Three Months Ended For the Six Months Ended

June 30, June 30,

2018 2019 2018 2019

US$ % US$ % US$ % US$ %

Supplier A 475,000 12 % (2,531,472 )(1) (162 )% 475,000 11 % * *

Supplier B * * 679,436 43 % * * 1,358,361 20 %

Supplier C 2,767,441 71 % 936,542 60 % 2,767,441 64 % 1,299,032 19 %

Supplier D * * 1,225,569 78 % * * 1,225,569 18 %

Supplier E * * 183,694 12 % * * * *

* Represents less than 10% of research and development expenses for the three and six months ended June 30, 2018 and 2019.

(1) Supplier A offered $3.57 million credit to offset previously issued invoices to the Company during the three months ended June 30, 2019.

Recent accounting pronouncements

(d) Recent accounting pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company's condensed consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.19.2

Description of Organization and Business Operations (Tables)
6 Months Ended

Jun. 30, 2019

Description Of Organization And Business Operations

Schedule of subsidiaries
Subsidiaries Date of incorporation Place of incorporation
/establishment Percentage of economic ownership

Xynomic Pharmaceuticals (Nanjing) Co., Ltd.
("Xynomic Nanjing") November 20, 2017 PRC 100 %

Xynomic Pharmaceuticals (Shanghai) Co., Ltd. ("Xynomic Shanghai") July 31, 2018 PRC 100 %

Xynomic Pharmaceuticals (Zhongshan) Co., Ltd. ("Xynomic Zhongshan") May 15, 2018 PRC 100 %

X

- References
No definition available.
+ Details

Name: xyno_DescriptionOfOrganizationAndBusinessOperationsTablesAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_ScheduleOfSubsidiariesTableTextBlock

Namespace Prefix: xyno_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.19.2

Summary of Significant Accounting Policies (Tables)
6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Schedule of concentration of suppliers

For the Three Months Ended For the Six Months Ended

June 30, June 30,

2018 2019 2018 2019

US$ % US$ % US$ % US$ %

Supplier A 475,000 12 % (2,531,472 )(1) (162 )% 475,000 11 % * *

Supplier B * * 679,436 43 % * * 1,358,361 20 %

Supplier C 2,767,441 71 % 936,542 60 % 2,767,441 64 % 1,299,032 19 %

Supplier D * * 1,225,569 78 % * * 1,225,569 18 %

Supplier E * * 183,694 12 % * * * *

* Represents less than 10% of research and development expenses for the three and six months ended June 30, 2018 and 2019.

(1) Supplier A offered $3.57 million credit to offset previously issued invoices to the Company during the three months ended June 30, 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592
+ Details

Name: us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.19.2

Cash (Tables)
6 Months Ended

Jun. 30, 2019

Cash Tables Abstract

Schedule of cash deposited in financial institutions
December 31,
2018 June 30,
2019

Financial institutions in the mainland of the PRC

—Denominated in RMB $ 523 $ 61,795

Financial institutions in the United States

—Denominated in USD $ 4,745,847 $ 1,130,149

Total cash balances held at financial institutions $ 4,746,370 $ 1,191,944

X

- Definition
Tabular disclosure of the components of cash and cash equivalents.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_CashTablesAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.19.2

Income Taxes (Tables)
6 Months Ended

Jun. 30, 2019

Income Tax Disclosure [Abstract]

Schedule of income taxes

Three Months Ended
June 30, Six Months Ended
June 30,

2018 2019 2018 2019

Loss before income taxes $ (4,708,461 ) $ (3,051,753 ) $ (5,327,391 ) $ (17,196,308 )

Income tax expenses - - - -

Effective income tax rate 0 % 0 % 0 % 0 %

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.19.2

Prepaid Expenses (Tables)
6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Schedules of Prepaid expenses

December 31,
2018
June 30,

2019

Prepaid research and development expenses $ 207,988 $ 62,980

Prepaid rental expenses 66,371 66,709

Prepaid health insurance - 20,658

Others 3,391 5,457

Total prepaid expenses $ 277,750 $ 155,805

X

- Definition
Notes to Financial Statements [Abstract]
+ References
No definition available.
+ Details

Name: xyno_NotesToFinancialStatementsAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_SchedulesOfPrepaidExpensesTextBlock

Namespace Prefix: xyno_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.19.2

Property and Equipment, Net (Tables)
6 Months Ended

Jun. 30, 2019

Property, Plant and Equipment [Abstract]

Schedule of property and equipment, net

December 31,

2018

June 30,

2019

Leasehold improvement $ 276,839 $ 289,470

Lab equipment - 195,586

Electronic equipment 4,379 14,153

Property and equipment 281,218 499,209

Less: accumulated depreciation (488 ) (54,413 )

Property and equipment, net $ 280,730 $ 444,796

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.19.2

Other Non-Current Assets (Tables)
6 Months Ended

Jun. 30, 2019

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of other non-current assets

December 31,

2018

June 30,

2019

VAT input tax $ 52,762 $ 86,735

Prepaid insurance 93,075 124,076

Deposits 9,339 8,754

Total other non-current assets $ 155,176 $ 219,565

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of noncurrent assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.19.2

Accrued Expenses And Other Current Liabilities (Tables)
6 Months Ended

Jun. 30, 2019

Payables and Accruals [Abstract]

Schedule of Accrued Expenses And Other Current Liabilities

December 31,

2018

June 30,

2019

Research and development expense-Contract Research Organizations $ 10,304,750 $ 10,288,625

Research and development expense-Contract Manufacture Organizations 1,874,956 3,125,901

License fee payable 1,000,000 1,000,000

Professional fee 824,360 1,010,112

Payroll and social insurance 147,692 109,599

Payables for equipment - 140,465

Payable for leasehold improvement 110,736 105,832

Others 144,767 308,544

Total accrued expenses and other current liabilities $ 14,407,261 $ 16,089,078

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.19.2

Redeemable Convertible Preferred Shares (Tables)
6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Schedule of Redeemable convertible preferred shares were issued by Xynomic Pharma before the Closing
Angel Preferred Shares Series A-1 Preferred Shares Series B Preferred Shares

Balance as of December 31, 2018 $ 580,256 $ 4,905,780 $ 2,424,712

Redemption value accretion 11,117 93,984 1,592,877

Conversion to common shares (591,373 ) (4,999,764 ) (4,017,589 )

Balance as of June 30, 2019 $ - $ - $ -

X

- Definition
Notes to Financial Statements [Abstract]
+ References
No definition available.
+ Details

Name: xyno_NotesToFinancialStatementsAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_RedeemableConvertiblePreferredSharesTableTextBlock

Namespace Prefix: xyno_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R33.htm IDEA: XBRL DOCUMENT v3.19.2

Loss Per Share (Tables)
6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Schedule of Basic and diluted net loss per share for each of the periods
Three Months Ended Six Months Ended

June 30, June 30,

2018 2019 2018 2019

Numerator:

Net loss attributable to ordinary shareholders $ (4,808,753 ) $ (3,051,753 ) $ (5,524,999 ) $ (918,894,286 )

Denominator:

Weighted average number of ordinary shares-basic and diluted 42,860,772 44,623,568 42,860,772 43,747,040

Net loss per share-basic and diluted $ (0.11 ) $ (0.07 ) $ (0.13 ) $ (0.43 )

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Notes to Financial Statements [Abstract]
+ References
No definition available.
+ Details

Name: xyno_NotesToFinancialStatementsAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R34.htm IDEA: XBRL DOCUMENT v3.19.2

Commitments And Contingencies (Tables)
6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Schedule of future minimum lease payments
Minimum
Lease Payment
Amount

Year ending June 30, 2019,

2020 $ 241,099

2021 236,467

2022 129,658

$ 607,224

X

- Definition
Notes to Financial Statements [Abstract]
+ References
No definition available.
+ Details

Name: xyno_NotesToFinancialStatementsAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of lessor's property under leasing agreements and property available for lease (not currently under lease) by property class, the gross amount, accumulated depreciation and net amount of as of the balance sheet date.
+ References
No definition available.
+ Details

Name: xyno_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTableTextBlock

Namespace Prefix: xyno_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R35.htm IDEA: XBRL DOCUMENT v3.19.2

Share-Based Compensation (Tables)
6 Months Ended

Jun. 30, 2019

Share-based Payment Arrangement [Abstract]

Schedule of tables summarize the company's share option activities
Weighted Weighted

average remaining Aggregate

Number of exercise contractual intrinsic

Granted to Employee shares price years value

US$ US$

Outstanding at January 1, 2019 - - -

Granted 100,000 1.00

Forfeited (75,000 ) 1.00

Outstanding at June 30, 2019 25,000 1.00 9.57 215,050

Exercisable as of June 30, 2019 25,000 1.00 9.57 215,050

Weighted Weighted

average remaining Aggregate

Number of exercise contractual intrinsic

Granted to Non-employee shares price years value

US$ US$

Outstanding at January 1, 2019 - - -

Granted 786,046 0.10

Forfeited - -

Outstanding at June 30, 2019 786,046 0.10 9.57 7,433,873

Exercisable as of June 30, 2019 589,535 0.10 9.57 5,578,436

Schedule of assumptions used in the option-pricing model
2019

Risk-free interest rate 2.77 %

Expected term 10 years

Volatility rate 36.1 %

Dividend yield 0 %

Exercise multiple 2.8

Fair value of underlying ordinary share 9.5573

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R36.htm IDEA: XBRL DOCUMENT v3.19.2

Description of Organization and Business Operations (Details)
6 Months Ended

Jun. 30, 2019

Xynomic Pharmaceuticals Nanjing [Member]

Date of incorporation Nov. 20, 2017

Place of incorporation /establishment PRC

Percentage of economic ownership 100.00%

Xynomic Pharmaceuticals Shanghai [Member]

Date of incorporation Jul. 31, 2018

Place of incorporation /establishment PRC

Percentage of economic ownership 100.00%

Xynomic Pharmaceuticals Zhongshan [Member]

Date of incorporation May 15, 2018

Place of incorporation /establishment PRC

Percentage of economic ownership 100.00%

X

- Definition
Date when an entity was incorporated
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationDateOfIncorporation

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: xyno_EntityPlaceOfIncorporation

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_TitleOfIndividualAxis=xyno_XynomicPharmaceuticalsNanjingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=xyno_XynomicPharmaceuticalsShanghaiMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=xyno_XynomicPharmaceuticalsZhongshaniMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R37.htm IDEA: XBRL DOCUMENT v3.19.2

Description of Organization and Business Operations (Details Textual) - USD ($)
1 Months Ended 6 Months Ended

May 15, 2019

May 14, 2019

May 31, 2019

Mar. 03, 2019

Jun. 30, 2019

Description of Organization and Business Operations (Textual)

Aggregate loan amount $ 610,000

Commitment from related party contribute loan $ 0.02

Shares value of not redeemed 5,000

Backstop agreement, description Entered into by and between Bison Capital and Yinglin Mark Xu, together with his assignee Bison Capital Holding Company Limited, has purchased from the Company 755,873 shares of common stock at a price of $10.15 per share for a total consideration of $7,672,111 (the "Backstop Shares" and "Backstop Subscription"). As a result of Backstop Subscription, the Company had at least $7,500,001 of net tangible assets remaining at the Closing after giving effect to the redemption of any Ordinary Shares by the public shareholders in connection with the Business Combination.

Yinglin Mark Xu [Member]

Description of Organization and Business Operations (Textual)

Aggregate loan amount $ 16,062

Shares value of not redeemed 803,080

Per share value $ 0.02

Xynomic Pharma [Member ]

Description of Organization and Business Operations (Textual)

Number of stock units issued 9,852,216

Bison Capital [Member]

Description of Organization and Business Operations (Textual)

Committed to provide additional loans $ 190,000

Private Units [Member]

Description of Organization and Business Operations (Textual)

Number of stock units issued 432,062

Initial Public Offering [Member]

Description of Organization and Business Operations (Textual)

Number of stock units issued 6,037,500

Merger Consideration Agreement [Member]

Description of Organization and Business Operations (Textual)

Number of stock units issued 42,860,772

Escrow deposit 1,285,822

Aggregate common stock, shares 9,852,216

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of additional paid-in capital (APIC) classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 5.T)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868742-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.30(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAdditionalCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_AggregateCommonStockShares

Namespace Prefix: xyno_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: xyno_BackstopAgreementDescription

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Commitment from related party contribute loan per share.
+ References
No definition available.
+ Details

Name: xyno_CommitmentFromRelatedPartyContributeLoan

Namespace Prefix: xyno_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_DescriptionOfOrganizationAndBusinessOperationsTextualAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_EscrowDepositShares

Namespace Prefix: xyno_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xyno_YinglinMarkXuMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=xyno_XynomicPharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=xyno_BisonCapitalHoldingCompanyLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=xyno_MergerConsiderationAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R38.htm IDEA: XBRL DOCUMENT v3.19.2

Summary of Significant Accounting Policies (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Research and development activities $ 1,567,799 $ 3,873,804 $ 6,892,109 $ 4,340,206

Supplier A [Member]

Research and development activities $ (2,531,472) ^[1] $ 475,000 ^[2] $ 475,000

Concentration and risk Percentage (1.62%) 0.12% ^[2] 11.00%

Supplier B [Member]

Research and development activities $ 679,436 ^[2] $ 1,358,361 ^[2]

Concentration and risk Percentage 43.00% ^[2] 20.00% ^[2]

Supplier C [Member]

Research and development activities $ 936,542 $ 2,767,441 $ 1,299,032 $ 2,767,441

Concentration and risk Percentage 60.00% 71.00% 19.00% 64.00%

Supplier D [Member]

Research and development activities $ 1,225,569 ^[2] $ 1,225,569 ^[2]

Concentration and risk Percentage 78.00% ^[2] 18.00% ^[2]

Supplier E [Member]

Research and development activities $ 183,694 ^[2] ^[2] ^[2]

Concentration and risk Percentage 12.00% ^[2] ^[2] ^[2]

[1] Supplier A offered $3.57 million credit to offset previously issued invoices to the Company during the three months ended June 30, 2019.

[2] Represents less than 10% of research and development expenses for the three and six months ended June 30, 2018 and 2019.

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=xyno_SupplierOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=xyno_SupplierTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=xyno_SupplierThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=xyno_SupplierFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=xyno_SupplierFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R39.htm IDEA: XBRL DOCUMENT v3.19.2

Summary of Significant Accounting Policies (Details Textual) - USD ($)
3 Months Ended 6 Months Ended

Apr. 03, 2018

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Mar. 31, 2019

Dec. 31, 2018

Summary of Significant Accounting Policies (Textual)

Net income $ (3,051,753) $ (4,808,753) $ (18,894,286) $ (5,524,999)

Net current liabilities 15,701,138 15,701,138

Retained earnings $ (51,519,477) $ (51,519,477) $ (34,323,169)

Research and development expenses description less than 10% less than 10%

Credit offset issued $ 3,570,000 $ 3,570,000

Stockholders' equity $ (15,035,326) $ (15,035,326) $ (28,290,970) $ (20,094,728)

Xynomic Pharma [Member ]

Summary of Significant Accounting Policies (Textual)

Preferred share conversion, description Xynomic Pharma issued convertible notes to Northern Light Venture Capital V, Ltd., and Bo Tan and received proceeds of US$2,500,000, which were converted into 776,633 Series B Preferred Shares in August 2018. Further in August 2018, Xynomic Pharma raised US$17 million by issuance of 5,281,101 Series B Preferred Shares to certain investors, including the conversion of convertible notes of US$2.5 million. At the Closing of the Merger, 755,873 shares of Backstop Shares were issued for a total consideration of $7,672,111.

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockConversionBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: xyno_ResearchAndDevelopmentExpensesDescription

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_SummaryOfSignificantAccountingPoliciesTextualAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_WorkingCapital

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: srt_TitleOfIndividualAxis=xyno_XynomicPharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R40.htm IDEA: XBRL DOCUMENT v3.19.2

Cash (Details) - USD ($)

Jun. 30, 2019

Dec. 31, 2018

Total cash balances held at financial institutions $ 1,191,944 $ 4,746,370

Financial institutions in the United States [Member]

Total cash balances held at financial institutions 1,130,149 4,745,847

Financial institutions in the mainland of the PRC [Member]

Total cash balances held at financial institutions $ 61,795 $ 523

X

- Definition
Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: xyno_TypeOfCurrencyAxis=xyno_USDMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=xyno_PRCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R41.htm IDEA: XBRL DOCUMENT v3.19.2

Income Taxes (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Loss before income taxes $ (4,708,461) $ (3,051,753) $ (5,327,391) $ (17,196,308)

Income tax expenses

Effective income tax rate 0.00% 0.00% 0.00% 0.00%

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 54 R42.htm IDEA: XBRL DOCUMENT v3.19.2

Income Taxes (Details Textual)
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Income Taxes (Textual)

Effective income tax rates 0.00% 0.00% 0.00% 0.00%

U.S. Federal statutory corporate income tax rate 21.00% 21.00% 21.00% 21.00%

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_IncomeTaxesTextualAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 55 R43.htm IDEA: XBRL DOCUMENT v3.19.2

Prepaid Expenses (Details) - USD ($)

Jun. 30, 2019

Dec. 31, 2018

Notes to Financial Statements

Prepaid research and development expenses $ 62,980 $ 207,988

Prepaid rental expenses 66,709 66,371

Prepaid health insurance 20,658

Others 5,457 3,391

Total prepaid expenses $ 155,805 $ 277,750

X

- Definition
Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765
+ Details

Name: us-gaap_OtherPrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidInsurance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidRent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Notes to Financial Statements [Abstract]
+ References
No definition available.
+ Details

Name: xyno_NotesToFinancialStatementsAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Prepaid research and development expenses.
+ References
No definition available.
+ Details

Name: xyno_PrepaidResearchAndDevelopmentExpenses

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 56 R44.htm IDEA: XBRL DOCUMENT v3.19.2

Property and Equipment, Net (Details) - USD ($)

Jun. 30, 2019

Dec. 31, 2018

Property and equipment $ 499,209 $ 281,218

Less: accumulated depreciation (54,413) (488)

Property and equipment, net 444,796 280,730

Leasehold improvement [Member]

Property and equipment 289,470 276,839

Lab equipment [Member]

Property and equipment 195,586

Electronic equipment [Member]

Property and equipment $ 14,153 $ 4,379

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R45.htm IDEA: XBRL DOCUMENT v3.19.2

Property and Equipment, Net (Details Textual) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Property and Equipment, Net (Textual)

Depreciation expense $ 30,612 $ 30,612 $ 54,593

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_PropertyAndEquipmentNetTextualAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R46.htm IDEA: XBRL DOCUMENT v3.19.2

Other Non-Current Assets (Details) - USD ($)

Jun. 30, 2019

Dec. 31, 2018

Other Non-current Assets

VAT input tax $ 86,735 $ 52,762

Prepaid insurance 124,076 93,075

Deposits 8,754 9,339

Total other non-current assets $ 219,565 $ 155,176

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DepositsAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: xyno_OtherNoncurrentAssetsDetailsAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_TaxesPayableNonCurrent

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 59 R47.htm IDEA: XBRL DOCUMENT v3.19.2

Accrued Expenses And Other Current Liabilities (Details) - USD ($)

Jun. 30, 2019

Dec. 31, 2018

Accrued Expenses And Other Current Liabilities

Research and development expense-Contract Research Organizations $ 10,288,625 $ 10,304,750

Research and development expense-Contract Manufacture Organizations 3,125,901 1,874,956

License fee payable 1,000,000 1,000,000

Professional fee 1,010,112 824,360

Payroll and social insurance 109,599 147,692

Payables for equipment 140,465

Payable for leasehold improvement 105,832 110,736

Others 308,544 144,767

Total accrued expenses and other current liabilities $ 16,089,078 $ 14,407,261

X

- Definition
Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedInsuranceCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedRoyaltiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: xyno_AccruedExpensesAndOtherCurrentLiabilitiesDetailsAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expenses related to license.
+ References
No definition available.
+ Details

Name: xyno_LicenseFeePayable

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: xyno_PayablesForEquipment

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses related to research and development in manufactue organization.
+ References
No definition available.
+ Details

Name: xyno_ResearchAndDevelopmentManufactureOrganizationsExpense

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses related to research and development in research organization.
+ References
No definition available.
+ Details

Name: xyno_ResearchAndDevelopmentResearchOrganizationsExpense

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 60 R48.htm IDEA: XBRL DOCUMENT v3.19.2

Redeemable Convertible Preferred Shares (Details)
6 Months Ended

Jun. 30, 2019

USD ($)

Angel Preferred Shares [Member]

Balance as of December 31, 2018 $ 580,256

Redemption value accretion 11,117

Conversion to common shares (591,373)

Balance as of June 30, 2019

Series A-1 Preferred Shares [Member]

Balance as of December 31, 2018 4,905,780

Redemption value accretion 93,984

Conversion to common shares (4,999,764)

Balance as of June 30, 2019

Series B Preferred Stock [Member]

Balance as of December 31, 2018 2,424,712

Redemption value accretion 1,592,877

Conversion to common shares (4,017,589)

Balance as of June 30, 2019

X

- Definition
The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of accretion of temporary equity to its redemption value during the period.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityAccretionToRedemptionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_RedeemableConvertiblePreferredShares

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=xyno_AngelPreferredSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=xyno_SeriesA1PreferredSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R49.htm IDEA: XBRL DOCUMENT v3.19.2

Redeemable Convertible Preferred Shares (Details Textual)

Jun. 30, 2019

shares

Redeemable Convertible Preferred Shares

Outstanding redeemable convertible preferred shares converted 34,695,395

X

- Definition
Number of shares issued for each share of convertible preferred stock that is converted.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644
+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: xyno_RedeemableConvertiblePreferredSharesDetailsTextualAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R50.htm IDEA: XBRL DOCUMENT v3.19.2

Shareholders' Equity (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended

Feb. 01, 2019

Jun. 30, 2019

Jun. 30, 2019

May 14, 2019

Mar. 31, 2019

Dec. 31, 2018

Shareholders' Equity (Textual)

Preferred stock, par value $ 0.0001 $ 0.0001 $ 0.0001

Preferred stock, shares authorized 50,000,000 50,000,000 50,000,000

Preferred stock, shares issued

Preferred stock, shares outstanding

Common stock, par value $ 0.0001 $ 0.0001 $ 0.0001

Common stock, shares authorized 200,000,000 200,000,000 200,000,000

Ordinary shares, shares issued 46,273,846 46,273,846 6,706,068

Ordinary shares, shares outstanding 46,273,846 46,273,846 6,706,068

Conversion of converted promissory notes 5,000

Mark Yinglin XU [Member]

Shareholders' Equity (Textual)

Cash considerations $ 4,971,358 $ 4,971,358

Convertible loans 2,560,753

Bison Capital [Member]

Shareholders' Equity (Textual)

Cash considerations $ 7,672,111 7,672,111

Convertible loans $ 140,000

Conversion of converted promissory notes 50,000

Common Stock

Shareholders' Equity (Textual)

Converted common stocks price per share $ 0.0001

Combination with Xynomic Pharmaceuticals, Inc. shares 1,955,246

Conversion of Rights to common shares, shares 646,955

Xynomic Pharma's ordinary shares 46,273,846 46,273,846 8,165,377 8,165,377

Xynomic Pharma's convertible preferred shares as the Merger Consideration Shares 34,695,395

Issuance of backstop common shares, shares 755,873

Common Stock | Bison Capital [Member]

Shareholders' Equity (Textual)

Conversion of converted promissory notes 5,000

British Virgin Islands [Member]

Shareholders' Equity (Textual)

Ordinary shares, shares issued 7,978,937

Ordinary shares, shares outstanding 7,978,937

Ordinary shares subject to possible redemption 6,037,500

Right to redeem public shares 6,023,689

Amount of right to redeem public shares $ 64,070,650

Share per price $ 10.54

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_CashConsideration

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: xyno_CombinationWithXynomicPharmaceuticalsInc.Shares

Namespace Prefix: xyno_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_ConversionOfPreferredSharesToCommonSharesShares

Namespace Prefix: xyno_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
It represents ordinary shares subject to redemption.
+ References
No definition available.
+ Details

Name: xyno_OrdinarySharesSubjectToRedemption

Namespace Prefix: xyno_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: xyno_ShareholdersEquityTextualAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xyno_MarkYinglinXUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xyno_BisonCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=xyno_BritishVirginIslandsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R51.htm IDEA: XBRL DOCUMENT v3.19.2

Loss Per Share (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2019

Mar. 31, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Numerator:

Net loss attributable to ordinary shareholders $ (3,051,753) $ (14,144,555) $ (4,708,461) $ (17,196,308) $ (5,327,391)

Denominator:

Weighted average number of ordinary shares-basic and diluted 44,623,568 42,860,772 43,747,040 42,860,772

Net loss per share-basic and diluted $ (0.11) $ (0.07) $ (0.13) $ (0.43)

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_DenominatorAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_NumeratorAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R52.htm IDEA: XBRL DOCUMENT v3.19.2

Licenses Arrangement (Details)
1 Months Ended

Dec. 31, 2018

Aug. 31, 2017

Feb. 28, 2017

Pharmacyclics LLC [Member]

Agreement, description Under the terms of the agreement, the Group made upfront payments of US$3.5 million in 2017 and 1st milestone payment of US$3.5 million in 2018 to Pharmacyclics which were recorded as research and development expenses in 2017 and 2018, respectively. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 2nd milestone payment of US$6,500,000 upon regulatory approval for the first indication for a licensed product in China or in the United States; 2) 3rd milestone payment of US$4,000,000 upon regulatory approval for the second indication for a licensed product in China or in the United States.

Boehringer Ingelheim International GMBH ("BII") (XP-102) [Member]

Agreement, description Under the terms of the agreement, the Group made upfront payments to BII totaling US$0.3 million which was recorded as a research and development expense in 2017. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 1st milestone payment of US$ 1,700,000 upon first dosing of a patient in Phase I Clinical Trial in the US or China; 2) 2nd milestone payment of US$ 4,000,000 upon first dosing of a patient in a pivotal Phase III Clinical Trial in the first indication in the US or China; 3) 3rd milestone payment of US$2,000,000 upon first dosing of a patient in a pivotal Phase III Clinical Trial in a second indication in the US or China; 4) 4th milestone payment of US$ 7,000,000 upon the grant of the first marketing authorization of the first indication in the US; 5) 5th milestone payment of US$3,000,000 upon the grant of the first marketing authorization of the first indication in China.

BII (XP-105) [Member]

Agreement, description Under the terms of the agreement, as of June 30, 2019 the Group was obligated to make upfront payments to BII totaling US$1 million which was recorded as a research and development expense for the year ended December 31, 2018 and was included in accrued expenses and other current liabilities as of December 31, 2018. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 1st milestone payment of US$7,000,000 upon first dosing of a patient in Phase II or Phase III Clinical Trial in the first indication either of which is intended to be a pivotal trial; 2) 2nd milestone payment of US$10,000,000 upon the grant of the first Marketing Authorization of the first indication. In addition, the Group will pay royalties at a certain percentage of the net sales. The royalty term commences from the first commercial sale of such licensed product in such country until the later of (i) the date on which such licensed product is no longer covered by a valid claim of the licensed patents, (ii) the expiration of regulatory exclusivity of the licensed product in such country, or (iii) the tenth anniversary of the first launch of the respective licensed product in the country in the indication, provided the licensed know-how is still proprietary, or such licensed know-how is no longer proprietary owing to a breach of its confidentiality obligations.

X

- References
No definition available.
+ Details

Name: xyno_AgreementDescription

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: xyno_AgreementsAxis=xyno_PharmacyclicsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: xyno_AgreementsAxis=xyno_BoehringerIngelheimInternationalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: xyno_AgreementsAxis=xyno_BIIXPMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R53.htm IDEA: XBRL DOCUMENT v3.19.2

Commitments and Contingencies (Details)

Jun. 30, 2019

USD ($)

Year ending June 30, 2019,

2020 $ 241,099

2021 236,467

2022 129,658

Total $ 607,224

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 66 R54.htm IDEA: XBRL DOCUMENT v3.19.2

Commitments and Contingencies (Details Textual) - USD ($)
3 Months Ended 6 Months Ended

Jul. 12, 2019

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Commitments and Contingencies (Textual)

Rental expenses $ 98,434 $ 24,249 $ 146,598 $ 40,275

Registration rights agreement description (1) all or any portion of the 1,509,375 shares of common stock of Bison issued to certain existing investors (the "Founder Shares"), (2) 432,063 private units issued by Bison to certain existing investors in conjunction with the consummation of its initial public offering (the "Private Units"),

Xynomic Pharma [Member ]

Commitments and Contingencies (Textual)

Legal contingencies, description The Plaintiff seeks $6,992,068 from Xynomic Pharma, plus interest at the contract rate of 1% per month. Xynomic Pharma must respond to the complaint by August 19, 2019.

Payable to plantiff $ 7,078,037

Accrued interest $ 273,467 $ 273,467

Maximum [Member]

Commitments and Contingencies (Textual)

Lease term 36 months

Minimum [Member]

Commitments and Contingencies (Textual)

Lease term 12 months

X

- Definition
Amount of interest payable on debt, including, but not limited to, trade payables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_InterestPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of damages paid to the plaintiff in the legal matter.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_LossContingencyDamagesPaidValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Describes the form and magnitude of the award the plaintiff seeks in the legal matter, which may include an unspecified amount of money.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_LossContingencyDamagesSought

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717
+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_CommitmentsAndContingenciesTextualAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_RegistrationRightsAgreementDescription

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_TermOfLease

Namespace Prefix: xyno_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_TitleOfIndividualAxis=xyno_XynomicPharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 67 R55.htm IDEA: XBRL DOCUMENT v3.19.2

Share-Based Compensation (Details)
6 Months Ended

Jun. 30, 2019

USD ($)

$ / shares

shares

Employee [Member]

Number of shares, Beginning balance | shares

Number of shares, Granted | shares 100,000

Number of shares, Forfeited | shares (75,000)

Number of shares, Ending balance | shares 25,000

Number of shares Exercisable | shares 25,000

Weighted average exercise price, Beginning balance | $ / shares

Weighted average exercise price, Granted | $ / shares 1

Weighted average exercise price, Forfeited | $ / shares 1

Weighted average exercise price, Ending balance | $ / shares 1

Weighted average exercise price, Exercisable | $ / shares $ 1

Weighted remaining contractual years 9 years 6 months 25 days

Weighted remaining contractual years, Exercisable 9 years 6 months 25 days

Aggregate intrinsic value | $ $ 215,050

Aggregate intrinsic value, Exercisable | $ $ 215,050

Non Employee [Member]

Number of shares, Beginning balance | shares

Number of shares, Granted | shares 786,046

Number of shares, Forfeited | shares

Number of shares, Ending balance | shares 786,046

Number of shares Exercisable | shares 589,535

Weighted average exercise price, Beginning balance | $ / shares

Weighted average exercise price, Granted | $ / shares 0.1

Weighted average exercise price, Forfeited | $ / shares

Weighted average exercise price, Ending balance | $ / shares 0.1

Weighted average exercise price, Exercisable | $ / shares $ 0.1

Weighted remaining contractual years 9 years 6 months 25 days

Weighted remaining contractual years, Exercisable 9 years 6 months 25 days

Aggregate intrinsic value | $ $ 7,433,873

Aggregate intrinsic value, Exercisable | $ $ 5,578,436

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=xyno_NonEmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 68 R56.htm IDEA: XBRL DOCUMENT v3.19.2

Share-Based Compensation (Details 1)
6 Months Ended

Jun. 30, 2019

$ / shares

Sharebased Compensation Details Textual Abstract

Risk-free interest rate 2.77%

Expected term 10 years

Volatility rate 36.10%

Dividend yield 0.00%

Exercise multiple $ 2.8

Fair value of underlying ordinary share $ 9.5573

X

- Definition
Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_SharebasedCompensationDetailsTextualAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 69 R57.htm IDEA: XBRL DOCUMENT v3.19.2

Share-Based Compensation (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended

Jan. 21, 2019

Aug. 28, 2018

Jun. 30, 2019

Mar. 31, 2019

Jun. 30, 2019

Jun. 30, 2018

Share-Based Compensation (Textual)

Share-based compensation $ (30,317) $ 7,683,282 $ 7,652,965

General and Administrative Expense [Member]

Share-Based Compensation (Textual)

Share-based compensation $ 30,317 $ 886,046

Employee [Member]

Share-Based Compensation (Textual)

Number of shares, Granted 100,000

Option vesting description Granted to an employee (100,000 shares): 25% of the options is to be vested on April 30, 2019, and 1/48 of the options to be vested each month thereafter. The employee resigned from Xynomic Pharma in May 2019 and the remaining unvested 75% of the options were forfeited.

Non Employee [Member]

Share-Based Compensation (Textual)

Number of shares, Granted 786,046

Option vesting description Granted to a non-employee (786,046 shares): 25% of the options is to be vested on August 31, 2019, and 1/48 of the options to be vested each month thereafter, subject to an acceleration vesting schedule that 75% is to be issued upon completion of Xynomic Pharma's merger with Bison Capital Acquisition Corp, and 25% to be issued in one year after the closing of the merger.

2018 Stock Incentive Plan [Member]

Share-Based Compensation (Textual)

Ordinary shares under incentive plan, description (i) 3,000,000 ordinary shares, (ii) 5% of the number of ordinary shares issued and outstanding on December 31 of the immediately preceding calendar year, and (iii) an amount determined by the Board. As of December 31, 2018 and June 30, 2019, 8,908,430 and 8,022,384 awards remain available for future grants under the 2018 Plan, respectively.

Number of shares, Granted 886,046

Grant date fair value of the share options $ 9.3653

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The detail description about the ordinary shares under stock incentive plan.
+ References
No definition available.
+ Details

Name: xyno_DescriptionOfStockAvailableInIncentivePlan

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_ShareBasedCompensationTextualAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=xyno_NonEmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=xyno_TwoThousandStockIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 70 R58.htm IDEA: XBRL DOCUMENT v3.19.2

Related Party Transactions (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended

Apr. 12, 2019

USD ($)

Apr. 12, 2019

CNY (¥)

Jan. 21, 2019

USD ($)

Jan. 21, 2019

CNY (¥)

Aug. 23, 2018

CNY (¥)

May 13, 2018

USD ($)

May 13, 2018

CNY (¥)

May 31, 2019

USD ($)

$ / shares

shares

Feb. 28, 2019

USD ($)

Feb. 20, 2019

USD ($)

Feb. 20, 2019

CNY (¥)

Aug. 23, 2018

USD ($)

Aug. 23, 2018

CNY (¥)

Jun. 30, 2017

USD ($)

Jun. 19, 2017

USD ($)

Jun. 30, 2019

USD ($)

Jun. 30, 2018

USD ($)

Jun. 30, 2019

USD ($)

$ / shares

shares

Jun. 30, 2019

CNY (¥)

shares

Jun. 30, 2018

USD ($)

Dec. 31, 2018

USD ($)

May 14, 2019

USD ($)

$ / shares

Related Party Transactions (Textual)

Advance from a shareholder $ 543,296 $ 536,905

General and administrative services $ 1,443,731 $ 745,286 10,222,980 848,761

Proceeds from advance amount 1,425,959

Accrued interest expense 17,723 32,811

Aggregated loan 610,000 $ 610,000

Convertible promissory note shares | shares 5,000 5,000

Administrative Services Arrangement [Member]

Related Party Transactions (Textual)

Fee for services $ 5,000 7,500 15,000 $ 22,500 27,500

Administrative fees 112,500 $ 90,000

Service purchased from shareholder [Member]

Related Party Transactions (Textual)

General and administrative services 44,915 93,968

Group payment amount $ 295,021

Xynomic Pharma [Member ]

Related Party Transactions (Textual)

General and administrative services 0 52,723 25,908 52,723

Interest payable 273,467 273,467

Zhongshan Bison [Member]

Related Party Transactions (Textual)

Proceeds from advance amount $ 1,425,959

Amount due from related party 112,455

Interest payable 64,093 $ 64,093 31,697

Annual interest rate 8.00% 8.00%

Due date Sep. 15, 2019 Sep. 15, 2019

Zhongshan Bison [Member] | RMB [Member]

Related Party Transactions (Textual)

Proceeds from advance amount | ¥ ¥ 9,435,000

Repyament of debt | ¥ ¥ 1,800,000 ¥ 7,635,000

Eigenbridge, Inc [Member ]

Related Party Transactions (Textual)

Amount due to related party 0 $ 0 80,640

Bison Capital [Member]

Related Party Transactions (Textual)

Convertible promissory loans $ 100,000

Short term debt outstanding $ 500,000

Aggregate order to finance transaction costs 404,900 404,900

Convertible promissory note amount $ 500,000

Convertible promissory note shares | shares 50,000 50,000

Bison Capital [Member] | Related Party Loans and Promissory Notes [Member]

Related Party Transactions (Textual)

Lender's discretion converted 500,000 $ 500,000

Aggregated loan $ 500,000

Additional private unit price | $ / shares $ 10.00

Private per units | $ / shares $ 10.00

Yinglin Mark Xu [Member]

Related Party Transactions (Textual)

Advance from a shareholder 130,335 $ 38,683 $ 543,296 $ 536,905

Converted shares | shares 2,560,754 2,560,754

Amount due to related party $ 2,008,936 $ 2,008,936 $ 0

Aggregated loan $ 16,062

Private per units | $ / shares $ 0.02

Convertible promissory note shares | shares 803,080

Xynomic Pharmaceuticals Nanjing [Member] | Zhongshan Bison [Member]

Related Party Transactions (Textual)

Repyament of debt $ 383,097 $ 747,189 $ 383,097 $ 262,743

Xynomic Pharmaceuticals Nanjing [Member] | Zhongshan Bison [Member] | RMB [Member]

Related Party Transactions (Textual)

Repyament of debt | ¥ ¥ 2,571,000 ¥ 5,064,000 ¥ 1,800,000 ¥ 2,571,000

X

- Definition
Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The average effective interest rate during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateDuringPeriod

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the required periodic payments including both interest and principal payments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DueToRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This element represents the aggregate cost of investments accounted for under the equity method of accounting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EquityMethodInvestmentAggregateCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest expense incurred on a debt or other obligation to related party.
+ References
No definition available.
+ Details

Name: us-gaap_InterestExpenseRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest payable on debt, including, but not limited to, trade payables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_InterestPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expense for shareholder services. Includes, but is not limited to, fee and expense for transfer and dividend disbursing agent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section 45
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268
+ Details

Name: us-gaap_InvestmentCompanyShareholderServiceFeeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount paid to managing member or general partner, affiliate of managing member or general partner, or affiliate of limited liability company (LLC) or limited partnership (LP) for administrative services provided to the LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_PaymentForAdministrativeFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_RelatedPartyTransactionDueFromToRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShorttermDebtAverageOutstandingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
It represents additional private unit price.
+ References
No definition available.
+ Details

Name: xyno_AdditionalPrivateUnitPrice

Namespace Prefix: xyno_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of Proceeds from advance to shareholder
+ References
No definition available.
+ Details

Name: xyno_ProceedsFromAdvanceToShareholder

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The Amount Of Proceeds From Shareholders Advance.
+ References
No definition available.
+ Details

Name: xyno_ProceedsFromShareholdersAdvance

Namespace Prefix: xyno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_RelatedPartyTransactionsTextualAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=xyno_AdministrativeServicesArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ShareholderServiceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=xyno_XynomicPharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=xyno_ZhongshanBisonHealthcareInvestmentLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: xyno_TypeOfCurrencyAxis=xyno_RmbMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=xyno_EigenbridgeIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xyno_BisonCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=xyno_RelatedPartyLoansAndPromissoryNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xyno_YinglinMarkXuMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xyno_XynomicPharmaceuticalsNanjingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 71 R59.htm IDEA: XBRL DOCUMENT v3.19.2

Subsequent Event (Details) - USD ($)
1 Months Ended

Jul. 10, 2019

Jul. 26, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Subsequent Events (Textual)

Stockholders' equity $ (15,035,326) $ (28,290,970) $ (20,094,728)

Subsequent Event [Member]

Subsequent Events (Textual)

Reverse stock split The Company called for a Special Meeting of its stockholders be held on August 26, 2019 for the purpose of authorizing the Company's Board of Directors to, in its discretion, to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio no less than 1-for-1.5 and no greater than 1-for-5 at any time prior to August 27, 2020

Securities purchase agreement, description The Company entered into certain Securities Purchase Agreement (the "SPA") with certain "accredited investors" as defined in Rule 501(a) of Regulation D as promulgated under the Securities Act of 1933, as amended (the "Purchasers"), pursuant to which the Company agreed to sell to such Purchasers an aggregate of approximate USD$10 million of units (the "Reg. D Units") of the Company, at a purchase price of USD$3.80 per Unit (subject to adjustment) (the "Reg. D Offering"). Each Reg. D Unit consists of one share of common stock and one-half warrant (the "Reg. D Warrant"). Each whole Reg. D Warrant can be exercised to purchase one share of the Company Stock at $7.00 per share and shall expire in three (3) years of the issuance, and have the rights and preference set forth in certain Warrant Agreement. Furthermore, the SPA provides, among other terms, a maximum offering in an aggregate of $15 million with the first closing of a minimum of $5 million upon delivery of the closing conditions set forth in the SPA, provided that no closing shall occur after September 30, 2019 subject to certain exception.

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_SecuritiesPurchaseAgreementDescription

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: xyno_SubsequentEventsTextualAbstract

Namespace Prefix: xyno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 73 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 161 326 1 true 47 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://bisoncapital.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://bisoncapital.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://bisoncapital.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Unaudited Condensed Consolidated Statements Of Comprehensive Loss Sheet http://bisoncapital.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveLoss Unaudited Condensed Consolidated Statements Of Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Unaudited Condensed Consolidated Changes In Shareholders' Deficit Sheet http://bisoncapital.com/role/UnauditedCondensedConsolidatedChangesInShareholdersDeficit Unaudited Condensed Consolidated Changes In Shareholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://bisoncapital.com/role/StatementsOfCashFlows Unaudited Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Description of Organization and Business Operations Sheet http://bisoncapital.com/role/DescriptionOfOrganizationAndBusinessOperations Description of Organization and Business Operations Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://bisoncapital.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Cash Sheet http://bisoncapital.com/role/Cash Cash Notes 9 false false R10.htm 00000010 - Disclosure - Income Taxes Sheet http://bisoncapital.com/role/IncomeTaxes Income Taxes Notes 10 false false R11.htm 00000011 - Disclosure - Prepaid Expenses Sheet http://bisoncapital.com/role/PrepaidExpenses Prepaid Expenses Notes 11 false false R12.htm 00000012 - Disclosure - Property and Equipment, Net Sheet http://bisoncapital.com/role/PropertyAndEquipmentNet Property and Equipment, Net Notes 12 false false R13.htm 00000013 - Disclosure - Other Non-Current Assets Sheet http://bisoncapital.com/role/OtherNon-currentAssets Other Non-Current Assets Notes 13 false false R14.htm 00000014 - Disclosure - Accrued Expenses And Other Current Liabilities Sheet http://bisoncapital.com/role/AccruedExpensesAndOtherCurrentLiabilities Accrued Expenses And Other Current Liabilities Notes 14 false false R15.htm 00000015 - Disclosure - Redeemable Convertible Preferred Shares Sheet http://bisoncapital.com/role/RedeemableConvertiblePreferredShares Redeemable Convertible Preferred Shares Notes 15 false false R16.htm 00000016 - Disclosure - Shareholders' Equity Sheet http://bisoncapital.com/role/ShareholdersEquity Shareholders' Equity Notes 16 false false R17.htm 00000017 - Disclosure - Loss Per Share Sheet http://bisoncapital.com/role/LossPerShare Loss Per Share Notes 17 false false R18.htm 00000018 - Disclosure - Licenses Arrangement Sheet http://bisoncapital.com/role/LicensesArrangement Licenses Arrangement Notes 18 false false R19.htm 00000019 - Disclosure - Commitments and Contingencies Sheet http://bisoncapital.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 00000020 - Disclosure - Related Party Transactions Sheet http://bisoncapital.com/role/RelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 00000021 - Disclosure - Share-Based Compensation Sheet http://bisoncapital.com/role/Share-basedCompensation Share-Based Compensation Notes 21 false false R22.htm 00000022 - Disclosure - Subsequent Event Sheet http://bisoncapital.com/role/SubsequentEvents Subsequent Event Notes 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://bisoncapital.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://bisoncapital.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Description of Organization and Business Operations (Tables) Sheet http://bisoncapital.com/role/DescriptionOfOrganizationAndBusinessOperationsTables Description of Organization and Business Operations (Tables) Tables http://bisoncapital.com/role/DescriptionOfOrganizationAndBusinessOperations 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://bisoncapital.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://bisoncapital.com/role/SummaryOfSignificantAccountingPolicies 25 false false R26.htm 00000026 - Disclosure - Cash (Tables) Sheet http://bisoncapital.com/role/CashTables Cash (Tables) Tables http://bisoncapital.com/role/Cash 26 false false R27.htm 00000027 - Disclosure - Income Taxes (Tables) Sheet http://bisoncapital.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://bisoncapital.com/role/IncomeTaxes 27 false false R28.htm 00000028 - Disclosure - Prepaid Expenses (Tables) Sheet http://bisoncapital.com/role/PrepaidExpensesTables Prepaid Expenses (Tables) Tables http://bisoncapital.com/role/PrepaidExpenses 28 false false R29.htm 00000029 - Disclosure - Property and Equipment, Net (Tables) Sheet http://bisoncapital.com/role/PropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://bisoncapital.com/role/PropertyAndEquipmentNet 29 false false R30.htm 00000030 - Disclosure - Other Non-Current Assets (Tables) Sheet http://bisoncapital.com/role/OtherNon-currentAssetsTables Other Non-Current Assets (Tables) Tables http://bisoncapital.com/role/OtherNon-currentAssets 30 false false R31.htm 00000031 - Disclosure - Accrued Expenses And Other Current Liabilities (Tables) Sheet http://bisoncapital.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses And Other Current Liabilities (Tables) Tables http://bisoncapital.com/role/AccruedExpensesAndOtherCurrentLiabilities 31 false false R32.htm 00000032 - Disclosure - Redeemable Convertible Preferred Shares (Tables) Sheet http://bisoncapital.com/role/RedeemableConvertiblePreferredSharesTables Redeemable Convertible Preferred Shares (Tables) Tables http://bisoncapital.com/role/RedeemableConvertiblePreferredShares 32 false false R33.htm 00000033 - Disclosure - Loss Per Share (Tables) Sheet http://bisoncapital.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://bisoncapital.com/role/LossPerShare 33 false false R34.htm 00000034 - Disclosure - Commitments And Contingencies (Tables) Sheet http://bisoncapital.com/role/CommitmentsAndContingenciesTables Commitments And Contingencies (Tables) Tables 34 false false R35.htm 00000035 - Disclosure - Share-Based Compensation (Tables) Sheet http://bisoncapital.com/role/Share-basedCompensationTables Share-Based Compensation (Tables) Tables http://bisoncapital.com/role/Share-basedCompensation 35 false false R36.htm 00000036 - Disclosure - Description of Organization and Business Operations (Details) Sheet http://bisoncapital.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails Description of Organization and Business Operations (Details) Details http://bisoncapital.com/role/DescriptionOfOrganizationAndBusinessOperationsTables 36 false false R37.htm 00000037 - Disclosure - Description of Organization and Business Operations (Details Textual) Sheet http://bisoncapital.com/role/DescriptionOfOrganizationAndBusinessOperationsDetailsTextual Description of Organization and Business Operations (Details Textual) Details http://bisoncapital.com/role/DescriptionOfOrganizationAndBusinessOperationsTables 37 false false R38.htm 00000038 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://bisoncapital.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://bisoncapital.com/role/SummaryofSignificantAccountingPoliciesTables 38 false false R39.htm 00000039 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://bisoncapital.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://bisoncapital.com/role/SummaryofSignificantAccountingPoliciesTables 39 false false R40.htm 00000040 - Disclosure - Cash (Details) Sheet http://bisoncapital.com/role/CashDetails Cash (Details) Details http://bisoncapital.com/role/CashTables 40 false false R41.htm 00000041 - Disclosure - Income Taxes (Details) Sheet http://bisoncapital.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://bisoncapital.com/role/IncomeTaxesTables 41 false false R42.htm 00000042 - Disclosure - Income Taxes (Details Textual) Sheet http://bisoncapital.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://bisoncapital.com/role/IncomeTaxesTables 42 false false R43.htm 00000043 - Disclosure - Prepaid Expenses (Details) Sheet http://bisoncapital.com/role/PrepaidExpensesDetails Prepaid Expenses (Details) Details http://bisoncapital.com/role/PrepaidExpensesTables 43 false false R44.htm 00000044 - Disclosure - Property and Equipment, Net (Details) Sheet http://bisoncapital.com/role/PropertyAndEquipmentNetDetails Property and Equipment, Net (Details) Details http://bisoncapital.com/role/PropertyAndEquipmentNetTables 44 false false R45.htm 00000045 - Disclosure - Property and Equipment, Net (Details Textual) Sheet http://bisoncapital.com/role/PropertyAndEquipmentNetDetailsTextual Property and Equipment, Net (Details Textual) Details http://bisoncapital.com/role/PropertyAndEquipmentNetTables 45 false false R46.htm 00000046 - Disclosure - Other Non-Current Assets (Details) Sheet http://bisoncapital.com/role/OtherNon-currentAssetsDetails Other Non-Current Assets (Details) Details http://bisoncapital.com/role/OtherNon-currentAssetsTables 46 false false R47.htm 00000047 - Disclosure - Accrued Expenses And Other Current Liabilities (Details) Sheet http://bisoncapital.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses And Other Current Liabilities (Details) Details http://bisoncapital.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables 47 false false R48.htm 00000048 - Disclosure - Redeemable Convertible Preferred Shares (Details) Sheet http://bisoncapital.com/role/RedeemableConvertiblePreferredSharesDetails Redeemable Convertible Preferred Shares (Details) Details http://bisoncapital.com/role/RedeemableConvertiblePreferredSharesTables 48 false false R49.htm 00000049 - Disclosure - Redeemable Convertible Preferred Shares (Details Textual) Sheet http://bisoncapital.com/role/RedeemableConvertiblePreferredSharesDetailsTextual Redeemable Convertible Preferred Shares (Details Textual) Details http://bisoncapital.com/role/RedeemableConvertiblePreferredSharesTables 49 false false R50.htm 00000050 - Disclosure - Shareholders' Equity (Details) Sheet http://bisoncapital.com/role/ShareholdersEquityDetails Shareholders' Equity (Details) Details http://bisoncapital.com/role/ShareholdersEquity 50 false false R51.htm 00000051 - Disclosure - Loss Per Share (Details) Sheet http://bisoncapital.com/role/LossPerShareDetails Loss Per Share (Details) Details http://bisoncapital.com/role/LossPerShareTables 51 false false R52.htm 00000052 - Disclosure - Licenses Arrangement (Details) Sheet http://bisoncapital.com/role/LicensesArrangementDetails Licenses Arrangement (Details) Details http://bisoncapital.com/role/LicensesArrangement 52 false false R53.htm 00000053 - Disclosure - Commitments and Contingencies (Details) Sheet http://bisoncapital.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://bisoncapital.com/role/CommitmentsAndContingencies 53 false false R54.htm 00000054 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://bisoncapital.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://bisoncapital.com/role/CommitmentsAndContingencies 54 false false R55.htm 00000055 - Disclosure - Share-Based Compensation (Details) Sheet http://bisoncapital.com/role/Share-basedCompensationDetails Share-Based Compensation (Details) Details http://bisoncapital.com/role/Share-basedCompensationTables 55 false false R56.htm 00000056 - Disclosure - Share-Based Compensation (Details 1) Sheet http://bisoncapital.com/role/Share-basedCompensationDetails1 Share-Based Compensation (Details 1) Details http://bisoncapital.com/role/Share-basedCompensationTables 56 false false R57.htm 00000057 - Disclosure - Share-Based Compensation (Details Textual) Sheet http://bisoncapital.com/role/Share-basedCompensationDetailsTextual Share-Based Compensation (Details Textual) Details http://bisoncapital.com/role/Share-basedCompensationTables 57 false false R58.htm 00000058 - Disclosure - Related Party Transactions (Details) Sheet http://bisoncapital.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://bisoncapital.com/role/RelatedPartyTransactions 58 false false R59.htm 00000059 - Disclosure - Subsequent Event (Details) Sheet http://bisoncapital.com/role/SubsequentEventDetails Subsequent Event (Details) Details http://bisoncapital.com/role/SubsequentEvents 59 false false All Reports Book All Reports xyno-20190630.xml xyno-20190630.xsd xyno-20190630_cal.xml xyno-20190630_def.xml xyno-20190630_lab.xml xyno-20190630_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true ZIP 77 0001213900-19-016052-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-19-016052-xbrl.zip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
;E:%=C!O/!(,H/QMV+-HFFP@-=38H)G?XH / M.L[,7*% "(AY)7*R4F"UP$\O%]^5 W()EG//6#=!C/1:+;7>;$=+ $R4IGV1 MX*8OK,F$F1;?:7'KQ,R<],<7;AL'8SW@F@=5A1A7,$HBD6X<8!G=5NZY'+D; M@HF)H^)\]Y[UA+O_WM8-2H.A'0+4HTB+/4NQ#_DC[68;L8OQ2412ULQXS9P3 M+"Y7LM=C"[ZK:NV6VNATLK1$^31.++??9XX[@36[AQ\G.JSE@@:'-6PTU78/ MQNJURHQ%L\?CB?6U,)ZWX'SHOG#F/)1+5]C8$P;C?A9WYLG-H:O*!%HK MZUS% CL30XAT*TE=10\"'2/TT;+PD?EHJ<'27"Z%8Z)6YV-M:MK; ?52[S34 M;K,]1[X2"C1%UE0NI6S^8SYQL_C .PS2R' MMGF6(X>-=@GJI[N'!^7^^HM"68WJI2_F(NS9W9Q NO.VVI>Z#UJ-O!_+#BFZ MS0)07[Z?"JO'L:-4 !E^M5QPG,#2\/%@DDD1"&!50US\J/O"ZGV_'TPJ0,Q, M(''YQ!4XR[S#\W>%I0/EJP3BPW#ML\+1"D]&/HX]!L8N/#_VE6O,&&P%Q$K@ M]F!]WPEFVSB6N6G!U[KU)IL>3UZ3WB5/+&>. ^\((TFA/9TLKCH+UW>R0''K M@2-GWYU1I_C4A:2.Y)W#\LZV&BK^P6 7T+-4VZH((&I2MFZ<(3: MS:+V ;>17ZL'@6<-0NZ!88E$)@XO DR%6S:*M6S<7:&V=AGSRN8*;YIJM];% M*/9*L LF?WM<^#;46DM[1?BVU%:]J?:6G/T\+7Q[6E?M]F#C=XM/S:V)\4X/ MFN%7'QAFB)P7ZL^='-E;\\7JGT&4"+TZA Y]\GB99?X/LN QY@VPZ".6JA"? M2_*?#^;C[87DV+*4;*KM>D-M MM8O=;TE)R9/[I61#[30[:JU9OH7/7F(>6^E>4GSP]78A:?H"2;_):=J2G) < M?EUAHY==_[D!W]0NM/*MUHKI6>ROG!:Q:L4]&"2Q%CBKV-V7Q)HG5G,7Q%I5 M(3/WC[V/&H]#5'L45\7]8\QXS38_^XE'"X+46!K4H'HGP%:L *S3'S"@^EQ] M^QP$.ZG4S.'0G=9EEF3"U(F':#U^!C MBFTJCQ9E9*)*.RI-FRM+XP7GEH>':^R02KJ?W= V@26>&.<)W0FLHA>5+RR@JW:HK_GD+G;GJ6^W,M47(/MU<7=\^7#\H M_2]?^K>_7G^^OGTL 6J.DM]!.Z[<$BKQI>68# ?-%!]:.2(AZ0V_@VJOS2", M+HC6HWU$\%"?8-[ TI@9MF7XRJ=/5\J;L\QW9V^KBM4^Z5ZBRN[&43ZR@4?] MQD$"==2DT$ZA#(JH;*1J1%VQY]=$65P/%0LCP8;D_4Z3X=Q!H-.-'KK#J^5\ MZXD7[#V[GFV"4&'Q^*Z'?>"COV@\ L, ^02#*%B"Z8@;1/YTW.?SL?N,L8HL M8P#(XCY[%0B3W%W/^YY.)MCK'&CR'Y9][R=?^>U#_TJQG+$UL +74Q7=]ET" M "=SL&BO/V#?+G+(0OE-#?7X6G?<@^<\7L^)4XA\HYF3>)"W%C=DLZ7'.>HG:TX73H MH8B?ZK,)<06\]?7AA\9%2YE8MHTEE< RR-U$_ +.4V<]VCX^!;!-"3\UH:DJM2>72BP(5&] M)YW\.:(68 7[841="0/.BP Z/9'TY4[/B!-X;(05J-AO=@%C'U;PK5*'IXJ( MT5:CUK0A7F^3&HPZ\#_I-H$1%> .+0\H"Y(ONOJ&WPH@-C'>9^.:H8%/*%=C MR]%QDXO"VJ\.W4GT )N)^3\K];=*PRN&JQG?08)P$0PYL,6%P3ZL#W8R?S%@ MKWQOYIE2YT,=5FGVOH0Q=<-7*H^YGV''*<3-$\AN571(1. )R/ES#1 M_:1_A)[E [?3;/HP$"(UF@Q%*^T!NLTC;U3Z00S+(<@=>JSCC2%3"XR$BT4C M^'4<4WA,V&"I522,5^ (CTW0A('_L.$0UQO(;-FT0D3,S+UAF35#D2XN2 ,M M8_-O+;J-"Z])8Q8M$9Y2F<72STV^$R/APUJK+VZ)<'^I. M$+5,+[. A:H95R2-,=Z=%8\S)* <()N%5\71N$(./NGTA6<%@"L>B0(@%B0@ MS4JL@93GHR]""U^F6('4&PH7IF,[>LX!P1ALT2R5"8X%+I@3RP-^[ 4O)8BN MJQ=7TO [0@):&@,,7/H-7@,4DA,X=!,/ZE^4+#"M@]$%V)6AB4+=XLLA?BQE7"U?__VWO7YK:1G&'T^ZDZ M_X&5DZF-JV0/+Z(NL_M,E6([N]Y*8A_;,[/S?DG14LOFA"*UI&C'SZ]_ 70W M;R(E4J(DVN9<$ELBNP$T&@V@<2F]&%Q6 GF+#']K/&;S!3\C,L-%6U)F9G*Y MSR5DQK:'&7 G1:X#V+LEK7MX$_;9E>4>7X\^ 7<(LQX^5P8#W>BKW,!7I'%/ MTY]9=[XU!;E]UXD.4V'+8S(GB ^4R'14PY?8-52:*"A[$0B>MPH&(=I]7&[R MTX.L0/(.T.>6:\]@_A/"T&?HX @B.S?VE$3':QADCC84+G@KF)1$-M\##@(: M"21IGKZE/-)Z7 I 6I%8 *A?*J>2S6](HI U] M@TQ.EC69]JM<#@1!VKY?/37\8C_BHD@@+HK 6')/Y(%G'!$$J[P/>NW06:28*X P=@D#T6'W\NM038O*G^0K'2D9OXEPF\NL=>$TD:2.G W<>Y$R M.>D@I>;<45X[7[[XA*5W<:SR[H38XL4V*W3Z?["/^!&+1E0D40N&#)2X/>78 M>T35A?<)?P1:P7GH6* %2D%/&@>^'=\9CI2(T"R@$3(9/XWMRW0=> EZ2')TWLY#LQM1/O*:(7)"J+W'A$@+DU MZ$ZQ6@=V>20ZQ?;ZZ],\(B\0WX(KG2%)UX"T-OF*(251P2!=.NT3>*4D*[[G MC0P*8:V9^[?6FGM;&[7]YI='LJ5C^;M:I*NT9^*+UXR9D?*K+1M4?%F4#RFK MB!9:E?/;_ZQ)I(K*N>@*CP>^]A*,;HNI8H\Y, '22<+=EV"OO3)M]R,'(GIW3I= \[&61"3MO@-L1X=8BQT=00X]/+ M+U\N;C&P^$89?3U33B^_WEY\_>?YU].+\YO&Q!JOO4Y4UM\G[HOKHOG6LU[^ M@B_SX :E!4[T6CCX@W74!';]C)=9I#((D;0$U%*X5;8S=E'1VP,SM=G-NZ!> M[00X=$1>?&()\Y\7C44S>XS!)0Z1BO2P.99%P@/*H>M(5#)LF,YV>*20-YUB M] EN2,:O.\'C]M3ZP_A5<-=VYJ1W8JJ@B2;SMO++UTNJJKF[-NC7#]'X+Q3.QJEN1I:MU5%$Z;,^;NG(1K6W7 M7]O%^F^8_UW7\AF]3K?7;\KR[6LGZS6O9-DCNK(4K7;FU\04FC[L],Q!4YAB M]9[>P3[+)7J7B)XH@U"/5O6^LF)4&LJ=\$8$>$_M=W2]NUN];@98C-=X M3>3$%ZID[4MSD-\*<),PW4>E1/\4GOV*$9$@2KM#^AQ^&PXZ7:.;36NM#$;) M)BX1$%VUH_=-"836[77,83:YMM'>@]8MNHE;]*X1;M%K=H^=H/@-Y#4%T!2" MM1\!]%(<6KN8FO^+[+DBS$;&,9PZ%(;!+]]/O=D6HZE14)MY*7MFS'_ D;R;UB%$6O,W81QM3]#[P&!CZ%D:@=#O//^I0 M2 5!\2=\Y\ H_PF5#POOGE&(!XU/%Y(\E)5Q+-Y]A$,:9I@K%V*J=T=1B[,; M$"C,#TZ4JU0.I!WDX<+=ME'H48I&>$E*7U%4"7\98$+Y#>3!2((P"F6Z8>/0 MIY =932FJ!%M.#2H(YHDZP?MB*+%1.[BW//%=3[!@(-H'5,==@P0\J);%PR# M-Q'P%. (:DE$3CL(0@[6"N)_(%)]\CB45.(I> JIT2Q?8\>?YWA'ALS6T\GAT/4Y(P M X93W9/\2?/_(9X^%4]S.###,\F/:8IVE!34@D'/):FDX)3W%#&C$'Y='G\1 M\;,<$YGY@\F__,)\#&HXQ0S5"1/L2P\*L$%@.,_*!2>$7.YF]*^8$6"^*,L5U(4G6QG".Q.0$2-!",VB8H! &$9E?@7GOD'"_.E MZ6.*L*1+%='&3L0MO,N'[MV),EH0> L0G%$ 'X\'@D]($N#?/*>-%PZ0(3UX M$T#Z6%XA (*K(T*H2=":_A%A9@US6D) M<1/=6<4!4RP8^]Y3+)O_G@CO$= 3(&<(:AX:2VQ"$4*/1XIKNQ&T<:V%513) M8D>%@V,Q3W=ACO M>QSWJA0-+E'F4*BI%86_3-B,>(Q.A<3YLNIL$,< UBR0I%A0B\0B5.,@T4P# MSX)=*A/;,;IIX?"3XB^/UV2@("H!=1+BC@SBDJ%9(HM;'H=Q8U,8F(*E^+BB MQL/,\QG/P5\\>7GC![*:1W3EQMM+(B6BE\6>!38&/KZG3)FIV"]Y0^[$X"E3 M]JS0-CB IG<3WOTE-E]\4F-",E*HH]A0%/[I_:#N-5 M V(&)P61SME"5D_*!GG>6FYT\N/:LO^&N/V#!+/'P^58'4RHBF??)4-.XUGRQ M/H!G&STLH4%AXP-]& 44$UJT2$%BO8$-@'_@G!J'BV/T^;5; F=+!1T'*_=' MI'TGF&#_YQ)!D7MLECJ74$>*9'W)_<,Y-LM>@AP9V9_B;&'\B#H (@=&K1L'NQAB3(D*,M:=K_G M85)RJ4@!#&05A3CVW>&QXKQD#I$1#FZ@?) XP_GJ)GB&FDTG!5G!\O+$%L^? M6+($T/)8"8-[@LJJ?8?Z_)WW2"VBT6]*&S;$DC46ZL64+X4SY62ZY&.;0.X. MV3J!X=CB#V08K(0B+%)*)FP,W(J9.T0KFQ<]XXD!I/: 6G/\ 'O/%RX4ZC?R M#&;_0#U2)M9SD$C R5/*\SGY-;BK6@_R03W(XT9XD"]YCMN*P-I#7& Y+S 4 M%MVAH@8>=YM(YZBT):.\6$IK=>#0]*0\EX=_H$1'*^H -N@/]B)*I)SR(,PH MY-5G#@^NQ >B%+HI$TIQG,(EI*IX/ZHDN51%4OGPU0/;3M./VBNKUR=P)HT0 M.)_9O25KV(ETHO;*JA00EZ[R[Q"T,$T749?DLI&>4)@653-0!47EITO_WG)% M&JR\=;ARP,R" :?OCO!%F<3/ZQ9*"QP5)5XW$!^6B8*G5$CP!_XMTS8_@^8G M2LN>V8]VD,BWO0G)BX3N\="/TG6IG#'/FG:L)[2.K'LL.K8@2%P A6#@X)#O M+LX-M'@!1FN\2%5[2Z, UM:]=2\R&"-D*=N:.]"4@/F/-F:C)H7GQ ]3V==" M)>>$Y&Z^S#Q8/A3FP2P&RW;2"=T6A00K$UZA,0U)7!M:@ %D0AN+37@-G.A) M B%@['N@O.]UAD.\%QIPEWD:E(XR=T*>:8VW@[+(8T0L7Y!<^XD:+)'#^"2+ MS@QK\_%RFQ,)=,0!!,K=LRSAAXR'[-?L(Z+Y=:E'D;\]'4N=79L':Z)@(G]_ MT%&-/G*9[+Z<8JV.$M_EOM?[QG+@8TX"E+(E#J)L@KRO%AQ()F?"CR=YL:A6 M<]P%IUK.::KY3=Q Y\K' )_%LW# WGJ7_D@Z*3YY_J6,_J'(_G0[G89EL:Y- MZB@1F<;1I'&T:1R6KHTWC:-,XVC2.-HVC3>-HTSAV MF\:18(.4ETE4S:G%NLA6V+EF=(%\A3[C6RQ(;U&X9EM>IWIYG6Y3R^M MW9Z?*5>CZ]L_E=OKT=>;T>GMQ>77YM36R5RYM"5UWD9)G5'*34FA[3(.]+#\ M6%2"XW4S9K\!G&DW@C&OA(=3<*:5Y,TFL&9?;U+=WD^KTR<)E*7LQ8XB\WHP MT4?Y3]@1I6CYU0H^=GI^N7Q%U%%$^S!*=@3[ISVJG;W:CXLK3T'&>E3@BDD=K M87A$U$ ME3B#]V>A/Z:ZPYE(KW9Y\BM-$ZVS>WS8R;F#3&]VOF:BH\R@,S1Z M<@NK^]P7%<1H>YIO=)HWXSB_B:ZZQ?X6F5\\QH"B1:<8]T^QU!3XV;P37STQ MH@TJ(XV/->.D417\S[%)Z9UO3^Y!>E^XXY-.+HWC -L_/":/=H E M]J.0#!@O#8PQ,P)U@?D0'03-*0! D4P5-*]TB#=+ITZ.:L@BV8,U$ZOJ\9$2?=2X.=9]I1+ M1$CL]Y!:VO>#]N#:\<'5C)-KQ&T)T;G HD9Y(L8E$873GE:;1C-^L4">=T1# M(10!43@C 3+W%KP-0+IR!,K[OYCE+![& M&&'(2U'0V?+9GF&[9>6#_ $][R N@P=[?J1\>!>-0M/32.^.TB6.+2I5L/J\ M&E,#(1P4TI]=+@YF?Z70A6 M'PMD#E#<@R:A$0A83Y: PI;6B6QF),?$MY[XB2Q;C<.'8'V8T4P\[X8GNF8& MY"MOV9-4VY9H"0O6'XL43*-./4M:2\P_&*U)[L[PCNI:\J-2.=89L.=9(=7J"0/)9_0EK:.X%>,;09AHW4&O!^3 M#%U=-[K<.7IRRV-:C$RW2Q3&(%DD)^-YBK)..$S=[_2$G$M/RZ/6\Z9.'=BR MP1?EV[LA'2KB*QDA/?B)HY +GD0DH1U'_8SBKD/3J S(TF*TG%V2LW']0?PG MN2WG:--[8,=TC2.E!!.>* 4>M,Z*5Q-23+C+M(ZFZ9VN:;9+Z2K_!EN?['$M M&[:>OY:P=7O=@K7L=_L=;3 LN9:726] 9!(N;7ZJ$,:-6D\!/)A0?M XG405 M3))")JU7Z1VSKW& Z:K#Z*C#/B]GAHGU4IY$4@1F&VP3YZ9,H=VV:*IP^73O00@AMX9:%HU0%9ZC8;\.^=!*A]!@:2D'7S<9XB=Y(/FLCW$2/C? 27<&VL -R(;N8/=U(E]"6 M#+J?AJ04*\KK6KDD<19Q4"2!,O:"A2QNZ;)$;4M+^2A="Z?>[$XHWQTAHV3= M2"&J1)&2OP6B^Y1P$DS X!ES)Y,OZK[%$H1?%<@[%"H"U5'NP@65^,'B:\G6 MOAWN)$H61$'?"Y62$E5S(@,KO\+E9ZR'^>[HA*:]F*:&HKQ,AD 489U\^LD+ MG4G"ILJ=B2JYX+?LD;2R!^KY^C'I%TI,H$P\%A#2&*7*TO,A?EC2Q4I44L7+ MES&H.('RP 8+US@]1&]=NNC03 :4U=27OJH %*"@J ENKM>9E21IIP>D&,/ M] X#62YV#2%NL)Q.[G=\, (#2_A1'5)):9^ MQMERK$4+BCP.5(L.4%X=R_,[,MO7P3/7!XZ>V,'89_RM<(X8OS>%#07C4=6A3(%"B7HG;DB=6C8KNW =ZE\6J2EWS/+)O1BZ M5 A/5! 2VHO0I96Q%3R@R!#TM/$HQW;:6:)D*$%KET(MLWR>[-=;M"[9??GF M=>Z+E&6(K ,TE\Q/@/ ZPZ3(IH\&NIB,=P1YU9(+FF 4/@8YE](]Y'&UXMT& M0FYA\21+<2V*'";NG+&\5J9\5DZCN^SY58;MQ5S(_5VUVQD"*/;RR)*R]Y%47I9YDB$VB7Y ML(")I:9JRJ=X.?/478C@KXXH6"2&CU:-"A>"$%M8F!N#@]D+OG',M6.V:[G( M;O7D+I;.Y'@+ P&?^*&5W/E1G73)!/-L3 S5\2.)M3.2OUH;MP$F;D/:C(@0 MON4(OH:9N:N21FC>E3DC^]%0:-MC!!NWFWCM.#H1\59C"+)3UZ3;^B,%3_&P M M 6X'SE1R'L=!Y/E2H ):W:Y/5W)R42=%7ZZ*)@M_A^"C154:"6ZRAQ.-T: M,&1L7< /J*HD)DE5IXMO_.,:@HZ#"RUP9,!@PA\7V/C7:D'6,9%TK+U77 M2IQ-_)E9*@!Q^<$ K,*%G(KNGQG%]\ \W]DS?&UC+,/4'M,#,)IU#^LLC Y0 MW -4CAPI7&GIN!X4%^0M'XC7!=&N\<91KNVL\^@F8[Q7!^%M LO0Z Q[@R58 MLDY= J)\.."=Y9 ;Q^=YKE$AUS7LA.Y?A*+ U<(^,W=@?%"I;!Z% MY8G34U2@ZZ.L],)[;J3"X>#8O)A_^C@L9UU&4@6]-8[]W]">2&^JJ+X:%SH7 MZ56/:-PRXAQ3Q]5[C,^)C[_L= MM%4S68.VJ%B+M6SS(*F:)Y@/ADYS,KA"-KQ]%8.7$F[S%T))IK MR*UN+,^>7F2<)P\$O&5(NIHL[M\.HIM48AAQLQOUNA0^*7R8,*>.6QX&! ?4 MHX"?SL$#8XND>1B7XZM0H");VR)^Y'**A(A=F4^M=W/QK='U^_'%TC/"KH'B;D0_90\WM:&0L_)Q$4Y/9L[WC-)_/CNF4PPSSV67TJ;VG)YPPQK MS$]ZJK"*%QV1?S5RS$;W @LX"K!4<\#X?1Q:WCPV-78E$MF4*-(G.HTP*6\^ M]]"IGWE67#F2E@&8$98GBNAK:@)-;NX1P^M-N]>!0>O M3]5#>>"P\RROYGAVPL2B=D14IWH*IQXH5-A&K2-NBH&YW:@A'R_]C&=P\M%, M!Y*XDTD<^&<'!%'DBP>^"O%Y4 + 4O[ 0YV%9GDD@,/Q"8CG1,'/C&Z">X@@ MHS8R462T0!BT2BMR=SB@,7/Z8>@2&3G/3IY'R,Q20\AM0D.(;F)A"@1!KV.VNWER,!TZ(O<<7<,=I>"*4#DF12E MW,B_R\Z^$QF.@ MD]=:$T7[N3O(OIIZCV0G;_**83*,TD3B3KD18)AW?N_*ZX?,N6Z+A$)IA:6C MI4-7S-5?1H,N_V&K3AEF!;[YN\DD5Z1T$0+B0U_LOJJ,P94V0]N>,_C1FN@? M:)%%#'J5*":SM-4IH@U7/@),G#LB](DBZH1_:*D(PHPW>B9QLAR+-$*%+* @ M#I \_IPCAC1)362[<8/5N,/G6%3<$23@,YTD*IW=4GA$$!7-(:)'I!("45X7 MT6F;U!WC0CR)RP"AO]&[HM0/.MQY3B3JF>2($*V"HFLB/XY9)*]'*A(!5XD? M\/.E8CZ2G+Q5.BT$@I4\[-/'>J+O\GFD"2%'TWL6D'.V?!-._H\0FVZ242ZZ MZF4">J@UZ!* Q4W=]Q:PT+B#8=DBO4$7*F^\S7N<7W)*CG!]N./RH*:ILZY1 MV.':@R6T>U0*L9TLTA(V8]9DDY>WDDVMB+@E\RQVIK]4ON=*>MZRGKET;>#E MWA:9'AC5'%'KK\"*NRT47WBM^3KC:SV[(S*E7@]* MHRC>LB:4]K#)#DVSK]R;%\WC35\//TAO^>O!2$;&A6"LOAJDP);S;3>PQTW: MMBO0$*IPU 2#.J-D/2WGTL=2&J=5 ^]T$:*N='+>C[D=9+A=78A/+O!1\L)=\T]K]Z>D.Z,0&1D,OW'7;W5SX2I& M&!:V#91X43_TS96:28&S-Q?,HS='O96*3172E8"Q'AKN Z@M M%(&69@>B6:M)M>=TB]!+1>C@]T;+-]HR"3Y[F92,*"_$OL+X6RL0,) R\<([ MA^7<8=>L4E28*^86O9J&ULV]C*_UYN#MKD4EA:]=B1VNQ/#$[+V6E=JC[F6M17O4-64EVJ.N*2O1C*,N6[BL MKCSWTZW"+U4A Y^ M;]3FYY;2)S9*"ECG/&HS-/:X&"M=6>U*['$EVJREIJQ$O],UC,Z@;^QY.=H4 MW5?(3.9@V#$-L]W935B,]K1KRDJTIUU35L+LF/T!G'C[5LCWE:7;S*;.7[UT MQWN94C-1)J%/[8E3_84)M)P>PV^L%?87R[7NV8RY"VP>[[-@#@2T43^9>CX! M,F$+YL\H_XY(.+5L7Z'X;]1?,KW:,9]$YI($U+8\V;&=?S+&&6"K8;-VQ:6D M+AQI:HT7GA\HMCMV0G(&X"34\3XX(4ANEUM)']]9N,+8XIZY 3W,&\K;V-C> M"D(_;@F?!AP_D<"#*@:JX#AT+$0!=#_1O_[.QN;NED.SS[P)$\[Z]J=VR;]E4VTE@E>=]V# M"OI%LQ)D5IISA\F/J2G<;JC]5*"87-O!]^.ISQA(": 4 S'LKTIQ;G1,DG[2 M+U:GU\S_TR'<$+F0G/^8LS&=RW"&-^V. YY!EJ\J,^EEL#JC>>-YW#]02V[$7S_F[Z;"+:/1.M&K4;L[F.+,?00\%C?399LYR8,]A"5OL M5=D;5X$K8N HH4/:,3%(TN7RI71$X>!0$"K=^/6Z3:>HQ MGH3*;RQH9P\18D4D,]C-^**MX*$[B M2?X,M\D_)B$0LUCW "6Z%( ,:P8A>U%3%3K"E:GOS3BN+$"]Q7YDW+$@P$7B M,*G1/$;G(@&R"E'E"2@14S.BVH,=+#P?MVUB- 00_0F6SRTK6@R;!7QZN38/ M,*+KB1'@'>XKX<#QB6&8N45[=R+.F0#GM!=!9C-G1DZO>H[3(OTRF.72,\/^ M&T;49+VVYPH([[@$HJ)C:Z;!> ):Q"$TRD8 M^N0D>/TM@"$J^=.]$+C<"09"<"T:BQ[5F37!K0<-@7CP1T36I[R+^\) M__J=:' NI[I9>&!U70HL/LS#.\<.'O@ __8>7 +A7Z'C\%UM#/ZNC!P'"$#B MMZ-\ AK"%+#R(]=RG@-8E7][H0\_HQM0[2IL8N/81QW%4I[ FCZVQF,V1Q"M ML35A,WNLT*2]?^7S8A0&Q7N6T(K.G9&H,P%*"Y#EYOL;>6]AI<2N=R?10DQY['KH1S(D=!]ARZ$0 MG O_ZIMBW]'RU3N)*9]++EP5UW: 2C$SI5W,8OT"SD#<[8V.[D*J_N/G,#B^ MMZSY+V=V,'8\=$Q?3I-?<)3F D MQ[&JP7\+C__<.S;4=[\VQ-M8VM$8*\8;:\MOH3A)6TWU156S::LBM=54VVJJ M;EM-M:VFVE93?=E(OT6HK:2Z;N[BP&U-55>V\'WE MM317-LU]Y;A7@+^E0*M1M.=5B]!;0:BMI'KX0J ?^N9*S:1*F<:C-T>]E8I- M6Q6TN@!I:78@FK6:5'M.MPB]5(0.?F_45E(MI5)L5+I)KZ:AM66T=K@6E12^ M=B5VN!)M:;FFK(2N@8 R][TMVC*JKY&5VJ.N,6O1'G5-68GVJ&O*2C3CJ-M5 M]9'"",<,9&^NXE]IYGX+X:YM;NZ+BH]NX^S;W-PV-]=M'4)M?NZZN8M3%-BM(-3FYQX^P[38W&MDJF1+P#;7M*79#L!K-:GVG&X1>JD('?S> MJ,W/+:5/;)04L,YYU&9H['$Q5KJRVI78XTJT64M-68E^IVL8G<&*;LAMBFY[ MVI5D)G,P[)B&V>[L)BQ&>]HU927:TZXI*V%VS/X 3KRL0BY/(_I1)M#&/7"W M;UI;I@VNZ)T[>K+\27+$WV5O^%$0A#/^V9MOB5N!O9L5G[U2FSA,>'9-T1Y# M[:>"/7YM!]^/I]@BW$9*L6"A^*LR[!I]):Z?](NE^9KY?SJ$%IP+R?F/.1M3 MFA'S9TUSL<$SR/+)[5=:N(#2$\T;IXK@$"OE2+-]=KG0_>XY<"PX<-;D[Z;# M+J+1.]&J4;LYF^,,3O )QZOURS"6,S_/[4^L MOGU]_/KVPOX3+FZ/O]T?@T/*3?_ M&EV?WY3 -TQ9%'F M4K1PH1XH3V T*3;(*OCH[EGY#PBEF3U6KN#;F:7F'+J> '=UKIH MR+J!#:86G!?XU10L=^\)OOQE+_3;#0]$G%R>$1K@[SA$Z9>F^T%&[CUSE.@0 M56[:JA KZ87L!'PV.M9:HE4EVL=]D^S ^58?+<=RQ_(B\XR-&=9G4@R>_%UL M\T@1]U,UA%?"E#M8@7NL.!<_X96K!FBLWFH5'PAJ/?8:_-\S]H&D=32MVUK^L MP-.AT1D.NJ\$&:UC#O7.8,5-RLMRR*]2A+C/*,#MLO! XYG-X*=-BJ#5@BGRP7D\'';ZO6(YT!)P#0%5K=\Q!Y7OX$L1L&E1C6E# MX'5$-!:K9O7%"95/#'QKX5HM]5OJ'Z"#1=.O*]+(O?B[B=&"8$W<*'04RW'D M58*7R OSHVL,9?T5AG@"/K5=T(6-;J@@'C+"WW^:2 L/_X MN?H-;?6[W;<6;?D*7<'M?4-[W]#>-[3W#>U]0Y-IV-XWM/<-[7U#(Y!I[QL: M=."V]PWM?4-[W_ B"=C>-[3W#4WSN;;4;ZG_5JE?D$:TH3-X*;$_O O8?T/F M+LX?X8^MTX)*>(VK7B(<+[PYI2B+7R5YU8WRAE;=/Q2E".4OF%-'KH#6*Y,+ M5*A;UY_ ?UD,8WX;E<&N]%TE&+U_$[.KB*IXO MHA$;AS[F,5^%_OC!"I@RNO=A(\(& I9NHKG*]:=%V(92.<99N!J78>G'?%+.@*'_.7RAF\, M(L.R746L,#K'<];X X[Q[N9J].Z(K[=\[9T5+[PM%_X=JI<3-K5=-J$9X<'K M$.2EJ6H?K"/4/*_9?>A0@J=RAD_/0=Z&#G9UGO#<68(Z =1H3'E2VM P.OB" M!7!-X&$.F009YC[J*//0#T++%5>DGO+T8(\?DF10+,2,.K@&(++I[Q >B8=1 M+!<>$HVF<6)K#B#^L&?XZV\W9^\U59G9CH,(4+JOO0@$+(#:"2#U&W[T[HA@ M$+>R8O8.ENJT$$I.9FHGBJ/@N,;)0%7F@#^^KWP(PKN_&* .$%H37&]3[C.PHV W(MUB& M+6L!'>\5#Q^A@AWX$8$PLX!IPAG QQ<)I\GRUGO-C)B)=A=E ]I^ $LGT@61 M ^$95XREO(_?".?PQX0Y-IS^SY(.XCV9N @;%#.HT]@*+#H2#5BF!Z"^ZT6S M8D3OX9)_BL$BS/( TOGV(]@7) M P$WW@$#M]\B7H!B\R[B3TH]C-78XL!M_1>UTX2#[H1_FO()8_PW&8/&7>*BO^@0(%Q0-\ M!-R%*Z%\M8*)]5^^L7UQ1@>17>0\<\::6SX1E"1HL+!\T?0[]Q8V2B]\ MCN1=M! @%FUW[(04>S3W%C"@;3EPH*!\(GX30D(*F5@\Y2_1:]#@\E7K5S/+ MH5+R$; M2!6 +Y[Y]I\PE]X#(8T2&PO$@1Y!+A/;Q>-&+@2(6C'"'=9WH:GI+$G \S>$ MQ#V&@V?NV.2.)JU'O/=9C(060Z"8IFJBJ =%#S4WT]3HURZ<+URM%P=(6CTR M0'\D'SK-[W@+!535"?.7#SPG=''[2C#Z,C;A., M0 6&@8+0@3'$.T$8S+DY!!E)-==" *= M!0$2X0\V@1\G%IPEG#'[7"5'YOP[43VA$27/'B(ZJN8Q,()[/#A CN$'H&*( M)BQNDN]L47!L[.FP:,+FC]TTF R@XR$ M5P;W]S4<$N3/.46O]-0>"VOWPAU[ (_0_V$@+D](*F%8!$N810%(RP5WE]#S M:)PZ*&'@>'(5[1@P/-9.3)H/O@*;VEJ0[RCZUJ2W@;@+6#5TM2!-O(A4?225 M#J9L)([9#VO,O1A\1GCXCKL)\!&2BQ961W7O(_D7$X8\+& L2V(J,2'Q;73. M3;DC@3N4'F%Q<:7%JEB),6(JR)7^$Y[2&Z(*%>^!XMJ.>B-07,S9\J9]:Q8 M#A#$M5!< ]\Q1SJ3[H!D>+2AVVM.0^&RX?+AZ1)Y3T!CD.O#33=:(26U.@)X M7ODH"7'$.0'ZB6(J)01VHCI.WKHMYNS=Z#>C.V9Y01X:_-K;S#4-748@[9RQJW!&R3 &Y0 KVMT@6-[ M^P(OAWK?QK!WO-FWFW .',#\2Y=](:=0%FY[ L-XWN)858\!J1^!_8MK.__S M;N&'[)WR\RY(5QJV-$W[IJJJ>USQ[@L$>Y@ >W-.T) 34E@L/N\;>!$B)35H(=E* :+L1(.MV8BG8]!W 5H9- M\1*D#*/JPZ%J[&V#E5GQDI#K_5Z_V]W;%BO##\V$O(QP* GYT.B9W29)XT^@ M#I?BX?4V\H#GA0>QF$$6SG@NKN1;.MXM9E+7H97P=!:3U7S,,IP.>!Z M!^+'4L#U#\2/A<"E^1'TP6'W@#)_-71FK]\?[E- 9M=$7C&H&\,U$VI]T_F M,M]RX-G1!%WJ_(;YD=7H&-!47=>'@X3!M6;2&F"LZAT8= ?]I$FR>P@KYE =')BZF\)NZGW=.##S;@K[ MH<7"BZ%Y'K^(X;Y1]!!W']\P_]$>EW*#=8>:>6BNJ8K!.BVF)B'2 +#R>'6K M]1X:P][F$NX2KU_VH"UT!]VD'"XS;5V@5E4:M&ZO-]0. VM5]0$LOJ3+>\]D MK:1&#/L]8TL.X,D4J/;BM>F,?66+#7ESW<8N.5-E?53K)TB0,\GF&*]CF_HP MKK3J&V#,6V[R!P0C['*ART]7>;6'2U7O1+ZU99^"_3%$]?,P:") M*\M?/-=Q"AGZ0-.6HCNE!3KV&8]*9!K/GM! M@&.>\C!+V[V_G#,>.!-\I)Y2_+E;ZP<+OMBNASEZ$E@X8M*CG%,0X1>V>/ F ML5@*ZN"R8ZVO#7N&FA)\>\.@8<2K*C2/34/O&T.MI5WU/0W?FUK?-%K:53^M MCKM]==#M-8/OX&2,WQL]6K9#6?S>*85@)Z-8/UJ!/:Y': T&PV[*T5<1BAT@ M45UXF'IWF'3J'QZ'[3?QX7&HOID&ZJ!.',A:Q,A:GSV T@$F8F)?P1ZT[]U3 MS-YRQ\^WON4&%N7%P?:CWWC6VRA*&>;[%G9L+?<@0[4[S-BU]4-Z0(+4H,ON M=_DJ;3>SIW:S'I37MGS;ZM^KH#W47MJ(M(?D\T-Q[4X(M2U'Y4P+)\3EM"8^ M0F6F;^I&/R;1BAFW!&Y[)65WL%56/O3AT.QKQI[HMJ5240&V]NN7J3Q77&*U'$UW6ZSN\O9?Y]<1C%\OOQZ?_G9]??[U5AG=W)S? MWI0KK;>NHU,-2;AY/3JVHH,8<('6 &AJLU^4< [;<6P%+$VB3()Q 3%>8M,G MDB8$+M42X&)%L4BNR")?L@[+U',<[PDDPR_[PSU5H&-?K;H:T+^I;''GHO8) M)>K0UM]59WE[EFRATTCID*T+PQOR]]+')!NO+9W+*Q9%D0^E@Y:_,=O*LN3&J_F.)5)SLL M,IK>!6R*.^3MGVFJR+-B=>2,S;W 7KR]]DK#CF'4T]EF]T9*8XDXZ/3->OHK M'5:^ENC,4=S>Y-9;8+$JJEVU['[8QFIX]0U4--/L:"ND:MO$9O=KH&O#CMDK M/J?WVLJFQ/7 4MN:\0.;A Z[G-)+_.FOGBNVX;;7"JWOK/6=M;ZSRMZ5UG?6 M^LY:WUD3@&E]9ZWO;$NT6]_9OMU-K>^L,?*L]9VUOK/6=U9,V=9WUOK.WNH: M'-9WMARDF&@:4-(K)KUIU$.:\E:OK&<<#IX5_K>4X^R4__QM%'R[G'XSM&]G M;/P-3,G^K:I^X__=7N9^OJ[45D\7G:SSH:@*Z"BXG)9,=!CT0+LM-;FDKE ? M9>V*B*S[(-70 ,TP7N@B4#8"N0+10*D#G:XZ'%)IRG+D?DAG)#)MBB#9".(J M[ ;G?G4HOX*T%4AC&J896<^R&;?+:M.]NA+F9[E/I: M%V2(GJRS4!7*6K&L(OUZZF"H)LM9;0MYXHF]D+[?ZYK#9/99 H"RL%4A6%_M M#@;)BA(KYKMF$\9FX@C&"7W/<4"/BJH-4>4,.'&F#+NTGEJ^CPV"1S-<@3P( M!\>:?@PT$H5 1^X]5_>,O5 !ZINIKJ#; 'FSG'.%&TMC_/Z*N([6IVH M]"7S@2E&,;!8$:),M=.A:O8'ZDM;H W0;L@2?:R\1'I7[_8U_64O42FTURW1 M:,)[.UO.%:C-%^ZI-;?1%[*78U?K#=5>8J,4 +,)S!7.!*/7A0>3Z:5EX1B/ MPUE(I>96%2[(33C?E0$[,'O=E#90!<(Z$:RP /U^+YF>O270MVR&S2O]9['- M+/_2OZ%&E[];3LBNF+^J5[B/'F!5*^(546J\PTTBCNLUB15>-_M)2+K1M&H ?Q,!4@"^ND^X-Q,M!9!KND:]/ ]!^%H0: #IU^W$ LA-+)"\0K+LC?(; MPE\SY2^"(&R*G.&P; GV'N5++? >0J[42NB]R),=DGJGC^ MWF?WH$9Q)\/E%'T4LSD:N=<,GO#9K, -O1N?Y4;@[0S'G?DH:U^%VGV3S5R( M'?@B=[P4-?@@7\)2U.)SS,#XV8:_)E2VC8_.W'&=[IFE]B^:8123/1>:NC#8 MEZ"I3-)MY4IOV.OJR>8=AZ#J[J7&EG3=1$@8ACD<%"OB!R!L+3(@/<9*HZP6 M5WF14JCR?U(!1"L VP*-0H?XCD!+E+$_&'EU=0F)%6!MBD%5RFX&%<7EQ5=[ M0#:*7H8?,Q(\/F+)98FA%PQ_*Y'Y:R1E1@*F:GML[Y 6W)>5D&_'6F_8'V( MR]9 -Q/[KCDPAD-=:^S:7;.%9;ML5]0_]@7NOIDH%>-76U.$.LNB M[[1)1-'=ZE[)4;]@;!8:E:3F*T"I2!1F6@WUADN=;M$7V\GBAN!RUM?V\*N MXR]+9A6B\7)EUF8HE9)9K_\H+B1>/2*+=+*/5L FB!!@8Y54#=>'EO5,?9A, MVLB?:G. :NC05 G[JGW[#*V_.^1WJJ35 \;FIFF_-S#T@7X8ZM5J4]8+VH&W M_%HM8Q_KMKMCOAXPMG#([%YDU'L2[X>@#3CG(EC^R5SF6PXU9#)!J9EW"6YYX91!I(DX;'.>]].)JB\$J8T%WRX@K<%;S)VR :![.;V" M&>T@\/SGK]Z"!2 4KK$>11 U829G+?^S3FXONG(SZ5)H*S"K+$-RCM\ MDT% MT#:LL"D,&TJ59'92);#VBM,6^M,K0' 7$F=KB&O2P/)!Y%MWIUNA0.3TNKVA MN?Y0*@!PA6!-77<=2)X:B)PQ-'-%ZEH ,\C-[FR75+L_[,7#?^"SF3V^@@=G MUIB%5$4LN'#')[7X3;3N<*CUC CNDG/O%.(-!:XV[#43C6V"!F!Y#'/X O': M*!Q@9Z#6HLV5A&UO0D<;8C/SRDR?K[V!YC>U%^A3KZ<'?!^VHZ$.DC%=,W%MT-; WT!5.GENO=&8\G%N'D#0WC)_MOM3 M=^.YJ[):M]OM#]6$8Z34S#D*T9BQ28! $-[G[3:>/+*^W*@@I8X3"EJ):9> MN[@PS)SYB^;PDO&6/*5T>01&U[<>F1X/7C.I'85 M<>,Y*Y-&Z^KF,')(K)NR#OC,!'SFL6;(E,+_\^"!(?]@N1_MP'/_Q2QG\3"& MP6))\=F>V7"LE?.SO%"TY&O7L[LE/$^__KFDV'>-Q,U/63S7;032GL[872T" M]KC?[0TT;?WVBV:M!2DOKW"^U8L0Z9?/=;$):%K# M(M"R\VT+6\V\$2DU>^*,M?-5Y8NA"CNT@/:IR0H%)=[[H+B!3>E/;-?RGU=Z M32MZF_J:80YR9%S1K+6 N0631,E]H6KN#;AN!CBI2_QIN_>.[7ZQ_.__ M"4M%4@YZ V,_8.==H6P*MF:HAK$_>&9&\.]P=Z31\SY=,K& MB\OI^8\QZ,;W[!H.[4OWU H>P%+&O]!:?K2<+1PC:=5G.$R:^56FKQOT>GS+ MWHR)5COVY"O;E=I1;J)M#PIRF 3V0H:LD=LDZ3$!,)QPPB87KO#@RHL*V26B M9N>\68N5E^A.O: M>[:RNQ7 -FS8A648LTW1RJ6FW MIUV@-^'=7V#88_B,])*N*I IO"8??5#%@H??;?_>=B\"QW(GI:N^]U2#EU O M!TVEE)!;# @*831\Z)K9RR6_DXJ_UI.*OPZ_UH.;;O22Y3^K0ULE2V=OZ*YR MQ6\,:&["LJB/?N7#.;BF>\PF6*SHB*.I)\E.K(70I./IK> !A%9@3YB_'-:; M7T88?8W"[?B?WTH5 4]>!2W-N#4\=$=?+3&7,J97@R/IF,PBHN7GI:W%Q2N; M:!4=ME6IIYL]M6\FXJ37 K1K#"K2&_2C3.W3 \._82'O8W.H&?TF+80H/*UM M@$MW.!SVD[FCAT-&YMYL6K/ZN MZE)D\M"KCDE_38>3[>%. ^LG'Y_@1$3(X M>K+\R24=\<%EN @6(+)A6^G1HW#YYMP]>&(#(XS:H.X8Y[$>&.0AE*5>NQE:C*'?^@_EC.Z#&Y2]*]5@" M_*"4V7++@>9L&FLKEC:(. GUX ^&=9'89 1ZO77/Q-2,W!W;J^"_56O5>T"\ MJFV2-6ZDG2ARJS!J$"&KJO,OCT4VQ"S#).K)"V"3H+IR6YJJ6VN+]6W"FM%\ M*60^U!9=AVY:<7J-#%4>PQ= W$/(PP,2N+SR]DITD)(8-9"0#3RIMR'FW?II M[RHK"-=L9ME82PP#+S#"-K0<3'O3ZY"MOUX-_^Q]T$D4@5+X8VQ,Q-\#D!1%S[[Q9%SGK,:PN8";;#>PQA;/4R74/5P='HB;6_\M!/HFT&GS3G*-/N#KI'U M_>^/5)OP[B?+]GDKU" (9W+:.1N#F#RS'^T)8HED]+W >YFK!M?C_RT*] M%S+][F%7-<=>/-=***-7A\%0'O#:=M^J*:NH"J ,:.J?->RFM0#ME$VN[>#[ M)Y\QRCUDP:+>W:3WU[;$J1'N'>^G<@9Y:9-;/QGL; >ML[)K0V)X L=*5DM) MS4OALV+=OA1T?J(KL@T7F02'0>'.N#*I?BOWZPCQ2CHZHJ M_J]X(A1?X3>='>6##=^;/RG>5%D\,,7E5ZGP6^9)102>PUR*%VM3BNQ9S,VL8$KG6=E[L/W].P82P=,+%]Y9I;?H:%@>I@?,+*3::%8<@V4J>15A_;$<&LY.@'() MR.L\GXC(Z/)+6]OVI#]^ATT/%.4M;VJQE+@:3#RB?- $XW N./I% MT6-F\?B. ]; U^Z8@H7?8 S@B='V6,*B"JB=KS"B\:DF;$F7QI2<*JBGGZ MRR@\P73("'@+PR8G-,PK 4M= 24$&#AG!(F #%& M;P(<:2[Z6Z#,F'\/ N#)!@ HDE\1H?Q*HJZ%^2U+F3V, M=X]QNNK)/2AE.%#B7,@C29\G-A%)Z.?X3!=M,)['CCV660J__A:=1W@Z!I*! M+#E=AW[]I^^%;]\:)J$M *0Z=NIYSC>$^ZQY&PXN,_N0S"I/%!H MEC -?E&T(T6'IXJ(T.N8XAPD\9$8S)K/?>\1) -J$02"[0,U;=".QEPTX1>6 MXO"<[PFH0]XD'.,3RND#:%B@:.'/^"KVCX(GJ !)\'=%!\7-+X:I&REU:V$* M8$W<20U 2;TGC]$WW0F#Q$X8)/-//?: *8;,O\!DI =FS\C>X9UCHK2J&C8' M,-#'BPOX"R0\\@X0%VS\B.L%5NR=Q[Y>)56UG1.OTDRW!6G42' MD@7/+VQ\'B"'#0XH7"BG0!+LR*/<^C;\*;GB!EF$>(48==7F43*'-29 MY7]GI/A8X>+!\V7?F=1#>9#\73'![%L!@+&K^0G_VN4(!25&5G(ZC_WBXC]7 MY86%11^F3,K$ED4ID-JS,^M[.8FB;2]/I#@GM1(L:7@QWR#&L6U18(V8DM=D MB8]=LN)Y$QY1_L5)E%NS\FWMQLBQ?H5=*_%K9B-9%YSR M7-^/A<("1UHK"S6UU+[Z$NVK49E]=8(;IFAUGH#M:$E\61A* =/(4L;,QU9S M"JC4J'6#=ALY@=A""2Q @-O>_+UGVC%H.0$Z8QB$#/ 8&OK"'R,Y\5T<*PB! M9GDZ!GTQYB760+]?V X-A/6MB=KHL$/)NB/C79,P7 !6*J*XZ&B &."GLY] M1Y8"&I ] :/+LF<2L_AM&!E83?B_\"O8&[8?43G!H.P';*3 ?K2!!$O#Y./4 M06[CKBTN:M"2M5S7QI1;]*FEUM&Q0A?>%9_%^F_N-&1'"LJ)7V,^Z."3>,4R M28/YW?6>CA^$R06&(G(#[XW]VVVL 2P:=HFGX^)FWA'X=N:_ 1W/IGK +YH MSSK%.YX%, )1C L&M*C*"/VH%*EH?R@+,H#):X^Q'HKMA(L5]2]6E<)<83P> MJR=:PG9<,WL-P*XM7[D:V.Y>@*9LM%UT%6+5?&=BH #F;H>/W M-&XWD"DZ4"*;8L.Z"^9 U1.UC]:#4@OL&]>,6%M>?AM*;ELK0>_JW3Y6M#L, M,3< ?Z?DW+J.1G>HFOV!>F#FK 3_N@2(6S;#:K'^,]:O6SQCR4-R)B=K6FWB M#]UP]VOP3T)LE89N7VAMSCM#8SCH-A&S;86,9@[U0;^.1PP^T6WL%[#19N%,MI\["[/GE_@L6^2DJM!MOH=5,5GJM.O#GD#Z"I;P6[I@][ MYF 3V*.I-X1^4XA[:E_7NY4A3IU9&+ET.:47R@J4P%]\^V+]P%&C>&NC]T6< MFHD!:YF(@Q]-I.DK)BH@Q#4@+DI/;MZE(5,$K6<.BWDE/>'6T%5NF*KJ?7-? MP*VUN++GY*!K%/-L_91;;6'E*-3%4C8&Z-,0^-:UCJL..T3=EP!-\CCXM>"+ PPQ_Y[$ XHY_X44N-/;# MYN$'-H68>" O/^"8[SYY/)2(GX3OCCK*!_U(Z1IZ1^T9RMRW']'#A;2+ JSN MGL4TJ\>W">^_0G=,2%"H O<-N4$XFT6.+!H9QD>_W#R\<^PQ? IG-([&8;P2 M4.!%'X(8*>IEB)]EIL]>$&#*!M[;N>/G,VMFW;/@Q@MA@(*%ZB<6J@]&A]0: M150&OVB6H@K]D5<.T&1A3Z=*P-CW0'G?ZPR'2-%!7E!01YD[(??;8J@D^CX% MG2BO1/')QSA5M)_0$\JC3DZR@44S#&)!SQS>[,#"\!%FNV#9B4ZCUOI'2 MCDI L1O ZVSSVNNJ0^,0.&6L_CIQ,K3><+MU(J-"=-_B9M(U0X."!['=S!V[ MG(S1>[']%MX%[+\AGD&/\$=2S$0=>N#,P'A#BIBXF3.ZXOC"^/6,D+!! C*\ M%GI@3C+\3>^)BT1Y@SGBB)ZE>P$6!!AHYRK:,6!VK)V8-!=\!4>%QHF]->AL(NK!G M#,\^I(47D:B/)-*SM:97KW9*6[AAP#9T@7D5^F.\ZJN@+60.(;4*@S#B9+QH M31S9,32*!$>)X!$G[\W5Z-T1/[KE:^_PJI9-*.0F.NS?X8WLA$TI+!H>NL8 M1U/5/EA'N(37_*X*D3O#)^> 5>CPV]@XDCD!T&A,UXW:T##HOML2?"+T 0&N M3_H*<"IV%J6@2WX-E^ Q?F].)V+ 0+/"O_$B*1Z" C7OX:E[P6\4FP1F#FD< M-V?O-36Z%X=ON2;$X0"T3@ AH99(-4W,W.&L.)>DG5-,/]VQGKTW3@8J'>;X MKO(A&38Z^2OD'9THYWB=E9B=="K0A4@EQ"M=4A"7]$.Z4W?9 M\8/E3)4GRZ=;W=0D?_ /HSF>@+N9DOX2Q(V+$H2)- 9^H2[13,V>7(@;#L)" M>=\_43GR_#F$"GZ"Q:$+3L8O#7T,Z36.*)(@"H*P10]9'M/Z8#TR?B')(XSQ MLSFY=_#Z%]9[@=(,6!(T4^43Z&/=^@SSV?\4AJ87MY2!AT,^T MR$:WL?(]#-^Q>51R"DL!?>J2%2@.TDZ^R0GMC6&GB;#?&S9?B"@*&4R28,=8 MOQ\SDD[RBK2<+,MQ!>)-OM39@^]7T=5^Y;+9X1P$+/,O7;9TM/-\)WL"XWC> MXEA5CP?K7>9585O1AG0];,OU/;24N[(0DAJ@+NI5NP'4JIILK+1+N'/\#1O# MC9>H6F]_@*]CX=LGKRS!=;4QY*X ==?8&W.OVY+%4"?%Q7 GXF+=QBL'FZ;6 M#UP9)L4CN;0T&S9GP:O G>FE<$@I7 GN_IY.CS)BH1*]]R?.UO'W)R_T2[/W MH#'LO0+LE-#0#B+1RD*G[T2DK6/5*DO>W].2E^%4L G*$-4XB,Y;%KKN81BR M)'3F81BR&+IE&;2A_IH.@(@#'C!TL*B/N7&LJY*J@(.Q\@(DF_$_W^OT#$/A<3'*1R4BB+@#0T-:NOPHIT X M"#*?=[(W,+Y%SA ,H>]'9OS=<^2T0"#-CC[0.IJJK9@^875'_K6.2):0+MAQ M'"E#3IXL;04]XL3($V7$;Y5.TQF^7RC#MZ/T3;,SZ!N)F\6/UO@[S#V78!$M MQ6)R3S/ECG#74]3G#9T8_4ZOKWNB0CM0[#PY? U8=LV!,1SJ6B-V2P3R-4/]CTUD?L\&615I&%-" MK?:-/(2#IZ_W.9=@KOAOL70\29BL?E&A:4Q=;/_XI"J85_6!^EVVS$* M%[$<)FJP\9Y:\$LB_^#"O?4M-[#&%8P-:8B+5M28E/V?L'P_->Q)G6PV7@' M+')G(<-$$$R0GEQ9/EX,;QBEMAJ7G/ Z51T,DX5S2X)2(P:9F+2J&*B'A#U# M_7/[GKEWOCVY9Q?NN.G 9PA?&?B!VNMNC\ UDX4A+J>)MY_/V%V1LIXIF!EY MU"J&,\K7KF=W2]B>?OTSZQ099+J8K@)\6R172*N=(MGO&>;>D*Q_)5,NU3$+ M%U@$)/AJN7^!4"DC#7MZ/WG=OGOLA_O%OO$L/\SK#GL@;NAW^]I@^(JQK\8- M)HK[/7*##O])>NC'^K8"L'9Z@&&@O6YZK+;V!H::#/C?,?9)\Z*;2"-JL7\% M>R'^/F$D@3Z)!$CIE,][3FK1-+UKFDFTRH.:1?-C&( 9' 2)&L.G7K"XG-(' M8&N?NPL[-2Q^7:;X!2&:<@!$JY> Y[,' X,JGO&YE7'(9M2 #3%)7UC$_@N> MH(BA^)NTK:P=^55-&7D3E34(K"CAL+3%XP5-5@E>QFDUEV;6)S/A4__SME)-?U;[].W2_(5*WJOJ-_W=[^4T;YGR.:7DS1D67Z4#R M>(&_T0\[^#::8%(+S\U^9 *&(%'9O.3B)G,Q*^!8'X%*%$2J 55=-YN#ZXH0 MOUIP[3<+UZ* P3IPU1K&PT7AAW7@6N.R"C'WR?/3@,$;5=N(U+**6GI[K@)O M6U32FR]==[$&5(;I\[(*)ND3*=G6ZRS$#$A^1NW61UHB'VU0=(8605S6DBO? M=VU3Y'[E0PR/M1+66J*=FF.[WW^9>MX"0S\_PR_*#_IH\3QG__,.X*74Z7?B M4]]SX-.'Q6+^R\\_/ST]G?RX\YT3S[__65=5XV?\^F=\\)T87D[@>./4N Z> M]YXOAWWPD2C_GXR?5N7GCG7'G"BN^AN\%5^,;C:TMKNA]=T-;>QNZ.[NAC9W M-W1O=T/W=S?T8'=##W>X97:Y'7>X'[4=;DAMASM2V^&6U"KM27DLC/ST')8_ MEL/ CVO.!/'$SU,X>X[EB/)UK&>5 4),Y/&/\>%C%582^TCX__-.VXX"6L'9 MHC6! %HQ ;15!)!CID $;<4+_7$T49F3.PM<@D01&#]F#GSNWH-NX![_=O/N M5YE]I(QX/0LV4;"G5IS$PNN]8&(*?(\%)^8^>[2],'">XW9RCQ[JH[+TF*SZ M,2%5B_<8H)H>5+TL$+U!4CU,3O[Q'-D[5UM<]LV M$OY\-W/_@>>9F^O-G2PKSJN;M"._M9IQ+(VMM$F_=" 2DM"0@ *0MG2__@#P M100)0J#DE,Q)^9"1@=W%[CX B%V Q-L?EX'O/$#*$,'OCGK')T<.Q"[Q$)Z] M._IPW^G?7PP&1\Z//_SMKP[_]_;OG8YSC:#OG3F7Q.T,\)1\[]R" )XY/T$, M*0@)_=[Y!?B1*"$?S^]N^)^Q_#/GQ?')Q'4Z'0MIOT#L$?KA;I!)FX?AXJS; M?7Q\/,;D 3P2^ID=N\1.W#V)J LS6O'X M:GF'/LXC_#JZ *>W[X?@UVO@#KW58G&R^NWSDOWDO9E.\)?QBLWFXS>#Q04Z M_]0?!9\FGWZ.FWS+W#D,@,.!QNS=4MV/[V_N)=U13'BV M]!'^K"/OO7GSIBMK4](2Y7)"_53T:5=43P"#F61>BPST"+,08%>A]\*,(4_\ MHAM7*J1(2_HR)D4IJ0<+= RZQS/RT.457=$'.B>]SFDO)8]89P; (F.9 C:1 MHI,*/0LE/F1:'EFC86(T+-/S0CUI)UPM= UD51HV3#". KW_O9!V!5^7$W4X M%:3(S?@V,ZD,W,H*]=(:C79B8&8,$\0(=L$"A<#G(SWHIN.53U(^#" .KPD- M+N$41#YWVY<(^&B*H'?DA(#.8"C&%%L %UI(3 %0Q2NQ)"G@6SER$'>NR,C MA6B7:R%;]N 482352R:6GM-Q4O;\3X ])Y;EY(2][1;%Y(1'#'I#_(/\O:"0 M<3&2Z887)(P)2063"WPW\NOQK%71LB0%J<>WQN <^&)2N9]#&++8Z6J1V& '*;9O#$'&--9Y7Z\TP MG&X#@_.=TL2_]A:6#QA$'N(.RMR6]UKF5S:<7I" &S_G-.@!WA"6C)A=!)B! M?5X -FNI"N)U8\YPZBC-.:*] \A:C"[F ,\@&^#[.1\3<^)[?&W.GZ#(1:$- MQD9^,\0OZD* MC"/;V5M +B%S*5J(=H;3(9T!C/XK%>7KN?.((0P9&RY$=,S+$J1J\I@A?"56 M?CQV] F+*!1_K*4+C/+RYID?:79V<_*SH[%Q$F25-!_'"YJ M;_T^Y/$QO26XXT941,M]QK),246=V>NG1:]+*8X0^MR_GRG$S)S< \+P*3",[F'H>+3M!*D?M*>0^\F2(FB!E16D&Z441I+5,)R?4R:3&,?+^HI-/$8@I M/5PE*_9RN=GS+TNK+W-H(4NF3V,%*B=FUI3!5\#J<.?;Q_CH5 MN?&43JE(>8G%2.);3879Q:78,A7AY&3LK:,O2!"@4*:N^#..SZ,BN(9X'=^; M",R.+\><:U%RG:D(VUL$[J O4E[ZW@YPW;$00Q/[);P.2&W_UQ5:79[*8B-Q9R#.&.\EK._3H\F#'Z)N$E7 M#V(B2).(A5*SFTOAZYK?D0+VV+TR;TK,V5AM!M>6QPQ-*<:US^0ZWZ6_]G=# MNMX>R%@$/UOMGB2<9BQ+8?$6>RC.=W%3^PNIW?#*0UF+PPQA*6BN,QSW'3FQ M1Y+')?>WV>NE@%GN".^]/W.[+'FWEHO-WBW%S/DMF(.7"]LN>4_KJ\S>+H7/ MQ7V9@\ V3YO8<\-)IR,P2E0%[=F3AX MVI 85X*&C61F'$I!>#Z+WB]FT0^P5"1NE?C:2&*&HQQ05V1X#TC4RTA=PA @ M?ZMD5LIJ1JX4E&^5S4K:.J!:"YHQ7(91^J[33A+,&#_%J>\,8R=IBQF-'VE3('6[8>IHY#Z5_IZ19W9 M\:7\0'E?8._[?$76O^!\(XT9A%)RP+@U<,##Z&ME/K(C-:-3RA78H'.8JO3[ M,\J@,9.842GE :KW.N=G -J]B HCZXM^,P8EH+WNA@>GFGE=Z[4K%EEM1&9%Z6H7O=FUF$H*;NB MBN-U%6:7E^+\XK[HP=GE5[14GU?7FUU?BO5U;W(= ##M3*O9P\UT9D!*.0#C M&UX'9"R049[D]N1FG(QG"*IQ.CRV*TX*E)_=U31F9&H<)]C[P6-V=,\&C=X& M./1ONIO@<'H'0/2^5K<4K4C-X)3R )O!V?L)K.KUX4*T;R8RPZ*)\*M>-3Y, M8L7W7PMG)[1U9O=K=M;5=V'_'YTN_A.3R1V<.O++^V?B\^GOCA@*%K[X3KXL MFU,X?72;]J_CLW[7@9^"F)$&WX\KZ$K.B-I.%4!*!N24KI9@ N1*;^ M^?*JFRJ?"@A1*-A'N68MP05XHRL(B_.BE?1Q1U>L\ZI[WC)?/6FM918NV&>DJD?%LHH;_P MP[+YE$&T^Z)6BU7W@>@:9E5,XD=GS6VK@/%VD0K+9?M:QB[T0Y:6[*A-^=Z. M[=61LK;0Q^+*$IO>D>>\C1E%+WDC>F?OY8[*;*?(UEHHG4^>*:0KX>Q7M7IM MGC']H[.6LITR'E$?\Z*R9:T]IQ:N5K&:S ME"F>R<1E2SM,JOJ[FK;48\.4FMR:),,OL;[Z?2"[D2@;$W%$]E<4SCT*'O$U MH6,:L?0@])&T0)Q;M*9'OB^V3-\=A302JR9QZ]<97TTAXHWEHL^+XE<0TKI) M?&D+KX 3<1E%O#2,ZP*">51'5X,0!H*;.XC'?7P-%@D)/U$2+5)2Q$E,)J^3 MP=>4!/ED@$@+4S2)0GA# $Y-KD%?P^38.#[ABWJ9V7D"T]:!\7": ,'NH O1 M@U"KC[WB%Q'@,CSWB?LYM747 ?6-EQ>1G86IC"=P@+C"SHM\R(;33:;:D;;! MJ$2].QXO\ZAESE&XA _0)_(TW?H;Y+%9ML0;#8NCAO!/'IPI*L.IR.L@#P&: MOCE:B> &VC9 >"7O81OY_ $PG(HCVY0_%9)&8V.,%+5-B"D8GYWP["G49SQ8 M?KR$"\)0F'[G.-%;6V7?NQ1])?L3Z-N?S2B<\7E:S-T$WX<<155M(T7#VI\# M]S,+R:+/54R."V1O]:7Z;Z!INL,D)Q4R[4ICUT30A@&[GEO20\Q\COD#NGS9 M,Z3]!X"DBGS1D[Q(B6BK,-)LN7 MB$9@)12Y)3@Y7)R:55G;TJ6$#0R")I"3IKQR69RTAOEI=D<9VX= 7(;W56,@ MG-SY+>>D #%&Z.J6A/+X^AV:S4/& [SXV2BM5!^?._!O^VAZJJ>KJKHZ**TM MMF%KWM!@@K!L043I'WE9@-P1%Q_P168DKT)E?*5YG MTK1E:'-S;V5!$MRY; MT^CR4>="Z#&1D^A[#\*W8Y([#KV.!S?2M7:6RNL^8"P2C8I/:'@<*KI2$;2D M;6N_73]$J@PT4GP3$.8/ZR==48>>GJRU%O;=+Q%B*$R?A:77*/FTX4<>] :X MXD4QY9ZG)#Q]8J&M]5X2!UY#F*PL"P&B4K'U0O-K=_)80\8CN R@K&?KZ]IJ MBCYOF);FOR?$DAZWGI^VX/RVW/ >X&@*W%"DQVM[8C-S6YVA/FVRU,7Z@90: M;D/8<&Y-[%F)JZR1!]7\JZZBI8&M\D$QF;G,G)+"^D%&T)15KZ)&#,$$=6BHLS$:8> M94W==!^[AVY$Y7IN%/&'"\@ESS5F65,W;=:OA'[FDB[B@^.I^J72MCX;S?NL MVOYFS] T-EDJI\9]W\:)MM[GN>#+F! M/Z+H 83P T8A_[G.4Q@IFC[]T_<"A).'V0.\A_2!ZY5_[?P]#";KS* ]^;9[ M4QX) 'J*1_H5H/YJ@JB7O%^D&E)9V[C>UPC++%;ZZ%7UKJQM7.]S\2Y7\O#] MF?B>>!238 'PZ@8%G-E3#;$G;]RR_/$]<6B/R3-MRERMVE:'H7'K/G'/^PB_ M!_3SQTBU0U_5N,;57<>VB[7'EOMHL? 1I$,,5>5U%:W1=OQ(]-KF*]JC[9Q/ MEA7Z*E6MT?B:1%2OL%+3'GWY8J!"WWQ-X_KJ]VAO ?Z#SPVJ 7:D+;6(KP[Q M; Z0C4DEVI;:]-N\P'V M"OH;*1K77ZS"DP7YQP^%Z4);U;C&^?5W]$GP5+'RR@E#N=ZDZ5]8V MKC=?=(_G)&*\OTK-E,TYU0@[TL8M2A[F*]=';F&0ZJL:U_B:6H<0WOH7B#J]\S/IHV$35N1;9>E5/C MSQ#XX=P5*=[LW5EM%JT^6^.67J$9Q!.*O!G7TBUD9?5UC>M\%TP*&;Y<0>/: M71(W$B7BK)]\(W" IX1/DC)LF(ADO9L=+;.C!;5NZ$PON>SU!EWDM$ZEX@.J3=45],Z M];>Z;RJNEI"ZB(&O6SU M94_?]"LR8J2. !)GY-.WO?M!_F,F)H*VOBAB=UGE.'^4OA;+G]Q!O?!LSNNI M&TWD$8C=3;_A0U!(8O7,S[&U;XS: :B?L+9D;IT3JJOY\\>AA[B^X@#7IG&HJGLI0Q^]*6G=[L8\=9R5NW^S8MR8*%K7 MMRJN[ZLPS9:Z=6:F]^#IKL$K&FE'VSH3ZUXF5S1[>_[6N:+&Q5Y%+VS%^BT[ MH&*D[R*A=>XHWQI6M>393-@ZXS0W?O6SIH>4S$1 M6U$VW9Z_>;*I4+5+53:5=-FXF_+ M2-,*T9JGG2:?%]4WV;J9N'5&5EW351GJ6)*WSM#"/5A53YV-9*TWK#)#O8&L M0=N,/\?.?_P-02P,$% @ :X /3[@O O>$ <-P !4 !X>6YO M+3(P,3DP-C,P7V-A;"YX;6S576U3XS@2_GY5]Q]\;%W=7M5E(##,SK SMQ5@ MV*.*(11D]K;NRY:Q%="-8V5D!\C]^I/\DMC6B]N.;0D^\!+4[>Y^)'6WU)(_ M_O*R")PG1"-,PD][XS<'>PX*/>+C\.'3WM>[T>3N[/)RSXEB-_3=@(3HTUY( M]G[YYY__Y+"OCW\9C9P+C +_Q#DGWN@RG).?G6MW@4Z<7U&(J!L3^K/SFQNL M^"?D]]/;*_9G^K@3Y_C-P;WGC$8 ;K^AT"?TZ^WEAMMC'"]/]O>?GY_?A.3) M?2;T6_3&(S!V=V1%/;3A];(.R5\/SP\/QA\.WAT=O'F9,ZG/W9C]BW_&_G7P MGGT;'\_&;T^.WY\<_?0?X'-B-UY%F^<T<(=X9!CXJ&]G(ISD=&-/WSXL)_\ M-V\JM'RYIT'^C*/]7)P-9_9?K&E?D"3")U$BWA7QW#CI4K6/<90M^%^CO-F( M?S0:'XZ.QF]>(G\O-WYB04H"=(OF#O_)^LCFJ?+$, MF%'V=Y#TU VX9>\>$8JC.M&DC7N2Y<:ES B/*,:>&S023$K9G91?0W?EXQCY M9R3T41@EOT0DP#X;S3X?CHC#%TWG9V2QI.B1M<%/Z(I$M?;M@/50>IX]NN$# MBB[#NT=F[D<2^&S*/4=S[.%X-S4AG+O3LF14-WJ\",AS+4Y:HNYD.T>11_&2 M#_SI?$H?W!#_+YD&V-1PNHIPB*)HNN0ND'U6*W0[;AU:>K58N'0]G=_AAQ S M.%TVQWD>6;%)+GRX8?![&-6;OA&7[J3G,-?)5FS3W9,O6;"T0#/WI=XXDJ;= MR7%#T=+%_N>7)1^RM;(HFG4.:1)% !>KI^I..C9FZ IMX&'62)Y\EC[U"KOW., Q8$ V9M2=#K?( M1RP2O \0\Q\LPX@Q^Y7UNSEBS_83]U$K?A,>'V&\KIWWE!3=2<7C MB!M$DT?5R2-KVZ$DV$M[$Z4\&.!CM%8@-4F'7H L%CA./#_KZ*S'<*?#LEG M. &0=CDR AY*L4@X7L^8/2+7 \4(=70=CX 13[M\'LLRZ$#)40U9E]'*?82^ MKQA.HAMQ,Q;8S/D%W'.&6>0Z-$TRC-KRZC7EA MXE_8<(H"7J+A6%R:8EZCXNA,@*(^XZ18:)": W$RS#A6[(;-G:&J=*< M4S\1*TQ:-<4@42)P.H4RZ#T> [HI"+&IV.$*DP-ZS9#+_&J?I6\ M"]Y#KP<"T6O%S) N0+1VX=EM# C$0-*TER@0*(Z:HD^I@.#6$O86JP*MIZ?J M/5H%2PFA'DI:(/:-F/0=:P,-#2(V$&T#Q6_+;]AX&ZA,"U9&] .A_8<^UR/ MA\8==83]Y#I Z30DO:[50\6KI1PD)X.&-V .0TH-'&2-&?6>63898+740TD[ MWDW<\=#R0E.-)DSZWZ4"^T$0>6][0N#45$>ED\YS V\5)%!G8&3DY5?%7-_2=E(53XM&K^/+BPY*\ATS(36T6^WU3 M7^84"\R"%IH268D/V<=_I%%T%H7F#PC<>Q0DC_TC:U=IMF].8)[B<__! M?O!HY\D-$H\2G[F4KIE'28J0U8H R:L*%CK2A'H.H2S:^K2WF4Q=ZI6ZCUCF MF[78C_B2"FV>V)6U4*>+"I-ASGA%^>(P3Z0WB6,[N\W0( MV!U!Q# ,#XUBV, *UB%8K@M3S1FVC"4% *_)U/]"@7\9SN@JBJ^9=X+-V0HB M.P:'%A2MNM9!E"^IW01N&M](*CME$YF."@;2D1F0( I;AU)A>H4,(45S&"YO MS>"B5=$Z0 H+G[5>7];6H.BG;OAM^H2H3]VYS@]6VYGVAVJ35WJ27$'KNE"V M(QG=N&N^A+L)HM(%]R8=K#DGTVX4C&5;(UF']C6)4:Y%8?F%2QZX483G&/FU M0#=B8MH+@S%N81KKX#U?H1FI"%^'IH[&M*L&@U>ON'5824[6:)VV5:Y/ <,K MF@GO8N)]DY['$5&0M36[^)/MK7*Y:I;LI(U-]R2U\<45'I6JUO4HOD5'0@@F M8DO3D1 8$)62UJ%QR[=I0N1_=FF(PX>(Q6JKQ2IQ$)6SZ"(^$%K3<0T8,;@A MK,-PXON86\(-;ESL7X9GZ9:2)@51$9@.9,!HU:AL'T3;WI169!7OM4B+)'D1 MRS6*I_.9^Z+-'ILQ@D%Z; &D[4QD'=2%X(XEP$WBIWI*TP$)5#=UO&LM;(!S MR_((14ED.EAI"1;X +=%X,W08DFH2]>I9OGF]&3!EZ,F<4SQ_2KF*Q8SDMZ: MI(:T!2O3,4Y+H%L;#0:_P460)E;0--2J^7&_JN45^WNPPB#YY5^E*J&C-E5" MSH\ESG_ON=BIBYO 2DJ_K2B]>8!*_>TSG.G<*3W%21YC2]8CIOSRJ?HCFAJ'"H\@L."4U*G&-$4<1+9,I!>BXU-^R,#W:4ZVM0VM&YP79.0E,6MG1HU)*9]FGGL M:^UI70_8ZI3*JZV9E#8V[07-HZZQH85XIRJ7>F<-Z"H*TXL;-B"OMZ:U\&>B M%D_1U?< *9'IK11[.H'&II)^,#+L^5$,B?$JS4Q'=U*I!3B&[Q#V#?-,MZQ/ MGK+D;ZZK6E 2F([IX(@KM;5\\$V>7!RD.PJ% IEL\?W4C; '')X01E8-8+CF MU3!;VBFZ&X3B.6[^":]7H"BYVXY4KBCAUY@LDKO55-5;G$$#>JN&77.<&FIK MY]92!V\J*>W"'#?=AX5R&3O$A?W.$0K)>]->_Z*2DVKL=-IC(W.'PL\QVY8Z0UA'6Z_NCCD'6L:WKD!FLY!^PE: M(M,+:CLC"#")?3'YQ/_O*A7R@M#)@M XNQ]7C:*&Q/32V,X8UIK#NH%XCI84 M>;@&LW(KTXM7.\,D4]HZ9%@F01&;T,]1^O,R+%^^HEV6J*&$(?C.7@2AQK%O MQJR3/$KJ#MJ#F]/#(/[I]4)<-M1K #J_$5CZGCH(T@H&,*C?OR:HM:9Z-5B+ MEQB(]QSS M;DQQ#R$_V=--UR8:P@RDMW01K@'.C0QEW<0E=%/EE7D-AK2&AZ5+=CN,ZUJ# M=3FX%?NMVYXV(UR]?^/XT:?N26KM8!X&NFIZ6C5:'^ M!0[=T-LMS)#RL,0!W:)E-NJF<^B-AE!Z2P,-#:0:!U1OJ/YK/XKR3/PG?CAT M1@J[\HHYJ)[,TE !@!1,O]<0"A8[6)*;GZ-[_=7!=:26!@2[CS_!/-9YDZ+D MA9=*P2$5B"P-#]J!J3")U3 62ZJ;#,TJE:7;?6U'I=PH5B.YR2+A,%9(+-WP M:X>AU!S#!C.74;3B;IN_%-AG2M!U6J0)"&C4I)9NV;4(:NK,TS]8VVI9($0Z M DLWV(# U)MB@%6)\OC=EN5FX2]@W$BI+-WF:C%D-$:Q+PV0O\KI!E',3_J4 M-V_4_JH9%]/)>1N=Q1,835>L=K@?J[_LMS]3Z :.;1':Y_D<>?%T_OG%2XX< MW++ !,VXF,Z0.T"^C=GLO":NOV&@VRJW[+S/.8H\BC?AQ8,;9B6O MS#*GJPB'*(JVAT@W6I0.POS$WY2)(R\@T8HB_L>6*3_I4F2;O$DS9^P4.?=[ MK(=W";J>SN_P0XCGV.,;/.D. 8/IA@2X=*ME2;WW5?4R9ERU CMGR\_9,NQ5 M*][WY#)_J,J<-NU5FL+98JE0XX.J4"F%DY'T*ERE^% NX+@J8$;EB'?I]21D MNO^H>KU92=A#4=B4.GU9;4[_#Z=T;44O M9.6G@%@4D3Q9+J7@,#F)PVB0!7JF\HB2DXOIS2*9'VZ^( M=U"7A!8]WY9#,C,J[N;N:1S*7]@N%?U0\(\9N9/0.V4&_0^WT;WR/&));,%K MIM3):49'?DZSIQBO]-IYA9$%M[DE!#X1&I\V/^6]\7 M.C?++&;.+GK8"#A M"FF(3D;!!Q>3D:%DK60E.GD%9US-38:369JDZ&07?+(F51E*#7G.HM'B2'#/ MJLQE*!7 *8Q.*\%[-TMDAM(5DM'HU!37483 /H [+ M==(+GKP8G$^JP?E@/EL>[>H4$9VT(N8=2H=FT=8Y?\5=H-!-\-ZMPJWL$5;J M/6,/6BE>EG+4Q6KV1GTG>]1 86?-^K86]AV6N0=#NY&:6I2%D*2%MD.!RZ-G M'71OA<@DC;<' J40<&NE%"*-2ZDQ4<($M3)T 879WDJA M+NI0-.^RH"Z9/[);$-@SSI0B\=:JQJ9KJK1F+5;*Z;6UKC2H/,U">HR:PG2Q M%PBC6BTL!>H<+4F$60X*'MIJ"M.U64V JM/;MBHC\$J5UN<(F5G3I2H+/)%X M 4Y^+T[E%ARU1\A8->?4;8&^[-6&^:?%'#E27WB7EK+V=C;&=]:7J;=9G\0 \W8/\I9-<<%0IF2"@0E[4S[RB[0 M4:IO7923J<7O\T91Q(SC!DQJD(?0TIDNP-X51:":=J-Z&;)@AA\7@L(I$I@^ MX=LMCBJ##'!"-)4_NB!4=U52*=&HX8[.*:#N:L(A>K\Y ?4QU6$;;R20Q@.K,S(!52J6#*%KY)75( MY>,H5:FS.(U_X_BS3_X/4$L#!!0 ( &N #T_L=?63@BD )VV @ 5 M>'EN;RTR,#$Y,#8S,%]D968N>&UL[5UM<]LXDOY^5?-FZVMVJ=1PG<3+) MSMR5;">SJG(LE^W,SNX7%TU"$B<2X0%)QYI??P!)27QKO% @ >JT'V8=&PUV M]X.71J/1_>/_/B\7SA,B48##GUZCV?#Q^X42Q M&_KN H?HIQ5R'^[]<7KU^=?'CU[LVK ME\]3RO6%&],_L=_1/[WZ@?[GY/3NY.W'TQ\^OGG_;\GOQ&Z<1)OOO'I^E?\O M(_]Q$83?/K+_/+@1E&0[ON;EYC,CE^_>G5R_.N7RUMOCI;N M41 R3#ST8DW%>FFB._GPX<-Q^M=UTUK+YP>R6'_CS?&:G4W/]*]^O"$H-CX] MSOY8;!IPNBXP'04?HU222^RY<3KZA!PY8 OVKZ-ULR/VJZ.3UT=O3EX^1_Z+ M-4ZIL@E>H!LT==C_T^&T^>I#$.'0YP3-/WI!1M"1]L!%/E_DJ&-5X]T1D7!\G%!E7*\ Z=G[H)I M]G:.4!R)6&MLW!$OURZA2IBC./#I\@::!%\2[B2G3LSXI2TIUH_GG!?XNQ(E+I(^W"Q1Y)'AD$W\RG9"9&P9_ MI,L 71K.DB@(411-'MEN27\G9+I=;QHUG2R7+EE-IK?!+ PHG"Y=XSP/)W21 M"V?7%'XO0&+5*_6BCWL&LXBW8AM]7QY3NVJ)[MQGL7(:FNKCXYJ@1S?P/ST_ MLBDKY 5HKI,?3$=KO&+[Y.])\,CFXQ42+CX",GW\3>@61*YP>.0EA&U(HRB2 MV&+Y5/JXHW.&)&@##]5&^N7S[*N7@?L0+()88D(J=Z1/AAOD(VH)/BP0W3_H M820.Z(]TW$T1_;:?;A]"]E7ZT+@6%K8V-@KCE7#= RGT<<7LB&M$TD^)^&EJ MJY&3P,M&$R',&&!S5,@03*)Q%\#+91"G.S\=Z'3$L$V''GPEYHD$JE(V@HA.\PPX8LU\A"AWQ,*UZFU>.3[K+3NQ?^68 M 0DZLX7E^.(2=6X7R_(H0=RUC2S'J@RM 7M9COF6W?5K.\N)HMY3-Q:K'+
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end

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 08, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	XYNOMIC PHARMACEUTICALS HOLDINGS, INC.
Entity Central Index Key	0001697805
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		46,273,846
Entity File Number	001-38120
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	D8

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 1,191,944	$ 4,746,370
Prepaid expenses	155,805	277,750
Total current assets	1,347,749	5,024,120
Property and equipment, net	444,796	280,730
Intangible assets, net	1,450	1,937
Other non-current assets	219,565	155,176
TOTAL ASSETS	2,013,560	5,461,963
Current liabilities:
Bank overdraft	2,035	4,954
Accrued expenses and other current liabilities	16,089,078	14,407,261
Promissory note - related party	404,900
Amount due to shareholders	552,873	3,233,728
Total current liabilities	17,048,886	17,645,943
Total liabilities	17,048,886	17,645,943
Commitments and Contingencies
Mezzanine equity:
Total mezzanine equity		7,910,748
Shareholders' deficit:
Preferred Stock (par value US$0.0001 per share as of December 31, 2018 and June 30, 2019; 50,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2018 and June 30, 2019
Common stock (par value US$0.0001 per share as of December 31, 2018 and June 30, 2019; 200,000,000 shares authorized, 6,706,068 and 46,273,846 shares issued and outstanding as of December 31, 2018 and June 30, 2019, respectively)	4,627	817
Additional paid-in capital	36,401,911	14,169,060
Accumulated other comprehensive income	77,613	58,564
Accumulated deficit	(51,519,477)	(34,323,169)
Total shareholders' deficit	(15,035,326)	(20,094,728)
TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT	2,013,560	5,461,963
Angel Preferred Shares
Mezzanine equity:
Preferred Shares		580,256
Series A Preferred Stock
Mezzanine equity:
Preferred Shares		4,905,780
Series B Preferred Stock
Mezzanine equity:
Preferred Shares		$ 2,424,712

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	46,273,846	6,706,068
Common stock, shares outstanding	46,273,846	6,706,068
Angel Preferred Shares
Preferred shares, par value		$ 0.0001
Preferred shares, authorized	0	23,435,379
Preferred shares, issued	0	23,435,379
Preferred shares,outstanding	0	23,435,379
Preferred equity, redemption value		$ 580,256
Preferred equity, liquidation value		$ 811,332
Series A Preferred Shares
Preferred shares, par value		$ 0.0001
Preferred shares, authorized	0	12,147,500
Preferred shares, issued	0	12,147,500
Preferred shares,outstanding	0	12,147,500
Preferred equity, redemption value		$ 4,905,780
Preferred equity, liquidation value		$ 6,964,223
Series B Preferred Shares
Preferred shares, par value		$ 0.0001
Preferred shares, authorized	0	5,281,101
Preferred shares, issued	0	5,281,101
Preferred shares,outstanding	0	5,281,101
Preferred equity, redemption value		$ 2,424,712
Preferred equity, liquidation value		$ 24,335,989

Unaudited Condensed Consolidated Statements Of Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Operating expenses:
Research and development	$ 1,567,799	$ 3,873,804	$ 6,892,109	$ 4,340,206
General and administrative	1,443,731	745,286	10,222,980	848,761
General and administrative to related parties	22,500	97,638	48,408	146,691
Total operating expenses	3,034,030	4,716,728	17,163,497	5,335,658
Loss from operations	(3,034,030)	(4,716,728)	(17,163,497)	(5,335,658)
Investment income		8,178		8,178
Interest income		89		89
Interest expenses to a related party	(17,723)		(32,811)
Loss from operations before income tax benefit	(3,051,753)	(4,708,461)	(17,196,308)	(5,327,391)
Income tax
Net loss	(3,051,753)	(4,708,461)	(17,196,308)	(5,327,391)
Accretion to preferred share redemption value		(100,292)	(1,697,978)	(197,608)
Net loss attributable to ordinary shareholders	(3,051,753)	(4,808,753)	(18,894,286)	(5,524,999)
Other comprehensive income:
Foreign currency translation adjustment, net of nil income taxes	56,040		19,049
Total other comprehensive income	56,040		19,049
Comprehensive loss attributable to ordinary shareholders	$ (2,995,713)	$ (4,808,753)	$ (18,875,237)	$ (5,524,999)
Weighted average ordinary shares outstanding - basic and diluted	(44,623,568)	(42,860,772)	(43,747,040)	(42,860,772)
Loss per share - basic and diluted	$ (0.07)	$ (0.11)	$ (0.43)	$ (0.13)

Unaudited Condensed Consolidated Changes In Shareholders' Deficit - USD ($)	Ordinary	Additional paid-in capital	Accumulated other comprehensive income	Accumulated deficit	Total
Balance at Dec. 31, 2018	$ 817	$ 14,169,060	$ 58,564	$ (34,323,169)	$ (20,094,728)
Balance, shares at Dec. 31, 2018	8,165,377
Redeemable convertible preferred shares redemption value accretion		(1,697,978)			(1,697,978)
Net loss				(14,144,555)	(14,144,555)
Foreign currency translation adjustment, net of nil income taxes			(36,991)		(36,991)
Share-based compensation		7,683,282			7,683,282
Balance at Mar. 31, 2019	$ 817	20,154,364	21,573	(48,467,724)	(28,290,970)
Balance, shares at Mar. 31, 2019	8,165,377
Balance at Dec. 31, 2018	$ 817	14,169,060	58,564	(34,323,169)	(20,094,728)
Balance, shares at Dec. 31, 2018	8,165,377
Net loss					(17,196,308)
Share-based compensation					7,652,965
Balance at Jun. 30, 2019	$ 4,627	36,401,911	77,613	(51,519,477)	(15,035,326)
Balance, shares at Jun. 30, 2019	46,273,846
Balance at Mar. 31, 2019	$ 817	20,154,364	21,573	(48,467,724)	(28,290,970)
Balance, shares at Mar. 31, 2019	8,165,377
Issuance of backstop common shares	$ 76	7,672,035			7,672,111
Issuance of backstop common shares, shares	755,873
Conversion of promissory notes and Rights to common shares	$ 5	499,995			500,000
Conversion of promissory notes and Rights to common shares, shares	55,000
Conversion of Rights to common shares	$ 64	(64)
Conversion of Rights to common shares, shares	646,955
Conversion of Preferred Shares to common shares	$ 3,469	9,605,257			9,608,726
Conversion of Preferred Shares to common shares, shares	34,695,395
Combination with Xynomic Pharmaceuticals, Inc.	$ 196	(1,499,359)			(1,499,163)
Combination with Xynomic Pharmaceuticals, Inc. shares	1,955,246
Net loss				(3,051,753)	(3,051,753)
Foreign currency translation adjustment, net of nil income taxes			56,040		56,040
Share-based compensation		(30,317)			(30,317)
Balance at Jun. 30, 2019	$ 4,627	$ 36,401,911	$ 77,613	$ (51,519,477)	$ (15,035,326)
Balance, shares at Jun. 30, 2019	46,273,846

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (17,196,308)	$ (5,327,391)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	7,652,965
Investment income		(8,178)
Amortization	491	203
Depreciation	54,593
Changes in operating assets and liabilities:
Prepaid expenses	119,758	(349,272)
Prepaid expenses to a shareholder		93,968
Other non-current assets	(64,827)
Accrued expenses and other payables	1,500,041	2,583,442
Amount due to shareholders	(48,797)
Net cash used in operating activities	(7,982,084)	(3,007,228)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of short-term investments		(4,447,904)
Sale of short-term investments		2,807,199
Purchase of property and equipment	(52,340)
Cash withdrawn from Trust Account	63,310,884
Net cash (used in)/provided by investing activities	63,258,544	(1,640,705)
CASH FLOWS FROM FINANCING ACTIVITIES:
Bank overdraft	(2,919)	(33,128)
Proceeds from advance from a Series B shareholder		1,425,959
Repayment of advance from a Series B shareholder	(746,811)
Proceeds from issuance of convertible notes		2,500,000
Proceeds from promissory note - related party	444,900
Proceeds from short-term loan		906,810
Proceeds from issuance of backstop ordinary shares	4,971,358
Redemption of ordinary shares	(64,070,650)
Advance from a shareholder	543,296	536,905
Net cash provided by/(used in) financing activities	(58,860,826)	5,336,546
Effect of foreign exchange rate changes on cash	29,940
NET INCREASE/(DECREASE) IN CASH	(3,554,425)	688,613
CASH, BEGINNING OF THE PERIOD	4,746,370	100,344
CASH, END OF THE PERIOD	1,191,944	788,957
SUPPLEMENTAL INFORMATION
Interest paid
Income tax paid
Acquisition of property and equipment included in accrued expenses and other liabilities	$ 133,061

Description of Organization and Business Operations (Details)	6 Months Ended
	Jun. 30, 2019
Xynomic Pharmaceuticals Nanjing [Member]
Date of incorporation	Nov. 20, 2017
Place of incorporation /establishment	PRC
Percentage of economic ownership	100.00%
Xynomic Pharmaceuticals Shanghai [Member]
Date of incorporation	Jul. 31, 2018
Place of incorporation /establishment	PRC
Percentage of economic ownership	100.00%
Xynomic Pharmaceuticals Zhongshan [Member]
Date of incorporation	May 15, 2018
Place of incorporation /establishment	PRC
Percentage of economic ownership	100.00%

Description of Organization and Business Operations (Details Textual) - USD ($)			1 Months Ended		6 Months Ended
	May 15, 2019	May 14, 2019	May 31, 2019	Mar. 03, 2019	Jun. 30, 2019
Description of Organization and Business Operations (Textual)
Aggregate loan amount					$ 610,000
Commitment from related party contribute loan				$ 0.02
Shares value of not redeemed					5,000
Backstop agreement, description					Entered into by and between Bison Capital and Yinglin Mark Xu, together with his assignee Bison Capital Holding Company Limited, has purchased from the Company 755,873 shares of common stock at a price of $10.15 per share for a total consideration of $7,672,111 (the "Backstop Shares" and "Backstop Subscription"). As a result of Backstop Subscription, the Company had at least $7,500,001 of net tangible assets remaining at the Closing after giving effect to the redemption of any Ordinary Shares by the public shareholders in connection with the Business Combination.
Yinglin Mark Xu [Member]
Description of Organization and Business Operations (Textual)
Aggregate loan amount			$ 16,062
Shares value of not redeemed			803,080
Per share value			$ 0.02
Xynomic Pharma [Member ]
Description of Organization and Business Operations (Textual)
Number of stock units issued	9,852,216
Bison Capital [Member]
Description of Organization and Business Operations (Textual)
Committed to provide additional loans					$ 190,000
Private Units [Member]
Description of Organization and Business Operations (Textual)
Number of stock units issued		432,062
Initial Public Offering [Member]
Description of Organization and Business Operations (Textual)
Number of stock units issued		6,037,500
Merger Consideration Agreement [Member]
Description of Organization and Business Operations (Textual)
Number of stock units issued	42,860,772
Escrow deposit	1,285,822
Aggregate common stock, shares	9,852,216

Summary of Significant Accounting Policies (Details Textual) - USD ($)		3 Months Ended		6 Months Ended
	Apr. 03, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Dec. 31, 2018
Summary of Significant Accounting Policies (Textual)
Net income		$ (3,051,753)	$ (4,808,753)	$ (18,894,286)	$ (5,524,999)
Net current liabilities		15,701,138		15,701,138
Retained earnings		$ (51,519,477)		$ (51,519,477)			$ (34,323,169)
Research and development expenses description		less than 10%		less than 10%
Credit offset issued		$ 3,570,000		$ 3,570,000
Stockholders' equity		$ (15,035,326)		$ (15,035,326)		$ (28,290,970)	$ (20,094,728)
Xynomic Pharma [Member ]
Summary of Significant Accounting Policies (Textual)
Preferred share conversion, description	Xynomic Pharma issued convertible notes to Northern Light Venture Capital V, Ltd., and Bo Tan and received proceeds of US$2,500,000, which were converted into 776,633 Series B Preferred Shares in August 2018. Further in August 2018, Xynomic Pharma raised US$17 million by issuance of 5,281,101 Series B Preferred Shares to certain investors, including the conversion of convertible notes of US$2.5 million. At the Closing of the Merger, 755,873 shares of Backstop Shares were issued for a total consideration of $7,672,111.

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (4,708,461)	$ (3,051,753)	$ (5,327,391)	$ (17,196,308)
Income tax expenses
Effective income tax rate	0.00%	0.00%	0.00%	0.00%

Income Taxes (Details Textual)	3 Months Ended		6 Months Ended
Income Taxes (Details Textual)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Taxes (Textual)
Effective income tax rates	0.00%	0.00%	0.00%	0.00%
U.S. Federal statutory corporate income tax rate	21.00%	21.00%	21.00%	21.00%

Prepaid Expenses (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Notes to Financial Statements
Prepaid research and development expenses	$ 62,980	$ 207,988
Prepaid rental expenses	66,709	66,371
Prepaid health insurance	20,658
Others	5,457	3,391
Total prepaid expenses	$ 155,805	$ 277,750

Property and Equipment, Net (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Property and equipment	$ 499,209	$ 281,218
Less: accumulated depreciation	(54,413)	(488)
Property and equipment, net	444,796	280,730
Leasehold improvement [Member]
Property and equipment	289,470	276,839
Lab equipment [Member]
Property and equipment	195,586
Electronic equipment [Member]
Property and equipment	$ 14,153	$ 4,379

Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
Property and Equipment, Net (Details Textual) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Property and Equipment, Net (Textual)
Depreciation expense	$ 30,612	$ 30,612	$ 54,593

Other Non-Current Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Other Non-current Assets
VAT input tax	$ 86,735	$ 52,762
Prepaid insurance	124,076	93,075
Deposits	8,754	9,339
Total other non-current assets	$ 219,565	$ 155,176

Accrued Expenses And Other Current Liabilities (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accrued Expenses And Other Current Liabilities
Research and development expense-Contract Research Organizations	$ 10,288,625	$ 10,304,750
Research and development expense-Contract Manufacture Organizations	3,125,901	1,874,956
License fee payable	1,000,000	1,000,000
Professional fee	1,010,112	824,360
Payroll and social insurance	109,599	147,692
Payables for equipment	140,465
Payable for leasehold improvement	105,832	110,736
Others	308,544	144,767
Total accrued expenses and other current liabilities	$ 16,089,078	$ 14,407,261

Redeemable Convertible Preferred Shares (Details)	6 Months Ended
Redeemable Convertible Preferred Shares (Details)	Jun. 30, 2019 USD ($)
Angel Preferred Shares [Member]
Balance as of December 31, 2018	$ 580,256
Redemption value accretion	11,117
Conversion to common shares	(591,373)
Balance as of June 30, 2019
Series A-1 Preferred Shares [Member]
Balance as of December 31, 2018	4,905,780
Redemption value accretion	93,984
Conversion to common shares	(4,999,764)
Balance as of June 30, 2019
Series B Preferred Stock [Member]
Balance as of December 31, 2018	2,424,712
Redemption value accretion	1,592,877
Conversion to common shares	(4,017,589)
Balance as of June 30, 2019

Redeemable Convertible Preferred Shares (Details Textual)	Jun. 30, 2019 shares
Redeemable Convertible Preferred Shares
Outstanding redeemable convertible preferred shares converted	34,695,395

Shareholders' Equity (Details) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
Shareholders' Equity (Details) - USD ($)	Feb. 01, 2019	Jun. 30, 2019	Jun. 30, 2019	May 14, 2019	Mar. 31, 2019	Dec. 31, 2018
Shareholders' Equity (Textual)
Preferred stock, par value		$ 0.0001	$ 0.0001			$ 0.0001
Preferred stock, shares authorized		50,000,000	50,000,000			50,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value		$ 0.0001	$ 0.0001			$ 0.0001
Common stock, shares authorized		200,000,000	200,000,000			200,000,000
Ordinary shares, shares issued		46,273,846	46,273,846			6,706,068
Ordinary shares, shares outstanding		46,273,846	46,273,846			6,706,068
Conversion of converted promissory notes			5,000
Mark Yinglin XU [Member]
Shareholders' Equity (Textual)
Cash considerations		$ 4,971,358	$ 4,971,358
Convertible loans			2,560,753
Bison Capital [Member]
Shareholders' Equity (Textual)
Cash considerations		$ 7,672,111	7,672,111
Convertible loans			$ 140,000
Conversion of converted promissory notes			50,000
Common Stock
Shareholders' Equity (Textual)
Converted common stocks price per share				$ 0.0001
Combination with Xynomic Pharmaceuticals, Inc. shares		1,955,246
Conversion of Rights to common shares, shares		646,955
Xynomic Pharma's ordinary shares		46,273,846	46,273,846		8,165,377	8,165,377
Xynomic Pharma's convertible preferred shares as the Merger Consideration Shares		34,695,395
Issuance of backstop common shares, shares		755,873
Common Stock \| Bison Capital [Member]
Shareholders' Equity (Textual)
Conversion of converted promissory notes			5,000
British Virgin Islands [Member]
Shareholders' Equity (Textual)
Ordinary shares, shares issued						7,978,937
Ordinary shares, shares outstanding						7,978,937
Ordinary shares subject to possible redemption						6,037,500
Right to redeem public shares	6,023,689
Amount of right to redeem public shares	$ 64,070,650
Share per price	$ 10.54

Loss Per Share (Details) - USD ($)	3 Months Ended			6 Months Ended
Loss Per Share (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Numerator:
Net loss attributable to ordinary shareholders	$ (3,051,753)	$ (14,144,555)	$ (4,708,461)	$ (17,196,308)	$ (5,327,391)
Denominator:
Weighted average number of ordinary shares-basic and diluted	44,623,568		42,860,772	43,747,040	42,860,772
Net loss per share-basic and diluted	$ (0.11)		$ (0.07)	$ (0.13)	$ (0.43)

Licenses Arrangement (Details)	1 Months Ended
Licenses Arrangement (Details)	Dec. 31, 2018	Aug. 31, 2017	Feb. 28, 2017
Pharmacyclics LLC [Member]
Agreement, description			Under the terms of the agreement, the Group made upfront payments of US$3.5 million in 2017 and 1st milestone payment of US$3.5 million in 2018 to Pharmacyclics which were recorded as research and development expenses in 2017 and 2018, respectively. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 2nd milestone payment of US$6,500,000 upon regulatory approval for the first indication for a licensed product in China or in the United States; 2) 3rd milestone payment of US$4,000,000 upon regulatory approval for the second indication for a licensed product in China or in the United States.
Boehringer Ingelheim International GMBH ("BII") (XP-102) [Member]
Agreement, description		Under the terms of the agreement, the Group made upfront payments to BII totaling US$0.3 million which was recorded as a research and development expense in 2017. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 1st milestone payment of US$ 1,700,000 upon first dosing of a patient in Phase I Clinical Trial in the US or China; 2) 2nd milestone payment of US$ 4,000,000 upon first dosing of a patient in a pivotal Phase III Clinical Trial in the first indication in the US or China; 3) 3rd milestone payment of US$2,000,000 upon first dosing of a patient in a pivotal Phase III Clinical Trial in a second indication in the US or China; 4) 4th milestone payment of US$ 7,000,000 upon the grant of the first marketing authorization of the first indication in the US; 5) 5th milestone payment of US$3,000,000 upon the grant of the first marketing authorization of the first indication in China.
BII (XP-105) [Member]
Agreement, description	Under the terms of the agreement, as of June 30, 2019 the Group was obligated to make upfront payments to BII totaling US$1 million which was recorded as a research and development expense for the year ended December 31, 2018 and was included in accrued expenses and other current liabilities as of December 31, 2018. In addition, the Group is obligated to pay the following development and regulatory milestone payments: 1) 1st milestone payment of US$7,000,000 upon first dosing of a patient in Phase II or Phase III Clinical Trial in the first indication either of which is intended to be a pivotal trial; 2) 2nd milestone payment of US$10,000,000 upon the grant of the first Marketing Authorization of the first indication. In addition, the Group will pay royalties at a certain percentage of the net sales. The royalty term commences from the first commercial sale of such licensed product in such country until the later of (i) the date on which such licensed product is no longer covered by a valid claim of the licensed patents, (ii) the expiration of regulatory exclusivity of the licensed product in such country, or (iii) the tenth anniversary of the first launch of the respective licensed product in the country in the indication, provided the licensed know-how is still proprietary, or such licensed know-how is no longer proprietary owing to a breach of its confidentiality obligations.

Commitments and Contingencies (Details)	Jun. 30, 2019 USD ($)
Year ending June 30, 2019,
2020	$ 241,099
2021	236,467
2022	129,658
Total	$ 607,224

Commitments and Contingencies (Details Textual) - USD ($)		3 Months Ended		6 Months Ended
	Jul. 12, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Commitments and Contingencies (Textual)
Rental expenses		$ 98,434	$ 24,249	$ 146,598	$ 40,275
Registration rights agreement description				(1) all or any portion of the 1,509,375 shares of common stock of Bison issued to certain existing investors (the "Founder Shares"), (2) 432,063 private units issued by Bison to certain existing investors in conjunction with the consummation of its initial public offering (the "Private Units"),
Xynomic Pharma [Member ]
Commitments and Contingencies (Textual)
Legal contingencies, description	The Plaintiff seeks $6,992,068 from Xynomic Pharma, plus interest at the contract rate of 1% per month. Xynomic Pharma must respond to the complaint by August 19, 2019.
Payable to plantiff				$ 7,078,037
Accrued interest		$ 273,467		$ 273,467
Maximum [Member]
Commitments and Contingencies (Textual)
Lease term				36 months
Minimum [Member]
Commitments and Contingencies (Textual)
Lease term				12 months

Share-Based Compensation (Details)	6 Months Ended
Share-Based Compensation (Details)	Jun. 30, 2019 USD ($) $ / shares shares
Employee [Member]
Number of shares, Beginning balance \| shares
Number of shares, Granted \| shares	100,000
Number of shares, Forfeited \| shares	(75,000)
Number of shares, Ending balance \| shares	25,000
Number of shares Exercisable \| shares	25,000
Weighted average exercise price, Beginning balance \| $ / shares
Weighted average exercise price, Granted \| $ / shares	1
Weighted average exercise price, Forfeited \| $ / shares	1
Weighted average exercise price, Ending balance \| $ / shares	1
Weighted average exercise price, Exercisable \| $ / shares	$ 1
Weighted remaining contractual years	9 years 6 months 25 days
Weighted remaining contractual years, Exercisable	9 years 6 months 25 days
Aggregate intrinsic value \| $	$ 215,050
Aggregate intrinsic value, Exercisable \| $	$ 215,050
Non Employee [Member]
Number of shares, Beginning balance \| shares
Number of shares, Granted \| shares	786,046
Number of shares, Forfeited \| shares
Number of shares, Ending balance \| shares	786,046
Number of shares Exercisable \| shares	589,535
Weighted average exercise price, Beginning balance \| $ / shares
Weighted average exercise price, Granted \| $ / shares	0.1
Weighted average exercise price, Forfeited \| $ / shares
Weighted average exercise price, Ending balance \| $ / shares	0.1
Weighted average exercise price, Exercisable \| $ / shares	$ 0.1
Weighted remaining contractual years	9 years 6 months 25 days
Weighted remaining contractual years, Exercisable	9 years 6 months 25 days
Aggregate intrinsic value \| $	$ 7,433,873
Aggregate intrinsic value, Exercisable \| $	$ 5,578,436

Share-Based Compensation (Details 1)	6 Months Ended
Share-Based Compensation (Details 1)	Jun. 30, 2019 $ / shares
Sharebased Compensation Details Textual Abstract
Risk-free interest rate	2.77%
Expected term	10 years
Volatility rate	36.10%
Dividend yield	0.00%
Exercise multiple	$ 2.8
Fair value of underlying ordinary share	$ 9.5573

Share-Based Compensation (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
Share-Based Compensation (Details Textual) - USD ($)	Jan. 21, 2019	Aug. 28, 2018	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Share-Based Compensation (Textual)
Share-based compensation			$ (30,317)	$ 7,683,282	$ 7,652,965
General and Administrative Expense [Member]
Share-Based Compensation (Textual)
Share-based compensation			$ 30,317		$ 886,046
Employee [Member]
Share-Based Compensation (Textual)
Number of shares, Granted					100,000
Option vesting description					Granted to an employee (100,000 shares): 25% of the options is to be vested on April 30, 2019, and 1/48 of the options to be vested each month thereafter. The employee resigned from Xynomic Pharma in May 2019 and the remaining unvested 75% of the options were forfeited.
Non Employee [Member]
Share-Based Compensation (Textual)
Number of shares, Granted					786,046
Option vesting description					Granted to a non-employee (786,046 shares): 25% of the options is to be vested on August 31, 2019, and 1/48 of the options to be vested each month thereafter, subject to an acceleration vesting schedule that 75% is to be issued upon completion of Xynomic Pharma's merger with Bison Capital Acquisition Corp, and 25% to be issued in one year after the closing of the merger.
2018 Stock Incentive Plan [Member]
Share-Based Compensation (Textual)
Ordinary shares under incentive plan, description		(i) 3,000,000 ordinary shares, (ii) 5% of the number of ordinary shares issued and outstanding on December 31 of the immediately preceding calendar year, and (iii) an amount determined by the Board. As of December 31, 2018 and June 30, 2019, 8,908,430 and 8,022,384 awards remain available for future grants under the 2018 Plan, respectively.
Number of shares, Granted	886,046
Grant date fair value of the share options					$ 9.3653

Related Party Transactions (Details)								1 Months Ended								3 Months Ended		6 Months Ended			12 Months Ended
Related Party Transactions (Details)	Apr. 12, 2019 USD ($)	Apr. 12, 2019 CNY (¥)	Jan. 21, 2019 USD ($)	Jan. 21, 2019 CNY (¥)	Aug. 23, 2018 CNY (¥)	May 13, 2018 USD ($)	May 13, 2018 CNY (¥)	May 31, 2019 USD ($) $ / shares shares	Feb. 28, 2019 USD ($)	Feb. 20, 2019 USD ($)	Feb. 20, 2019 CNY (¥)	Aug. 23, 2018 USD ($)	Aug. 23, 2018 CNY (¥)	Jun. 30, 2017 USD ($)	Jun. 19, 2017 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2019 CNY (¥) shares	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)	May 14, 2019 USD ($) $ / shares
Related Party Transactions (Textual)
Advance from a shareholder																		$ 543,296		$ 536,905
General and administrative services																$ 1,443,731	$ 745,286	10,222,980		848,761
Proceeds from advance amount																				1,425,959
Accrued interest expense																17,723		32,811
Aggregated loan																610,000		$ 610,000
Convertible promissory note shares \| shares																		5,000	5,000
Administrative Services Arrangement [Member]
Related Party Transactions (Textual)
Fee for services															$ 5,000	7,500	15,000	$ 22,500		27,500
Administrative fees																		112,500			$ 90,000
Service purchased from shareholder [Member]
Related Party Transactions (Textual)
General and administrative services																	44,915			93,968
Group payment amount														$ 295,021
Xynomic Pharma [Member ]
Related Party Transactions (Textual)
General and administrative services																0	52,723	25,908		52,723
Interest payable																273,467		273,467
Zhongshan Bison [Member]
Related Party Transactions (Textual)
Proceeds from advance amount						$ 1,425,959
Amount due from related party																					112,455
Interest payable																64,093		$ 64,093			31,697
Annual interest rate												8.00%	8.00%
Due date																		Sep. 15, 2019	Sep. 15, 2019
Zhongshan Bison [Member] \| RMB [Member]
Related Party Transactions (Textual)
Proceeds from advance amount \| ¥							¥ 9,435,000
Repyament of debt \| ¥													¥ 1,800,000						¥ 7,635,000
Eigenbridge, Inc [Member ]
Related Party Transactions (Textual)
Amount due to related party																0		$ 0			80,640
Bison Capital [Member]
Related Party Transactions (Textual)
Convertible promissory loans									$ 100,000
Short term debt outstanding									$ 500,000
Aggregate order to finance transaction costs																404,900		404,900
Convertible promissory note amount																		$ 500,000
Convertible promissory note shares \| shares																		50,000	50,000
Bison Capital [Member] \| Related Party Loans and Promissory Notes [Member]
Related Party Transactions (Textual)
Lender's discretion converted																500,000		$ 500,000
Aggregated loan																						$ 500,000
Additional private unit price \| $ / shares																		$ 10.00
Private per units \| $ / shares																						$ 10.00
Yinglin Mark Xu [Member]
Related Party Transactions (Textual)
Advance from a shareholder																130,335	$ 38,683	$ 543,296		$ 536,905
Converted shares \| shares																		2,560,754	2,560,754
Amount due to related party																$ 2,008,936		$ 2,008,936			$ 0
Aggregated loan								$ 16,062
Private per units \| $ / shares								$ 0.02
Convertible promissory note shares \| shares								803,080
Xynomic Pharmaceuticals Nanjing [Member] \| Zhongshan Bison [Member]
Related Party Transactions (Textual)
Repyament of debt	$ 383,097		$ 747,189							$ 383,097		$ 262,743
Xynomic Pharmaceuticals Nanjing [Member] \| Zhongshan Bison [Member] \| RMB [Member]
Related Party Transactions (Textual)
Repyament of debt \| ¥		¥ 2,571,000		¥ 5,064,000	¥ 1,800,000						¥ 2,571,000

Subsequent Event (Details) - USD ($)		1 Months Ended
Subsequent Event (Details) - USD ($)	Jul. 10, 2019	Jul. 26, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Subsequent Events (Textual)
Stockholders' equity			$ (15,035,326)	$ (28,290,970)	$ (20,094,728)
Subsequent Event [Member]
Subsequent Events (Textual)
Reverse stock split		The Company called for a Special Meeting of its stockholders be held on August 26, 2019 for the purpose of authorizing the Company's Board of Directors to, in its discretion, to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio no less than 1-for-1.5 and no greater than 1-for-5 at any time prior to August 27, 2020
Securities purchase agreement, description	The Company entered into certain Securities Purchase Agreement (the "SPA") with certain "accredited investors" as defined in Rule 501(a) of Regulation D as promulgated under the Securities Act of 1933, as amended (the "Purchasers"), pursuant to which the Company agreed to sell to such Purchasers an aggregate of approximate USD$10 million of units (the "Reg. D Units") of the Company, at a purchase price of USD$3.80 per Unit (subject to adjustment) (the "Reg. D Offering"). Each Reg. D Unit consists of one share of common stock and one-half warrant (the "Reg. D Warrant"). Each whole Reg. D Warrant can be exercised to purchase one share of the Company Stock at $7.00 per share and shall expire in three (3) years of the issuance, and have the rights and preference set forth in certain Warrant Agreement. Furthermore, the SPA provides, among other terms, a maximum offering in an aggregate of $15 million with the first closing of a minimum of $5 million upon delivery of the closing conditions set forth in the SPA, provided that no closing shall occur after September 30, 2019 subject to certain exception.